-DOCSTART- -X- - O

: PUNCT - O
Evaluating VERB - O
the DET - O
Effects NOUN - O
on ADP - O
Lovastatin NNP - B-MEDICINE
Production NNP - I-ORG
and CCONJ - O
Fungal NNP - B-PERSON
Morphology NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin RB - B-MEDICINE
, PUNCT - O
not ADV - O
simvastatin ADJ - O
, PUNCT - O
corrects VERB - O
core ADJ - O
phenotypes NOUN - O
in ADP - O
the DET - O
fragile ADJ - O
X NOUN - O
mouse NOUN - O
model NOUN - O

-DOCSTART- -X- - O

A DET - O
controlled VERB - O
and CCONJ - O
progressive ADJ - O
walking NOUN - O
program NOUN - O
for ADP - O
older ADJ - O
women NOUN - O
treated VERB - O
with ADP - O
Lovastatin NNP - B-MEDICINE
may VERB - O
induce VERB - O
a DET - O
boost NOUN - O
of ADP - O
brain NOUN - O
activity NOUN - O
linked VERB - O
to ADP - O
HDL NNP - B-ORG
- HYPH - I-ORG
C NNP - I-ORG
, PUNCT - O
which ADJ - O
could VERB - O
delay VERB - O
cognitive ADJ - O
impairment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
showed VERB - O
significant ADJ - O
antioxidant NOUN - O
property NOUN - O
with ADP - O
IC50 PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Enhanced VERB - O
production NOUN - O
of ADP - O
Lovastatin NNP - B-MEDICINE
by ADP - O
filamentous ADJ - O
fungi NOUN - O
through ADP - O
solid ADJ - O
state NOUN - O
fermentation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
we PRON - O
designed VERB - O
an DET - O
innovative ADJ - O
ternary ADJ - O
cocktail NOUN - O
chemotherapy NOUN - O
by ADP - O
using VERB - O
Lovastatin NNP - B-MEDICINE
( PUNCT - O
L)-loaded ADJ - O
Janus NNP - B-ORG
camptothecin NOUN - O
- PUNCT - O
floxuridine NOUN - O
conjugate NOUN - O
( PUNCT - O
CF PROPN - O
) PUNCT - O
nanocapsules PROPN - O
( PUNCT - O
NCs PROPN - O
) PUNCT - O
with ADP - O
ultrahigh ADJ - O
drug NOUN - O
loading NOUN - O
capacity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Loading VERB - O
Lovastatin NNP - B-MEDICINE
into ADP - O
Camptothecin NNP - B-ORG
- HYPH - I-ORG
Floxuridine NNP - I-ORG
Conjugate NNP - I-ORG
Nanocapsules NNP - I-ORG
for ADP - O
Enhancing PROPN - O
Anti PROPN - O
- ADJ - O
metastatic ADJ - O
Efficacy NNP - B-ORG
of ADP - O
Cocktail NNP - B-PERSON
Chemotherapy NNP - I-PERSON
on ADP - O
Triple PROPN - O
- PUNCT - O
negative ADJ - O
Breast NNP - B-LOC
Cancer NNP - I-LOC
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
has VERB - O
been VERB - O
shown VERB - O
to PART - O
protect VERB - O
mice NOUN - O
from ADP - O
late ADJ - O
radiation NOUN - O
injury NOUN - O
. PUNCT - O

Lovastatin NNP - B-MEDICINE
( PUNCT - O
20 CD - B-CARDINAL
to TO - I-CARDINAL
80 CD - I-CARDINAL
mg NOUN - O
/ SYM - O
d NOUN - O
) PUNCT - O
was VERB - O
started VERB - O
on ADP - O
day NN - B-DATE
1 CD - I-DATE
of ADP - O
radiation NOUN - O
and CCONJ - O
continued VERB - O
for ADP - O
12 CD - B-DATE
months NNS - I-DATE
. PUNCT - O

Lovastatin NNP - B-MEDICINE
, PUNCT - O
as ADP - O
administered VERB - O
in ADP - O
this DET - O
trial NOUN - O
, PUNCT - O
did VERB - O
not ADV - O
reduce VERB - O
the DET - O
incidence NOUN - O
of ADP - O
grade NOUN - O
2 CD - B-CARDINAL
or CCONJ - O
higher ADJ - O
rectal ADJ - O
toxicity NOUN - O
compared VERB - O
with ADP - O
historical ADJ - O
controls NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Cerasomal PROPN - O
Lovastatin NNP - B-MEDICINE
Nanohybrids PROPN - O
for ADP - O
Efficient PROPN - O
Inhibition PROPN - O
of ADP - O
Triple PROPN - O
- PUNCT - O
Negative PROPN - O
Breast PROPN - O
Cancer NOUN - O
Stem VERB - O
Cells NOUN - O
To PART - O
Improve VERB - O
Therapeutic ADJ - O
Efficacy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
is VERB - O
a DET - O
3-hydroxy-3-methylglutaryl CD - B-QUANTITY
- HYPH - I-QUANTITY
CoA NN - I-QUANTITY
reductase NOUN - O
inhibitor NOUN - O
that ADJ - O
is VERB - O
clinically ADV - O
used VERB - O
for ADP - O
the DET - O
prevention NOUN - O
of ADP - O
cardiovascular ADJ - O
diseases NOUN - O
. PUNCT - O

Lovastatin NNP - B-MEDICINE
also ADV - O
inhibited VERB - O
the DET - O
phosphorylation NOUN - O
of ADP - O
inhibitor NOUN - O
of ADP - O
nuclear ADJ - O
factor NOUN - O
  SPACE - O
( PUNCT - O
NF)-κBα PROPN - O
and CCONJ - O
the DET - O
translocation NOUN - O
of ADP - O
NF NNP - B-ORG
- PUNCT - O
κB VERB - O
into ADP - O
the DET - O
nucleus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

And CCONJ - O
comparative ADJ - O
gene NOUN - O
expression NOUN - O
analyses NOUN - O
were VERB - O
performed VERB - O
in ADP - O
buds NOUN - O
of ADP - O
decapitated VERB - O
shoots NOUN - O
and CCONJ - O
buds NOUN - O
of ADP - O
the DET - O
treatment NOUN - O
of ADP - O
biosynthetic ADJ - O
inhibitor NOUN - O
of ADP - O
cytokinin NOUN - O
( PUNCT - O
Lovastatin NNP - B-MEDICINE
) PUNCT - O
on ADP - O
decapitated VERB - O
shoots NOUN - O
. PUNCT - O

Results NOUN - O
indicated VERB - O
that ADP - O
decapitation NOUN - O
and CCONJ - O
cytokinin NOUN - O
increased VERB - O
ZR NNP - B-NORP
content NOUN - O
in ADP - O
buds NOUN - O
and CCONJ - O
internodes NOUN - O
at ADP - O
4 CD - B-CARDINAL
- SYM - O
8 NUM - O
  SPACE - O
h NOUN - O
, PUNCT - O
and CCONJ - O
induced VERB - O
bud NOUN - O
elongation NOUN - O
at ADP - O
96 CD - B-CARDINAL
  SPACE - O
h ADV - O
after ADP - O
treatment NOUN - O
, PUNCT - O
relative ADJ - O
to ADP - O
buds NOUN - O
in ADP - O
shoots NOUN - O
receiving VERB - O
the DET - O
Lovastatin NNP - B-MEDICINE
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
induced VERB - O
Kruppel NNP - B-ORG
like ADP - O
factor NOUN - O
2 CD - B-CARDINAL
( PUNCT - O
KLF2 NNP - B-ORG
) PUNCT - O
, PUNCT - O
Kruppel NNP - B-NORP
like ADP - O
factor NOUN - O
6 CD - B-CARDINAL
( PUNCT - O
KLF6 PROPN - O
) PUNCT - O
and CCONJ - O
Ras NNP - B-PERSON
homolog NOUN - O
family NOUN - O
member NOUN - O
B NOUN - O
( PUNCT - O
RHOB NNP - B-ORG
) PUNCT - O
genes NOUN - O
and CCONJ - O
preferentially ADV - O
led VERB - O
to ADP - O
viability NOUN - O
reduction NOUN - O
of ADP - O
Cisplatin NNP - B-ORG
- PUNCT - O
resistant ADJ - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
attenuated VERB - O
the DET - O
neurotoxic ADJ - O
effects NOUN - O
of ADP - O
β DET - O
- PUNCT - O
amyloid NOUN - O
peptide NOUN - O
( PUNCT - O
Aβ PROPN - O
) PUNCT - O
and CCONJ - O
affected VERB - O
the DET - O
metabolism NOUN - O
of ADP - O
APP PROPN - O
, PUNCT - O
reducing VERB - O
levels NOUN - O
of ADP - O
Aβ1 NOUN - O
to ADP - O
Aβ42 PROPN - O
and CCONJ - O
β ADJ - O
- PUNCT - O
site NOUN - O
amyloid NOUN - O
precursor NOUN - O
protein NOUN - O
- PUNCT - O
cleaving VERB - O
enzyme ADJ - O
1 CD - B-CARDINAL
; PUNCT - O
enhancing VERB - O
those DET - O
of ADP - O
αAPP CCONJ - O
, PUNCT - O
disintegrin NOUN - O
metalloproteinase NOUN - O
domain NOUN - O
- PUNCT - O
containing VERB - O
protein NOUN - O
10 CD - B-CARDINAL
, PUNCT - O
and CCONJ - O
β DET - O
- PUNCT - O
site NOUN - O
amyloid NOUN - O
precursor NOUN - O
protein NOUN - O
- PUNCT - O
cleaving VERB - O
enzyme ADJ - O
2 CD - B-CARDINAL
; PUNCT - O
and CCONJ - O
up ADV - O
- PUNCT - O
regulating VERB - O
expression NOUN - O
of ADP - O
α7 NOUN - O
nAChR NOUN - O
and CCONJ - O
stimulating VERB - O
phosphorylation NOUN - O
of ADP - O
extracellular ADJ - O
signal NOUN - O
- PUNCT - O
regulated VERB - O
kinase NOUN - O
( PUNCT - O
ERK)1/2 NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Protection NOUN - O
against ADP - O
the DT - B-ORG
Neurotoxic NNP - I-ORG
Effects NNPS - I-ORG
of IN - I-ORG
β NNP - I-ORG
- HYPH - I-ORG
Amyloid NNP - I-ORG
Peptide NNP - I-ORG
on IN - I-ORG
Cultured NNP - I-ORG
Neuronal NNP - I-ORG
Cells NNPS - I-ORG
by ADP - O
Lovastatin NNP - B-MEDICINE
Involves NNP - I-ORG
Elevated NNP - I-ORG
Expression NN - I-ORG
of ADP - O
α7 ADJ - O
Nicotinic NNP - B-ORG
Acetylcholine NNP - I-ORG
Receptors NNPS - I-ORG
and CCONJ - O
Activating PROPN - O
Phosphorylation PROPN - O
of ADP - O
Protein NNP - B-GPE
Kinases NNPS - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
promotes VERB - O
myelin ADJ - O
formation NOUN - O
in ADP - O
NPC1 NNP - B-LOC
mutant ADJ - O
oligodendrocytes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
inhibits VERB - O
visceral ADJ - O
allodynia NOUN - O
and CCONJ - O
increased VERB - O
colonic ADJ - O
permeability NOUN - O
induced VERB - O
by ADP - O
lipopolysaccharide NOUN - O
or CCONJ - O
repeated VERB - O
water NOUN - O
avoidance NOUN - O
stress NOUN - O
in ADP - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Development NOUN - O
of ADP - O
a DET - O
Modified PROPN - O
- PUNCT - O
Release PROPN - O
Formulation PROPN - O
of ADP - O
Lovastatin NNP - B-MEDICINE
Targeted VBN - I-ORG
to ADP - O
Intestinal ADJ - O
Methanogens PROPN - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
increases VERB - O
IDE NNP - B-ORG
release NOUN - O
from ADP - O
BV-2 PROPN - O
cells NOUN - O
as ADP - O
reported VERB - O
, PUNCT - O
but CCONJ - O
this DET - O
release NOUN - O
is VERB - O
mirrored VERB - O
by ADP - O
LDH NNP - B-ORG
release NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Evaluation NOUN - O
of ADP - O
the DT - B-LAW
Combined NNP - I-LAW
Effect NNP - I-LAW
of IN - I-LAW
Recombinant NNP - I-LAW
High NNP - I-LAW
- HYPH - I-LAW
Density NNP - I-LAW
Lipoprotein NNP - I-LAW
Carrier NNP - I-LAW
and CCONJ - O
the DT - B-ORG
Encapsulated NNP - I-ORG
Lovastatin NNP - I-MEDICINE
in ADP - O
RAW264.7 NNP - B-GPE
Macrophage NN - I-GPE
Cells NNS - I-GPE
Based VBN - I-GPE
on ADP - O
the DT - B-FAC
Median JJ - I-FAC
- HYPH - I-FAC
Effect NNP - I-FAC
Principle NNP - I-FAC
. PUNCT - O

-DOCSTART- -X- - O

Here ADV - O
, PUNCT - O
we PRON - O
report VERB - O
that ADP - O
the DET - O
cholesterol NOUN - O
, PUNCT - O
fatty ADJ - O
acid NOUN - O
, PUNCT - O
and CCONJ - O
triglyceride NOUN - O
synthesis NOUN - O
pathways NOUN - O
regulated VERB - O
by ADP - O
S1P NNP - B-ORG
is VERB - O
involved VERB - O
in ADP - O
SFTSV PROPN - O
replication NOUN - O
, PUNCT - O
using VERB - O
CHO NNP - B-ORG
- PUNCT - O
K1 PROPN - O
cell NOUN - O
line NOUN - O
( PUNCT - O
SRD-12B PROPN - O
) PUNCT - O
that DET - O
is VERB - O
deficient ADJ - O
in ADP - O
site NOUN - O
1 CD - B-CARDINAL
protease NOUN - O
( PUNCT - O
S1P PROPN - O
) PUNCT - O
enzymatic ADJ - O
activity NOUN - O
, PUNCT - O
PF-429242 NNP - B-ORG
, PUNCT - O
a DET - O
small ADJ - O
compound NOUN - O
targeting VERB - O
S1P NOUN - O
enzymatic ADJ - O
activity NOUN - O
, PUNCT - O
and CCONJ - O
Fenofibrate NNP - B-ORG
and CCONJ - O
Lovastatin NNP - B-MEDICINE
, PUNCT - O
which ADJ - O
inhibit VERB - O
triglyceride NOUN - O
and CCONJ - O
cholesterol NOUN - O
synthesis NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
investigated VERB - O
the DET - O
effects NOUN - O
of ADP - O
Lovastatin NNP - B-MEDICINE
against ADP - O
sciatic ADJ - O
nerve NOUN - O
crush NOUN - O
injury NOUN - O
in ADP - O
male ADJ - O
Wistar NNP - B-FAC
Rats NNPS - I-FAC
. PUNCT - O

Lovastatin NNP - B-MEDICINE
or CCONJ - O
vehicle NOUN - O
was VERB - O
given VERB - O
parenteraly NOUN - O
to ADP - O
rats NOUN - O
for ADP - O
7 CD - B-DATE
days NNS - I-DATE
postoperative ADJ - O
. PUNCT - O

In ADP - O
Lovastatin NNP - B-MEDICINE
treatment NOUN - O
groups NOUN - O
, PUNCT - O
a DET - O
single ADJ - O
dose NOUN - O
of ADP - O
agent NOUN - O
( PUNCT - O
2 CD - B-CARDINAL
and CCONJ - O
5mg NN - B-ORDINAL
/ SYM - O
kg NOUN - O
) PUNCT - O
was VERB - O
administered VERB - O
daily RB - B-DATE
. PUNCT - O

Results NOUN - O
showed VERB - O
that ADP - O
Lovastatin NNP - B-MEDICINE
in ADP - O
a DET - O
dose NOUN - O
of ADP - O
5mg NN - B-ORDINAL
/ SYM - O
kg NOUN - O
could VERB - O
significantly ADV - O
( PUNCT - O
P NOUN - O
< X - O
0.05 CD - B-CARDINAL
) PUNCT - O
accelerate VERB - O
regeneration NOUN - O
process NOUN - O
and CCONJ - O
functional ADJ - O
recovery NOUN - O
. PUNCT - O

Also ADV - O
results NOUN - O
demonstrated VERB - O
that ADP - O
morphometric ADJ - O
parameters NOUN - O
such ADJ - O
as ADP - O
mean ADJ - O
axonal ADJ - O
number NOUN - O
and CCONJ - O
myelin NOUN - O
thickness NOUN - O
were VERB - O
significantly ADV - O
higher ADJ - O
in ADP - O
Lovastatin NNP - B-MEDICINE
( PUNCT - O
5mg NN - B-ORDINAL
/ SYM - O
kg NOUN - O
) PUNCT - O
treatment NOUN - O
groups NOUN - O
compared VERB - O
to ADP - O
controls NOUN - O
( PUNCT - O
P NOUN - O
< X - O
0.05 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

These DET - O
findings NOUN - O
suggest VERB - O
that ADP - O
a DET - O
short ADJ - O
- PUNCT - O
term NOUN - O
course NOUN - O
treatment NOUN - O
with ADP - O
Lovastatin NNP - B-MEDICINE
can VERB - O
protect VERB - O
against ADP - O
sciatic ADJ - O
nerve NOUN - O
injury NOUN - O
. PUNCT - O

Findings NOUN - O
indicate VERB - O
that ADP - O
postoperative ADJ - O
administration NOUN - O
of ADP - O
Lovastatin NNP - B-MEDICINE
led VERB - O
to PART - O
accelerate VERB - O
regeneration NOUN - O
process NOUN - O
and CCONJ - O
motor NOUN - O
function NOUN - O
recovery NOUN - O
in ADP - O
nerve NOUN - O
crush NOUN - O
model NOUN - O
in ADP - O
rats NOUN - O
. PUNCT - O

This DET - O
effect NOUN - O
might VERB - O
be VERB - O
due ADP - O
to ADP - O
the DET - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
, PUNCT - O
immunomodulatory ADJ - O
or CCONJ - O
anti ADJ - O
- ADJ - O
oxidative ADJ - O
properties NOUN - O
of ADP - O
Lovastatin NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Since ADP - O
25-hydroxycholesterol CD - B-CARDINAL
( PUNCT - O
25-HC CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
a DET - O
metabolite NOUN - O
of ADP - O
cholesterol NOUN - O
, PUNCT - O
can VERB - O
suppress VERB - O
IL-1β PROPN - O
production NOUN - O
, PUNCT - O
thus ADV - O
reducing VERB - O
inflammation NOUN - O
, PUNCT - O
we PRON - O
evaluated VERB - O
the DET - O
effect NOUN - O
of ADP - O
25-HC CD - B-CARDINAL
in ADP - O
an DET - O
in X - O
vitro X - O
model NOUN - O
of ADP - O
mevalonate NOUN - O
pathway NOUN - O
alteration NOUN - O
, PUNCT - O
obtained VERB - O
using VERB - O
Lovastatin NNP - B-MEDICINE
. PUNCT - O

Our ADJ - O
results NOUN - O
showed VERB - O
that ADP - O
25-HC CD - B-PRODUCT
is VERB - O
able ADJ - O
to PART - O
reduce VERB - O
inflammation NOUN - O
but CCONJ - O
it PRON - O
is VERB - O
ineffective ADJ - O
to PART - O
restore VERB - O
autophagy NOUN - O
flux ADJ - O
and CCONJ - O
to PART - O
decrease VERB - O
apoptosis NOUN - O
levels NOUN - O
, PUNCT - O
both DET - O
caused VERB - O
by ADP - O
lower ADJ - O
protein NOUN - O
prenylation NOUN - O
; PUNCT - O
so CCONJ - O
, PUNCT - O
in ADP - O
spite NOUN - O
of ADP - O
its ADJ - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
action NOUN - O
it PRON - O
is VERB - O
not ADV - O
useful ADJ - O
to PART - O
rescue VERB - O
defective ADJ - O
prenylation NOUN - O
/ SYM - O
autophagy NOUN - O
impairment NOUN - O
- PUNCT - O
driven VERB - O
apoptosis NOUN - O
in ADP - O
Lovastatin NNP - B-MEDICINE
impaired VERB - O
mevalonate NOUN - O
pathway NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Since ADP - O
the DET - O
parasite NOUN - O
synthesizes NOUN - O
ergosterol VERB - O
instead ADV - O
of ADP - O
cholesterol NOUN - O
, PUNCT - O
using VERB - O
the DET - O
same ADJ - O
biochemical ADJ - O
pathway NOUN - O
and CCONJ - O
enzymes NOUN - O
, PUNCT - O
an DET - O
inhibitor NOUN - O
of ADP - O
HMG NNP - B-ORG
- HYPH - I-ORG
CoA NNP - I-ORG
- HYPH - I-ORG
Reductase NNP - I-ORG
, PUNCT - O
Lovastatin NNP - B-MEDICINE
, PUNCT - O
has VERB - O
been VERB - O
tried VERB - O
for ADP - O
its ADJ - O
anti ADJ - O
- ADJ - O
Leishmanial ADJ - O
effect NOUN - O
. PUNCT - O

Lovastatin RB - B-MEDICINE
, PUNCT - O
being VERB - O
an DET - O
inhibitor NOUN - O
of ADP - O
HMG NNP - B-ORG
- HYPH - I-ORG
CoA NNP - I-ORG
- HYPH - I-ORG
Reductase NNP - I-ORG
, PUNCT - O
inhibits VERB - O
infection NOUN - O
by ADP - O
cholesterol NOUN - O
depletion NOUN - O
, PUNCT - O
while ADP - O
chromium NOUN - O
chloride NOUN - O
complexes NOUN - O
, PUNCT - O
at ADP - O
their ADJ - O
higher ADJ - O
concentrations NOUN - O
, PUNCT - O
are VERB - O
reported VERB - O
to PART - O
exhibit VERB - O
cytotoxicity NOUN - O
. PUNCT - O

Lovastatin NNP - B-MEDICINE
and CCONJ - O
CrCl3.6H2O VBD - B-ORG
in ADP - O
combination NOUN - O
has VERB - O
appeared VERB - O
to PART - O
be VERB - O
ineffective ADJ - O
on ADP - O
promastigotes NOUN - O
but CCONJ - O
has VERB - O
induced VERB - O
cytotoxic ADJ - O
effect NOUN - O
on ADP - O
the DET - O
intracellular ADJ - O
amastigotes NOUN - O
through ADP - O
up ADJ - O
- PUNCT - O
regulation NOUN - O
of ADP - O
cellular ADJ - O
signalling NOUN - O
mechanisms NOUN - O
. PUNCT - O

3.6H2O CD - B-ORG
stimulates VERB - O
generation NOUN - O
of ADP - O
NO DET - O
, PUNCT - O
leading VERB - O
to ADP - O
reduction NOUN - O
of ADP - O
the DET - O
number NOUN - O
of ADP - O
intracellular ADJ - O
amastigote NOUN - O
, PUNCT - O
while ADP - O
Lovastatin NNP - B-MEDICINE
shows VERB - O
HPO NNP - B-ORG
- PUNCT - O
mediated VERB - O
killing NOUN - O
of ADP - O
the DET - O
same ADJ - O
, PUNCT - O
keeping VERB - O
the DET - O
host NOUN - O
cell NOUN - O
unaffected ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Conclusion NOUN - O
: PUNCT - O
Lovastatin NNP - B-MEDICINE
may VERB - O
play VERB - O
an DET - O
important ADJ - O
role NOUN - O
in ADP - O
antagonizing VERB - O
the DET - O
neurotoxicity NOUN - O
of ADP - O
Aβ PROPN - O
through ADP - O
a DET - O
mechanism NOUN - O
likely ADV - O
related VERB - O
to ADP - O
the DET - O
inhibition NOUN - O
of ADP - O
oxidative ADJ - O
stress NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Molecular PROPN - O
and CCONJ - O
Vibrational NNP - B-ORG
Dynamics NNP - I-ORG
in ADP - O
the DT - B-ORG
Cholesterol NNP - I-ORG
- HYPH - I-ORG
Lowering VBG - I-ORG
Agent NNP - I-ORG
Lovastatin NNP - B-MEDICINE
: PUNCT - O
Solid NNP - B-ORG
- HYPH - I-ORG
State NNP - I-ORG
NMR NNP - I-ORG
, PUNCT - O
Inelastic NNP - B-PERSON
Neutron NNP - I-PERSON
Scattering NNP - I-PERSON
, PUNCT - O
and CCONJ - O
Periodic NNP - B-ORG
DFT NNP - I-ORG
Study NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
upregulates VERB - O
microRNA-29b VERB - O
to PART - O
reduce VERB - O
oxidative ADJ - O
stress NOUN - O
in ADP - O
rats NOUN - O
with ADP - O
multiple ADJ - O
cardiovascular ADJ - O
risk NOUN - O
factors NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Magnetic PROPN - O
Resonance PROPN - O
Spectroscopy PROPN - O
Study PROPN - O
of ADP - O
Lovastatin NNP - B-MEDICINE
for ADP - O
Treating VERB - O
Bipolar PROPN - O
Mood PROPN - O
Disorder NOUN - O
: PUNCT - O
A DET - O
4-Week NUM - O
Randomized VBN - B-ORG
Double NNP - I-ORG
- HYPH - I-ORG
Blind NNP - I-ORG
, , - I-ORG
Placebo- PROPN - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
( PUNCT - O
LOV NNP - B-ORG
) PUNCT - O
, PUNCT - O
an DET - O
antihyperlipidimic ADJ - O
agent NOUN - O
, PUNCT - O
is VERB - O
characterized VERB - O
by ADP - O
low ADJ - O
solubility NOUN - O
/ SYM - O
poor ADJ - O
dissolution NOUN - O
and CCONJ - O
, PUNCT - O
thus ADV - O
, PUNCT - O
low ADJ - O
bioavailability NOUN - O
( PUNCT - O
< X - O
5 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
Inhibits VBZ - I-ORG
Cancer PROPN - O
Stem PROPN - O
Cells PROPN - O
and CCONJ - O
Sensitizes VBZ - B-PERSON
to ADP - O
Chemo- PROPN - O
and CCONJ - O
Photodynamic NNP - B-ORG
Therapy NNP - I-ORG
in ADP - O
Nasopharyngeal NNP - B-LOC
Carcinoma NNP - I-LOC
. PUNCT - O

-DOCSTART- -X- - O

LC PROPN - O
- PUNCT - O
MS NOUN - O
Method PROPN - O
for ADP - O
Studying VERB - O
the DET - O
Pharmacokinetics PROPN - O
and CCONJ - O
Bioequivalence PROPN - O
of ADP - O
Clonidine NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
in ADP - O
Healthy NNP - B-ORG
Male NNP - I-ORG
Volunteers NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Clonidine NNP - B-ORG
Hydrochloride NNP - I-ORG
Injection NNP - I-ORG
( PUNCT - O
Duraclon NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
clear ADJ - O
, PUNCT - O
colorless ADJ - O
, PUNCT - O
preservative NOUN - O
- PUNCT - O
free ADJ - O
, PUNCT - O
pyrogen NOUN - O
free ADJ - O
, PUNCT - O
aqueous ADJ - O
solution NOUN - O
of ADP - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

Clonidine NNP - B-ORG
Hydrochloride NNP - I-ORG
Injection NNP - I-ORG
, PUNCT - O
as ADP - O
formulated VERB - O
, PUNCT - O
does VERB - O
not ADV - O
require VERB - O
protection NOUN - O
from ADP - O
light NOUN - O
, PUNCT - O
oxygen NOUN - O
, PUNCT - O
or CCONJ - O
freezing VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Formulation NOUN - O
of ADP - O
a DET - O
stable ADJ - O
parenteral ADJ - O
product NOUN - O
; PUNCT - O
Clonidine NNP - B-ORG
Hydrochloride NNP - I-ORG
Injection NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Pharmacokinetic ADJ - O
parameters NOUN - O
were VERB - O
analyzed VERB - O
based VERB - O
on ADP - O
plasma NOUN - O
concentrations NOUN - O
of ADP - O
Glibenclamide NNP - B-GPE
from ADP - O
all ADJ - O
the DET - O
groups NOUN - O
by ADP - O
LC NNP - B-NORP
- HYPH - I-NORP
HRMS NNP - I-NORP
methods NOUN - O
using VERB - O
Glipizide NNP - B-MEDICINE
as ADP - O
an DET - O
internal ADJ - O
standard NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Here ADV - O
we PRON - O
show VERB - O
that ADP - O
treatment NOUN - O
with ADP - O
Acarbose NNP - B-PERSON
, PUNCT - O
but CCONJ - O
not ADV - O
Glipizide NNP - B-MEDICINE
, PUNCT - O
increases VERB - O
the DET - O
ratio NOUN - O
between ADP - O
primary ADJ - O
BAs NOUN - O
and CCONJ - O
secondary ADJ - O
BAs NOUN - O
and CCONJ - O
plasma NOUN - O
levels NOUN - O
of ADP - O
unconjugated ADJ - O
BAs NOUN - O
in ADP - O
treatment NOUN - O
- PUNCT - O
naive ADJ - O
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
( PUNCT - O
T2D PROPN - O
) PUNCT - O
patients NOUN - O
, PUNCT - O
which ADJ - O
may VERB - O
beneficially ADV - O
affect VERB - O
metabolism NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Diabetes NOUN - O
mellitus NOUN - O
is VERB - O
a DET - O
chronical ADJ - O
disease NOUN - O
nearly ADV - O
related VERB - O
to ADP - O
oxidative ADJ - O
stress NOUN - O
, PUNCT - O
whose ADJ - O
treatment NOUN - O
( PUNCT - O
in ADP - O
type NOUN - O
II NNP - B-ORG
variant NOUN - O
) PUNCT - O
consists VERB - O
in ADP - O
the DET - O
administration NOUN - O
of ADP - O
antidiabetic ADJ - O
compounds NOUN - O
( PUNCT - O
Andb NNP - B-ORG
) PUNCT - O
such ADJ - O
as ADP - O
Gliclazide NNP - B-ORG
( -LRB- - I-ORG
Gli NNP - I-ORG
) PUNCT - O
and CCONJ - O
Glipizide NNP - B-MEDICINE
( PUNCT - O
Glip PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
used VERB - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
diabetes NOUN - O
was VERB - O
selected VERB - O
as ADP - O
model NOUN - O
drug NOUN - O
, PUNCT - O
and CCONJ - O
was VERB - O
successfully ADV - O
loaded VERB - O
into ADP - O
commercial ADJ - O
polyvinyl NOUN - O
alcohol NOUN - O
( PUNCT - O
PVA NNP - B-ORG
) PUNCT - O
filaments NOUN - O
by ADP - O
HME NNP - B-ORG
method NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
treatment NOUN - O
decreased VERB - O
dilated ADJ - O
renal ADJ - O
tubule NOUN - O
number NOUN - O
, PUNCT - O
improved VERB - O
glomerulus NOUN - O
integrity NOUN - O
, PUNCT - O
and CCONJ - O
reduced VERB - O
inflammatory ADJ - O
infiltration NOUN - O
. PUNCT - O

Glipizide NNP - B-MEDICINE
blocks VERB - O
renal ADJ - O
interstitial ADJ - O
fibrosis NOUN - O
by ADP - O
inhibiting VERB - O
AKT NNP - B-ORG
signaling VERB - O
pathway NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
performed VERB - O
a DET - O
network NOUN - O
meta ADJ - O
- PUNCT - O
analysis NOUN - O
to PART - O
compare VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
12 CD - B-CARDINAL
single ADJ - O
- PUNCT - O
drug NOUN - O
regimens NOUN - O
( PUNCT - O
Glibenclamide NNP - B-ORG
, , - I-ORG
Glimepiride NNP - I-ORG
, , - I-ORG
Pioglitazone NNP - I-ORG
, , - I-ORG
Rosiglitazone NNP - I-ORG
, , - I-ORG
Repaglinide NNP - I-ORG
, PUNCT - O
Metformin NNP - B-GPE
, PUNCT - O
Sitaglitin NNP - B-GPE
, PUNCT - O
Exenatide NNP - B-GPE
, PUNCT - O
Liraglutide NNP - B-GPE
, PUNCT - O
Acarbose NNP - B-PERSON
, PUNCT - O
Benfluorex NNP - B-PERSON
, PUNCT - O
and CCONJ - O
Glipizide NNP - B-MEDICINE
) PUNCT - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
mellitus NOUN - O
( PUNCT - O
T2DM NNP - B-GPE
) PUNCT - O
. PUNCT - O

Liraglutide PROPN - O
was VERB - O
more ADV - O
effective ADJ - O
than ADP - O
Glimepiride NNP - B-ORG
, , - I-ORG
Pioglitazone NNP - I-ORG
, PUNCT - O
Sitaglitin NNP - B-GPE
, PUNCT - O
Exenatide NNP - B-GPE
, PUNCT - O
and CCONJ - O
Glipizide NNP - B-MEDICINE
at ADP - O
reducing VERB - O
glycated VERB - O
hemoglobin NOUN - O
( PUNCT - O
HbA1c NNP - B-PERSON
) PUNCT - O
levels NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
authors NOUN - O
present VERB - O
a DET - O
15-mo CD - B-DATE
- HYPH - I-DATE
old JJ - I-DATE
boy NOUN - O
with ADP - O
accidental ADJ - O
ingestion NOUN - O
of ADP - O
Glipizide NNP - B-MEDICINE
who NOUN - O
presented VERB - O
with ADP - O
encephalopathy ADJ - O
, PUNCT - O
seizure NOUN - O
and CCONJ - O
severe ADJ - O
hypoglycemia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Type NN - B-ORG
II NNP - I-ORG
diabetes NOUN - O
mellitus NOUN - O
is VERB - O
usually ADV - O
treated VERB - O
with ADP - O
Glipizide NNP - B-MEDICINE
. PUNCT - O

Glipizide NNP - B-MEDICINE
belongs VERB - O
to ADP - O
sulfonylurea NOUN - O
group NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Simultaneous PROPN - O
Determination PROPN - O
of ADP - O
Metformin PROPN - O
, PUNCT - O
Glipizide NNP - B-MEDICINE
, PUNCT - O
Repaglinide PROPN - O
, PUNCT - O
and CCONJ - O
Glimepiride PROPN - O
or CCONJ - O
Metformin NNP - B-PERSON
and CCONJ - O
Pioglitazone PROPN - O
by ADP - O
a DET - O
Validated PROPN - O
LC PROPN - O
Method PROPN - O
: PUNCT - O
Application NOUN - O
in ADP - O
the DT - B-GPE
Presence NNP - I-GPE
of IN - I-GPE
Metformin NNP - I-GPE
Impurity NNP - I-GPE
( PUNCT - O
1-Cyanoguanidine NUM - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
( PUNCT - O
0.6 CD - B-CARDINAL
or CCONJ - O
2 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
) PUNCT - O
was VERB - O
not ADV - O
able ADJ - O
to PART - O
reduce VERB - O
the DET - O
glucose NOUN - O
level NOUN - O
in ADP - O
wolframin NOUN - O
- PUNCT - O
deficient ADJ - O
animals NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
was VERB - O
found VERB - O
to PART - O
be VERB - O
a DET - O
low ADJ - O
- PUNCT - O
solubility NOUN - O
compound NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
dissolution NOUN - O
improved VERB - O
significantly ADV - O
( PUNCT - O
p VERB - O
  SPACE - O
< X - O
  SPACE - O
0.001 NUM - O
) PUNCT - O
from ADP - O
the DET - O
solid ADJ - O
SNEDDS NOUN - O
( PUNCT - O
∼100 NN - B-PERCENT
% NN - I-PERCENT
in ADP - O
15 CD - B-CARDINAL
  SPACE - O
min NOUN - O
) PUNCT - O
as ADP - O
compared VERB - O
to ADP - O
the DET - O
pure ADJ - O
drug NOUN - O
( PUNCT - O
18.37 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
and CCONJ - O
commercial ADJ - O
product NOUN - O
( PUNCT - O
65.82 CD - B-CARDINAL
) PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
, PUNCT - O
an DET - O
antidiabetic ADJ - O
drug NOUN - O
, PUNCT - O
suppresses VERB - O
tumor NOUN - O
growth NOUN - O
and CCONJ - O
metastasis NOUN - O
by ADP - O
inhibiting VERB - O
angiogenesis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
is VERB - O
a DET - O
frequently ADV - O
prescribed VERB - O
second JJ - B-ORDINAL
generation NOUN - O
sulfonylurea NOUN - O
which ADJ - O
lowers VERB - O
the DET - O
blood NOUN - O
glucose NOUN - O
in ADP - O
type NOUN - O
- PUNCT - O
two CD - B-CARDINAL
diabetics NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rhizopus NN - B-MEDICINE
stolonifer NOUN - O
is VERB - O
an DET - O
opportunistic ADJ - O
fungus NOUN - O
that ADJ - O
causes VERB - O
respiratory ADJ - O
infections NOUN - O
, PUNCT - O
sinusitis NOUN - O
, PUNCT - O
and CCONJ - O
otomycosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Inhibitory NNP - I-ORG
Effect NNP - I-ORG
of IN - I-ORG
Essential NNP - I-ORG
Oils NNP - I-ORG
on IN - I-ORG
Rhizopus NNP - I-MEDICINE
stolonifer NOUN - O
, PUNCT - O
Trichophyton NNP - B-NORP
mentagrophytes VERB - O
, PUNCT - O
and CCONJ - O
Microsporum PROPN - O
gypseum NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Antifungal ADJ - O
effects NOUN - O
of ADP - O
thymol NOUN - O
and CCONJ - O
salicylic ADJ - O
acid NOUN - O
on ADP - O
cell NOUN - O
membrane NOUN - O
and CCONJ - O
mitochondria NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O
and CCONJ - O
their ADJ - O
application NOUN - O
in ADP - O
postharvest NOUN - O
preservation NOUN - O
of ADP - O
tomatoes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

With ADP - O
the DET - O
help NOUN - O
of ADP - O
" PUNCT - O
interface ADJ - O
activation NOUN - O
" PUNCT - O
by ADP - O
adding VERB - O
sucrose ADJ - O
esters-11 NOUN - O
as ADP - O
surfactant ADJ - O
, PUNCT - O
lipase NOUN - O
from ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
was VERB - O
successfully ADV - O
immobilized VERB - O
onto ADP - O
the DET - O
carrier NOUN - O
with ADP - O
great ADJ - O
enhancement NOUN - O
of ADP - O
activity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
the DET - O
present ADJ - O
study NOUN - O
, PUNCT - O
the DET - O
antifungal ADJ - O
activity NOUN - O
of ADP - O
individual ADJ - O
and CCONJ - O
combined VERB - O
monoterpenes NOUN - O
against ADP - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O
and CCONJ - O
Absidia NNP - B-ORG
coerulea NOUN - O
was VERB - O
evaluated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
efficient ADJ - O
biotransformation NOUN - O
of ADP - O
progesterone NOUN - O
into ADP - O
11α NNS - B-DATE
- PUNCT - O
hydroxyprogesterone NOUN - O
by ADP - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
var NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
antifungal ADJ - O
activity NOUN - O
of ADP - O
the DET - O
essential ADJ - O
oils NOUN - O
( PUNCT - O
EOs NOUN - O
) PUNCT - O
of ADP - O
Eucalyptus NNP - B-ORG
staigeriana NOUN - O
, PUNCT - O
Lippia NNP - B-GPE
sidoides NOUN - O
and CCONJ - O
Pimenta NNP - B-GPE
pseudocaryophyllus NOUN - O
was VERB - O
tested VERB - O
in ADP - O
vitro NOUN - O
against ADP - O
plant NOUN - O
pathogen NOUN - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rhizopus NN - B-MEDICINE
delemar NOUN - O
causes VERB - O
devastating VERB - O
mucormycosis NOUN - O
in ADP - O
immunodeficient ADJ - O
individuals NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mycologically ADV - O
proven VERB - O
invasive ADJ - O
fungal ADJ - O
infections NOUN - O
were VERB - O
defined VERB - O
as ADP - O
there ADV - O
were VERB - O
the DET - O
histologic ADJ - O
evidence NOUN - O
of ADP - O
tissue NOUN - O
invasion NOUN - O
of ADP - O
hyphae NOUN - O
and CCONJ - O
the DET - O
recovery NOUN - O
of ADP - O
Aspergillus NNP - B-ORG
species NOUN - O
or CCONJ - O
agents NOUN - O
of ADP - O
mucormycosis NOUN - O
( PUNCT - O
Rhizopus NNP - B-MEDICINE
spp NOUN - O
. PUNCT - O

Anti JJ - B-PERSON
- JJ - I-PERSON
Aspergillus JJ - I-PERSON
mouse NOUN - O
monoclonal ADJ - O
antibody NOUN - O
( PUNCT - O
1:50 CD - B-TIME
; PUNCT - O
clone ADJ - O
WF PROPN - O
- PUNCT - O
AF-1 PROPN - O
; PUNCT - O
LSBio NNP - B-ORG
, PUNCT - O
WA NNP - B-ORG
, PUNCT - O
USA NNP - B-GPE
) PUNCT - O
and CCONJ - O
anti ADJ - O
- ADJ - O
Rhizopus JJ - B-MEDICINE
arrhizus ADJ - O
mouse NOUN - O
monoclonal ADJ - O
antibody NOUN - O
( PUNCT - O
1:100 CD - B-CARDINAL
; PUNCT - O
clone ADJ - O
WSSA NNP - B-ORG
- PUNCT - O
RA-1 PROPN - O
; PUNCT - O

-DOCSTART- -X- - O

Mucormycosis NN - B-ORG
is VERB - O
a DET - O
life NOUN - O
- PUNCT - O
threatening VERB - O
respiratory ADJ - O
fungal ADJ - O
infection NOUN - O
predominantly ADV - O
caused VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
species NOUN - O
. PUNCT - O

Here ADV - O
we PRON - O
show VERB - O
how ADV - O
, PUNCT - O
as ADP - O
opposed VERB - O
to ADP - O
other ADJ - O
filamentous ADJ - O
fungi NOUN - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
spp NOUN - O
. PUNCT - O

Mechanistically ADV - O
, PUNCT - O
lack NOUN - O
of ADP - O
intracellular ADJ - O
swelling NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
conidia NOUN - O
results NOUN - O
in ADP - O
surface NOUN - O
retention NOUN - O
of ADP - O
melanin NOUN - O
, PUNCT - O
which ADJ - O
induces VERB - O
phagosome ADJ - O
maturation NOUN - O
arrest VERB - O
through ADP - O
inhibition NOUN - O
of ADP - O
LC3-associated PROPN - O
phagocytosis NOUN - O
. PUNCT - O

Intracellular ADJ - O
inhibition NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
is VERB - O
an DET - O
important ADJ - O
effector NOUN - O
mechanism NOUN - O
, PUNCT - O
as ADP - O
infection NOUN - O
of ADP - O
immunocompetent ADJ - O
mice NOUN - O
with ADP - O
swollen ADJ - O
conidia NOUN - O
, PUNCT - O
which ADJ - O
evade VERB - O
phagocytosis NOUN - O
, PUNCT - O
results NOUN - O
in ADP - O
acute ADJ - O
lethality NOUN - O
. PUNCT - O

Host NOUN - O
and CCONJ - O
pathogen NOUN - O
transcriptomics NOUN - O
, PUNCT - O
iron NOUN - O
supplementation NOUN - O
studies NOUN - O
, PUNCT - O
and CCONJ - O
genetic ADJ - O
manipulation NOUN - O
of ADP - O
iron NOUN - O
assimilation NOUN - O
of ADP - O
fungal ADJ - O
pathways NOUN - O
demonstrate VERB - O
that ADP - O
iron NOUN - O
restriction NOUN - O
inside ADP - O
macrophages NOUN - O
regulates VERB - O
immunity NOUN - O
against ADP - O
Rhizopus NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Iron NOUN - O
restriction NOUN - O
inside ADP - O
macrophages NOUN - O
regulates VERB - O
pulmonary ADJ - O
host NOUN - O
defense NOUN - O
against ADP - O
Rhizopus NNP - B-MEDICINE
species NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Among ADP - O
them PRON - O
, PUNCT - O
Lactobacillus NNP - B-ORG
, , - I-ORG
Aspergillus NNP - I-ORG
, , - I-ORG
Pichia NNP - I-ORG
, , - I-ORG
Saccharomyces PROPN - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
were VERB - O
the DET - O
main ADJ - O
contributors NOUN - O
of ADP - O
proteins NOUN - O
by ADP - O
metaproteomics NOUN - O
analysis NOUN - O
. PUNCT - O

Whereas ADV - O
, PUNCT - O
only ADV - O
Lactobacillus NNP - B-ORG
, PUNCT - O
Pichia NNP - B-PERSON
, PUNCT - O
Rhizopus NNP - B-MEDICINE
appeared VERB - O
as ADP - O
key ADJ - O
actors NOUN - O
for ADP - O
saccharification NOUN - O
by ADP - O
secreting VERB - O
three CD - B-CARDINAL
glycosidases NOUN - O
and CCONJ - O
two CD - B-CARDINAL
glycosyltransferases NOUN - O
, PUNCT - O
and CCONJ - O
it PRON - O
indicated VERB - O
they PRON - O
were VERB - O
the DET - O
key ADJ - O
saccharifying NOUN - O
microbiota NOUN - O
in ADP - O
Jiuqu NNP - B-GPE
. PUNCT - O

Especially ADV - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
secreted VERB - O
the DET - O
most ADV - O
abundant ADJ - O
glucoamylase NOUN - O
. PUNCT - O

Rhizopus NN - B-MEDICINE
microsporus NOUN - O
, PUNCT - O
the DET - O
main ADJ - O
producer NOUN - O
of ADP - O
glucoamylase NOUN - O
, PUNCT - O
was VERB - O
positively ADV - O
correlated VERB - O
with ADP - O
volumetric ADJ - O
weight NOUN - O
of ADP - O
Jiuqu NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Post ADJ - O
- ADJ - O
exposure ADJ - O
prophylaxis NOUN - O
with ADP - O
isavuconazole NOUN - O
after ADP - O
occupational ADJ - O
exposure NOUN - O
to ADP - O
Rhizopus NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Pyogranulomatous ADJ - O
obliterative ADJ - O
laryngotracheitis NOUN - O
by ADP - O
Rhizopus NNP - B-MEDICINE
arrhizus PROPN - O
( PUNCT - O
syn NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rhizopus NN - B-MEDICINE
microsporus NOUN - O
is VERB - O
one NUM - O
of ADP - O
the DET - O
main ADJ - O
causative ADJ - O
agents NOUN - O
of ADP - O
mucormycosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mucormycosis NN - B-ORG
outbreak NOUN - O
due ADP - O
to ADP - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
after ADP - O
arthroscopic ADJ - O
anterior ADJ - O
cruciate NOUN - O
ligament NOUN - O
reconstruction NOUN - O
surgery NOUN - O
evaluated VERB - O
by ADP - O
RAPD NNP - B-ORG
and CCONJ - O
MALDI NNP - B-ORG
- HYPH - I-ORG
TOF NNP - I-ORG
Mass NNP - I-ORG
spectrometry NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
the DET - O
antifungal ADJ - O
potential NOUN - O
of ADP - O
a DET - O
phenolic NOUN - O
extract NOUN - O
obtained VERB - O
from ADP - O
rice NOUN - O
bran NOUN - O
fermented VERB - O
with ADP - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
CECT PROPN - O
7560 NUM - O
and CCONJ - O
its ADJ - O
application NOUN - O
in ADP - O
the DET - O
elaboration NOUN - O
of ADP - O
bread NOUN - O
was VERB - O
assessed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Fresh ADJ - O
tofu NOUN - O
was VERB - O
fermented VERB - O
by ADP - O
Actinomucor NNP - B-ORG
elegans NOUN - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
arrhizus NOUN - O
, PUNCT - O
Mucor NNP - B-ORG
racemosus NOUN - O
, PUNCT - O
and CCONJ - O
Rhizopus NN - B-MEDICINE
chinensis NOUN - O
, PUNCT - O
either CCONJ - O
alone ADV - O
or CCONJ - O
in ADP - O
various ADJ - O
combinations NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Oral ADJ - O
mucormycosis NOUN - O
due ADP - O
to ADP - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
manifested VERB - O
as ADP - O
localized VERB - O
left ADJ - O
buccal ADJ - O
mucositis NOUN - O
with ADP - O
a DET - O
1-cm CD - B-NORP
black ADJ - O
focus NOUN - O
before ADP - O
neutrophil NOUN - O
recovery NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

VATS NOUN - O
was VERB - O
performed VERB - O
and CCONJ - O
cultured VERB - O
lung NOUN - O
tissue NOUN - O
grew VERB - O
Rhizopus NNP - B-MEDICINE
species NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
effect NOUN - O
of ADP - O
β ADJ - O
- PUNCT - O
aminobutyric NOUN - O
acid NOUN - O
( PUNCT - O
BABA PROPN - O
) PUNCT - O
on ADP - O
Rhizopus NNP - B-MEDICINE
rot PROPN - O
produced VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
stolonifer VERB - O
in ADP - O
harvested VERB - O
peaches NOUN - O
and CCONJ - O
the DET - O
possible ADJ - O
action NOUN - O
modes NOUN - O
were VERB - O
investigated VERB - O
. PUNCT - O

Thus ADV - O
, PUNCT - O
our ADJ - O
results NOUN - O
demonstrated VERB - O
that ADP - O
BABA PROPN - O
was VERB - O
effective ADJ - O
on ADP - O
controlling VERB - O
Rhizopus NNP - B-MEDICINE
rot VERB - O
by ADP - O
inducing VERB - O
disease NOUN - O
resistance NOUN - O
, PUNCT - O
which ADJ - O
includes VERB - O
the DET - O
increase NOUN - O
in ADP - O
gene NOUN - O
transcription NOUN - O
and CCONJ - O
activity NOUN - O
of ADP - O
defense NOUN - O
- PUNCT - O
related VERB - O
enzymes NOUN - O
, PUNCT - O
the DET - O
enhancement NOUN - O
of ADP - O
cell NOUN - O
wall NOUN - O
strength NOUN - O
, PUNCT - O
and CCONJ - O
the DET - O
maintenance NOUN - O
of ADP - O
high ADJ - O
energy NOUN - O
status NOUN - O
in ADP - O
Prunus NNP - B-GPE
persica NN - I-GPE
fruit NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pathways NOUN - O
of ADP - O
pathogenicity NOUN - O
: PUNCT - O
The DET - O
transcriptional ADJ - O
stages NOUN - O
of ADP - O
germination NOUN - O
in ADP - O
the DET - O
fatal ADJ - O
fungal ADJ - O
pathogen NOUN - O
Rhizopus NN - B-MEDICINE
delemar PROPN - O

-DOCSTART- -X- - O

We PRON - O
sought VERB - O
to PART - O
identify VERB - O
the DET - O
nasal NOUN - O
and CCONJ - O
lung NOUN - O
epithelial ADJ - O
cell NOUN - O
receptors NOUN - O
interacting VERB - O
with ADP - O
Rhizopus NNP - B-MEDICINE
during ADP - O
tissue NOUN - O
invasion NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
ability NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
to PART - O
produce VERB - O
fumaric ADJ - O
acid NOUN - O
in ADP - O
the DET - O
presence NOUN - O
of ADP - O
glycerol NOUN - O
and/or CCONJ - O
various ADJ - O
monosaccharides NOUN - O
as ADP - O
carbon NOUN - O
sources NOUN - O
was VERB - O
examined VERB - O
for ADP - O
seventeen CD - B-CARDINAL
different ADJ - O
strains NOUN - O
of ADP - O
this DET - O
fungi NOUN - O
. PUNCT - O

The DET - O
production NOUN - O
of ADP - O
fumaric ADJ - O
acid NOUN - O
by ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
was VERB - O
also ADV - O
increased VERB - O
in ADP - O
the DET - O
dual ADJ - O
presence NOUN - O
of ADP - O
glycerol NOUN - O
and CCONJ - O
monosaccharides NOUN - O
like ADP - O
fructose NOUN - O
, PUNCT - O
galactose ADJ - O
, PUNCT - O
and CCONJ - O
mannose NOUN - O
. PUNCT - O

Understanding VERB - O
how ADV - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
utilize VERB - O
various ADJ - O
carbon NOUN - O
sources NOUN - O
may VERB - O
provide VERB - O
alternative ADJ - O
avenues NOUN - O
of ADP - O
fumaric ADJ - O
acid NOUN - O
fermentation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
co NOUN - O
- NOUN - O
utilization NOUN - O
strategy NOUN - O
to PART - O
consume VERB - O
glycerol NOUN - O
and CCONJ - O
monosaccharides NOUN - O
by ADP - O
Rhizopus NNP - B-MEDICINE
strains NOUN - O
for ADP - O
fumaric ADJ - O
acid NOUN - O
production NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

NGS NNP - B-ORG
plasma VERB - O
testing NOUN - O
identified VERB - O
a DET - O
pathogen NOUN - O
which ADJ - O
was VERB - O
cultured VERB - O
from ADP - O
infected ADJ - O
tissue NOUN - O
or CCONJ - O
blood NOUN - O
in ADP - O
4 CD - B-CARDINAL
of ADP - O
6 NUM - O
proven VERB - O
cases NOUN - O
; PUNCT - O
one CD - B-CARDINAL
patient NOUN - O
with ADP - O
localized ADJ - O
cutaneous ADJ - O
Rhizopus NNP - B-MEDICINE
had VERB - O
negative ADJ - O
NGS NNP - B-ORG
results NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

2 NUM - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
sp PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Silkworm NOUN - O
infection NOUN - O
models NOUN - O
have VERB - O
been VERB - O
established VERB - O
for ADP - O
Candida NNP - B-GPE
albicans NOUN - O
, PUNCT - O
Candida PROPN - O
tropicalis NOUN - O
, PUNCT - O
Candida PROPN - O
glabrata NOUN - O
and CCONJ - O
Cryptococcus NNP - B-ORG
neoformans NOUN - O
, PUNCT - O
which ADJ - O
are VERB - O
yeast NOUN - O
type NOUN - O
fungi NOUN - O
, PUNCT - O
and CCONJ - O
Aspergillus NNP - B-ORG
fumigatus NOUN - O
, PUNCT - O
Arthroderma NNP - B-ORG
vanbreuseghemii NOUN - O
, PUNCT - O
Arthroderma PROPN - O
benhamiae VERB - O
, PUNCT - O
Microsporum NNP - B-PERSON
canis NOUN - O
, PUNCT - O
Trichophyton NNP - B-GPE
rubrum NOUN - O
, PUNCT - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
, PUNCT - O
which ADJ - O
are VERB - O
filamentous ADJ - O
fungi NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
vitro ADJ - O
antimold ADJ - O
activity NOUN - O
of ADP - O
annatto NOUN - O
natural ADJ - O
dye NOUN - O
against ADP - O
Aspergillus NNP - B-ORG
niger ADV - O
, PUNCT - O
Neurospora NNP - B-GPE
sitophila VERB - O
, PUNCT - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
stolonifer PROPN - O
was VERB - O
evaluated VERB - O
with ADP - O
agar ADJ - O
well ADJ - O
diffusion NOUN - O
and CCONJ - O
agar NOUN - O
dilution NOUN - O
assays NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

CotH PROPN - O
was VERB - O
detected VERB - O
as ADV - O
early ADV - O
as ADP - O
24 CD - B-CARDINAL
h DET - O
postinfection NOUN - O
in ADP - O
plasma NOUN - O
, PUNCT - O
urine NOUN - O
, PUNCT - O
and CCONJ - O
bronchoalveolar ADJ - O
lavage NOUN - O
( PUNCT - O
BAL PROPN - O
) PUNCT - O
samples NOUN - O
from ADP - O
mice NOUN - O
infected VERB - O
intratracheally ADV - O
with ADP - O
Rhizopus NNP - B-MEDICINE
delemar NOUN - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
, PUNCT - O
Mucor NNP - B-ORG
circinelloides VERB - O
, PUNCT - O
Lichtheimia NNP - B-PRODUCT
corymbifera NOUN - O
, PUNCT - O
or CCONJ - O
Cunninghamella NNP - B-ORG
bertholletiae VERB - O
but CCONJ - O
not ADV - O
from ADP - O
samples NOUN - O
taken VERB - O
from ADP - O
uninfected ADJ - O
mice NOUN - O
or CCONJ - O
mice NOUN - O
infected VERB - O
with ADP - O
Aspergillus NNP - B-ORG
fumigatus NOUN - O
Detection PROPN - O
of ADP - O
CotH PROPN - O
from ADP - O
urine NOUN - O
samples NOUN - O
was VERB - O
more ADV - O
reliable ADJ - O
than ADP - O
from ADP - O
plasma NOUN - O
or CCONJ - O
BAL PROPN - O
fluid ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
previous ADJ - O
work NOUN - O
, PUNCT - O
we PRON - O
proposed VERB - O
a DET - O
novel NOUN - O
modified VERB - O
one CD - B-CARDINAL
- PUNCT - O
step NOUN - O
fermentation NOUN - O
fed VERB - O
- PUNCT - O
batch NOUN - O
strategy NOUN - O
to PART - O
efficiently ADV - O
generate VERB - O
L NOUN - O
- PUNCT - O
lactic ADJ - O
acid NOUN - O
( PUNCT - O
L PROPN - O
- PUNCT - O
LA PROPN - O
) PUNCT - O
using VERB - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
optimized VERB - O
fed VERB - O
- PUNCT - O
batch NOUN - O
culture NOUN - O
strategy NOUN - O
integrated VERB - O
with ADP - O
a DET - O
one CD - B-CARDINAL
- PUNCT - O
step NOUN - O
fermentation NOUN - O
improves VERB - O
L NN - B-ORG
- PUNCT - O
lactic ADJ - O
acid NOUN - O
production NOUN - O
by ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
extracellular ADJ - O
polysaccharide NOUN - O
( PUNCT - O
EPS1 PROPN - O
- PUNCT - O
1 NUM - O
) PUNCT - O
extracted VERB - O
from ADP - O
the DET - O
fermentation NOUN - O
broth NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
nigricans NOUN - O
has VERB - O
been VERB - O
proved VERB - O
to PART - O
enhance VERB - O
the DET - O
immunity NOUN - O
of ADP - O
immunosuppressed VERB - O
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Improving VERB - O
the DET - O
thermostability NOUN - O
of ADP - O
α NOUN - O
- PUNCT - O
amylase NOUN - O
from ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
by ADP - O
rational ADJ - O
design]. NOUN - O

-DOCSTART- -X- - O

Antifungal ADJ - O
effect NOUN - O
of ADP - O
phenolic NOUN - O
extract NOUN - O
of ADP - O
fermented ADJ - O
rice NOUN - O
bran NOUN - O
with ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
and CCONJ - O
its ADJ - O
potential ADJ - O
use NOUN - O
in ADP - O
loaf ADJ - O
bread NOUN - O
shelf NOUN - O
life NOUN - O
extension NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rhizopus NN - B-MEDICINE
oryzae VERB - O
is VERB - O
the DET - O
most ADV - O
prevalent ADJ - O
causative ADJ - O
agent NOUN - O
of ADP - O
mucormycosis NOUN - O
, PUNCT - O
an DET - O
increasingly ADV - O
reported VERB - O
opportunistic ADJ - O
fungal ADJ - O
infection NOUN - O
. PUNCT - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
work NOUN - O
was VERB - O
to PART - O
establish VERB - O
if ADP - O
the DET - O
Rhizopus NNP - B-MEDICINE
oryzaeCYP51 ADJ - O
genes NOUN - O
are VERB - O
uniquely ADV - O
responsible ADJ - O
for ADP - O
intrinsic ADJ - O
voriconazole NOUN - O
and CCONJ - O
fluconazole ADJ - O
resistance NOUN - O
in ADP - O
these DET - O
fungal ADJ - O
pathogens NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
isolate NOUN - O
was VERB - O
identified VERB - O
as ADP - O
Rhizopus NNP - B-MEDICINE
microspores NOUN - O
by ADP - O
ITS ADJ - O
sequencing NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Cutaneous ADJ - O
mucormycosis NOUN - O
caused VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
in ADP - O
an DET - O
immunocompetent ADJ - O
patient NOUN - O
: PUNCT - O
A DET - O
case NOUN - O
report NOUN - O
and CCONJ - O
review NOUN - O
of ADP - O
literature NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mucorales ADJ - O
species NOUN - O
were VERB - O
Rhizopus NNP - B-MEDICINE
arrhizus VERB - O
in ADP - O
16 CD - B-CARDINAL
( PUNCT - O
84 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
cases NOUN - O
, PUNCT - O
R. NNP - B-PERSON
  _SP - I-PERSON
arrhizus NOUN - O
/ SYM - O

Amylomyces PROPN - O
rouxii VERB - O
in ADP - O
2 CD - B-CARDINAL
( PUNCT - O
10.5 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
cases NOUN - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
stolonifer VERB - O
in ADP - O
one CD - B-CARDINAL
case NOUN - O
( PUNCT - O
5.5 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
silkworm NOUN - O
infection NOUN - O
assay NOUN - O
with ADP - O
the DET - O
pathogenic ADJ - O
fungus NOUN - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
was VERB - O
established VERB - O
. PUNCT - O

Microbial ADJ - O
culture NOUN - O
broths NOUN - O
were VERB - O
screened VERB - O
for ADP - O
anti ADJ - O
- ADJ - O
Rhizopus JJ - B-MEDICINE
antibiotics NOUN - O
using VERB - O
this DET - O
assay NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Anti ADJ - O
- ADJ - O
Rhizopus JJ - B-MEDICINE
activity NOUN - O
of ADP - O
tanzawaic NOUN - O
acids NOUN - O
produced VERB - O
by ADP - O
the DET - O
hot ADJ - O
spring NOUN - O
- PUNCT - O
derived VERB - O
fungus NOUN - O
Penicillium PROPN - O
sp VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Polysaccharide PROPN - O
( PUNCT - O
EPS1 PROPN - O
- PUNCT - O
1 NUM - O
) PUNCT - O
extracted VERB - O
from ADP - O
fermentation NOUN - O
liquor NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
nigricans NOUN - O
possesses VERB - O
antitumor NOUN - O
and CCONJ - O
immune ADV - O
- PUNCT - O
enhancing VERB - O
activities NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Polysaccharide VERB - O
from ADP - O
Rhizopus NNP - B-MEDICINE
nigricans NOUN - O
inhibits VERB - O
the DET - O
invasion NOUN - O
and CCONJ - O
metastasis NOUN - O
of ADP - O
colorectal ADJ - O
cancer NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
lowest ADJ - O
modal ADJ - O
isavuconazole NOUN - O
MIC NNP - B-ORG
values NOUN - O
were VERB - O
seen VERB - O
for ADP - O
Rhizopus NNP - B-MEDICINE
spp NOUN - O
. PUNCT - O

We PRON - O
confirm VERB - O
the DET - O
potentially ADV - O
useful ADJ - O
activity NOUN - O
of ADP - O
isavuconazole NOUN - O
against ADP - O
species NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
as ADP - O
determined VERB - O
by ADP - O
CLSI NNP - B-ORG
methods NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Although ADP - O
glycerol NOUN - O
contains VERB - O
many ADJ - O
types NOUN - O
of ADP - O
impurities NOUN - O
, PUNCT - O
it PRON - O
can VERB - O
be VERB - O
used VERB - O
as ADP - O
a DET - O
C NOUN - O
- PUNCT - O
source NOUN - O
for ADP - O
lactic ADJ - O
acid NOUN - O
production NOUN - O
by ADP - O
fungi NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Bioconversion NOUN - O
of ADP - O
waste NOUN - O
cooking NOUN - O
oil NOUN - O
glycerol NOUN - O
from ADP - O
cabbage NOUN - O
extract NOUN - O
to ADP - O
lactic ADJ - O
acid NOUN - O
by ADP - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rhizopus NN - B-MEDICINE
microsporus NOUN - O
NBRC NNP - B-PERSON
32995 CD - I-PERSON
was VERB - O
found VERB - O
to PART - O
hydrolyze VERB - O
fructooligosaccharides NOUN - O
( PUNCT - O
FOS NNP - B-ORG
) PUNCT - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
sucrose NOUN - O
, PUNCT - O
almost ADV - O
completely ADV - O
into ADP - O
monosaccharides NOUN - O
through ADP - O
the DET - O
production NOUN - O
of ADP - O
sufficient ADJ - O
amounts NOUN - O
of ADP - O
organic ADJ - O
acids NOUN - O
, PUNCT - O
indicating VERB - O
that ADP - O
the DET - O
complete ADJ - O
hydrolysis NOUN - O
of ADP - O
FOS NNP - B-ORG
was VERB - O
caused VERB - O
by ADP - O
the DET - O
secretion NOUN - O
of ADP - O
β NOUN - O
- PUNCT - O
fructofuranosidase NOUN - O
from ADP - O
fungal ADJ - O
cells NOUN - O
. PUNCT - O

The DET - O
total ADJ - O
length NOUN - O
of ADP - O
the DET - O
sucA NOUN - O
gene NOUN - O
was VERB - O
1590 CD - B-DATE
bp NOUN - O
, PUNCT - O
and CCONJ - O
the DET - O
SucA NNP - B-ORG
protein NOUN - O
of ADP - O
R. NNP - B-NORP
microsporus NOUN - O
NBRC NNP - B-PERSON
32995 CD - I-PERSON
belonged VERB - O
to PART - O
clade VERB - O
VIa NOUN - O
, PUNCT - O
which ADJ - O
also ADV - O
contains VERB - O
Rhizopus NNP - B-MEDICINE
delemar NOUN - O
and CCONJ - O
is VERB - O
closely ADV - O
related VERB - O
to ADP - O
Saccharomycotina NNP - B-PERSON
, PUNCT - O
a DET - O
subdivision NOUN - O
of ADP - O
the DET - O
Ascomycota PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Identification NOUN - O
of ADP - O
sucA NOUN - O
, PUNCT - O
Encoding VERB - O
β PUNCT - O
- PUNCT - O
Fructofuranosidase PROPN - O
, PUNCT - O
in ADP - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Improved VERB - O
continuous ADJ - O
fumaric ADJ - O
acid NOUN - O
production NOUN - O
with ADP - O
immobilised ADJ - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
by ADP - O
implementation NOUN - O
of ADP - O
a DET - O
revised VERB - O
nitrogen NOUN - O
control NOUN - O
strategy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Efficient PROPN - O
Heterologous PROPN - O
Production PROPN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
Lipase PROPN - O
via ADP - O
Optimization PROPN - O
of ADP - O
Multiple PROPN - O
Expression PROPN - O
- PUNCT - O
Related VERB - O
Helper PROPN - O
Proteins PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
we PRON - O
report VERB - O
the DET - O
isolation NOUN - O
, PUNCT - O
purification NOUN - O
and CCONJ - O
chemical NOUN - O
characterization NOUN - O
of ADP - O
CMHs NOUN - O
from ADP - O
Rhizopus NNP - B-MEDICINE
stolonifer PROPN - O
and CCONJ - O
R. NNP - B-NORP
microspores NOUN - O
. PUNCT - O

CMH VBZ - B-ORG
from ADP - O
both DET - O
Rhizopus NNP - B-MEDICINE
species NOUN - O
inhibited VERB - O
the DET - O
growth NOUN - O
of ADP - O
Bacillus PROPN - O
terrae NOUN - O
, PUNCT - O
Micrococcus NNP - B-PERSON
luteus NOUN - O
( PUNCT - O
M. NNP - B-PERSON
luteus PROPN - O
) PUNCT - O
and CCONJ - O
Pseudomonas NNP - B-GPE
stutzeri NOUN - O
( PUNCT - O
P. PROPN - O
stutzeri NOUN - O
) PUNCT - O
with ADP - O
a DET - O
MIC50 PROPN - O
of ADP - O
6.25 CD - B-CARDINAL
, PUNCT - O
6.25 CD - B-CARDINAL
and CCONJ - O
3.13 CD - B-CARDINAL
mg NN - B-ORG
/ SYM - I-ORG
mL NNP - I-ORG
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Rhizopus NN - B-MEDICINE
oligosporus NOUN - O
and CCONJ - O
Lactobacillus NNP - B-ORG
plantarum NOUN - O
were VERB - O
the DET - O
probiotic ADJ - O
FDA NNP - B-ORG
- PUNCT - O
approved VERB - O
food NOUN - O
- PUNCT - O
grade NOUN - O
cultures NOUN - O
used VERB - O
in ADP - O
this DET - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

( PUNCT - O
Rhizopus NNP - B-MEDICINE
spp NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
rhizosphere NOUN - O
, PUNCT - O
air NOUN - O
, PUNCT - O
and CCONJ - O
phylloplane NOUN - O
was VERB - O
dominated VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
stolonifer PROPN - O
( PUNCT - O
22.13 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
15.08 CD - B-CARDINAL
; SYM - O
24.01 CD - B-CARDINAL
) PUNCT - O
while ADP - O
Aspergillus RB - B-ORG
niger NOUN - O
( PUNCT - O
12.63 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
was VERB - O
the DET - O
dominant ADJ - O
flora NOUN - O
of ADP - O
non ADJ - O
- NOUN - O
rhizosphere ADJ - O
. PUNCT - O

Curvularia NNP - B-PERSON
lunata NOUN - O
while ADP - O
Rhizopus NNP - B-MEDICINE
stolonifer VERB - O
, PUNCT - O

In ADP - O
phyllosphere NOUN - O
, PUNCT - O
the DET - O
Chatuwa NNP - B-ORG
and CCONJ - O
Jaruwa NNP - B-LOC
, PUNCT - O
the DET - O
winter NN - B-DATE
generations NOUN - O
were VERB - O
mainly ADV - O
dominated VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
investigate VERB - O
the DET - O
transcriptional ADJ - O
regulation NOUN - O
of ADP - O
cellobiose NOUN - O
synthase NOUN - O
( PUNCT - O
CBS NNP - B-ORG
) PUNCT - O
in ADP - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Emerging PROPN - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
Infections PROPN - O
in ADP - O
India NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Eluates NOUN - O
from ADP - O
DNA NOUN - O
extraction NOUN - O
were VERB - O
tested VERB - O
by ADP - O
MUC NNP - B-ORG
PCR NNP - I-ORG
, PUNCT - O
which ADJ - O
detects VERB - O
known ADJ - O
pathogens NOUN - O
from ADP - O
seven CD - B-CARDINAL
Mucorales PROPN - O
genera NOUN - O
( PUNCT - O
Apophysomyces PROPN - O
, PUNCT - O
Cunninghamella NNP - B-ORG
, PUNCT - O
Lichtheimia NNP - B-NORP
[ PUNCT - O
previously ADV - O
Absidia NNP - B-ORG
] PUNCT - O
, PUNCT - O
Mucor NNP - B-ORG
, PUNCT - O
Rhizomucor NNP - B-ORG
, PUNCT - O
Rhizopus NNP - B-MEDICINE
and CCONJ - O
Saksenaea).ResultsThe ADP - O
proportions NOUN - O
of ADP - O
MUC NNP - B-PRODUCT
PCR NNP - I-PRODUCT
and CCONJ - O
ASP NNP - B-ORG
PCR PROPN - O
positive ADJ - O
BAL PROPN - O
specimens NOUN - O
were VERB - O
1.5 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
16 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
6.9 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
74 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
improve VERB - O
its ADJ - O
composition NOUN - O
, PUNCT - O
okara NOUN - O
was VERB - O
fermented VERB - O
using VERB - O
a DET - O
fungal ADJ - O
monoculture NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
oligosporus NOUN - O
( PUNCT - O
RO PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
a DET - O
coculture NOUN - O
of ADP - O
R. NNP - B-NORP
oligosporus NOUN - O
and CCONJ - O
yeast NOUN - O
Yarrowia NNP - B-GPE
lipolytica NOUN - O
( PUNCT - O
ROYL PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Solid ADJ - O
- PUNCT - O
state NOUN - O
fermentation NOUN - O
with ADP - O
Rhizopus NNP - B-MEDICINE
oligosporus NOUN - O
and CCONJ - O
Yarrowia NNP - B-GPE
lipolytica NOUN - O
improved VERB - O
nutritional ADJ - O
and CCONJ - O
flavour ADJ - O
properties NOUN - O
of ADP - O
okara NOUN - O

-DOCSTART- -X- - O

The DET - O
effect NOUN - O
of ADP - O
temperature NOUN - O
on ADP - O
the DET - O
mycelium NOUN - O
growth NOUN - O
kinetics NOUN - O
of ADP - O
four CD - B-CARDINAL
postharvest ADJ - O
fungal ADJ - O
isolates NOUN - O
( PUNCT - O
i.e. X - O
, PUNCT - O
Penicillium PROPN - O
expansum NOUN - O
, PUNCT - O
Alternaria NNP - B-PERSON
alternata NOUN - O
, PUNCT - O
Botrytis NNP - B-ORG
cinerea NOUN - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
stolonifer PROPN - O
) PUNCT - O
was VERB - O
assessed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

While ADP - O
10 CD - B-CARDINAL
diseases NOUN - O
are VERB - O
surveyed VERB - O
annually RB - B-DATE
, PUNCT - O
we PRON - O
focus VERB - O
this DET - O
article NOUN - O
on ADP - O
the DET - O
importance NOUN - O
, PUNCT - O
findings NOUN - O
, PUNCT - O
implications NOUN - O
, PUNCT - O
and CCONJ - O
impacts NOUN - O
of ADP - O
the DET - O
five CD - B-CARDINAL
most ADV - O
important ADJ - O
: PUNCT - O
downy NOUN - O
mildew NOUN - O
, PUNCT - O
Phomopsis NOUN - O
stem NOUN - O
canker NOUN - O
, PUNCT - O
rust NOUN - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
head NOUN - O
rot PROPN - O
, PUNCT - O
and CCONJ - O
Sclerotinia NNP - B-GPE
head NOUN - O
rot VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Here ADV - O
, PUNCT - O
sterol ADJ - O
patterns NOUN - O
of ADP - O
six CD - B-CARDINAL
clinically ADV - O
relevant ADJ - O
Mucorales NNP - B-PERSON
( PUNCT - O
Lichtheimia PROPN - O
corymbifera NOUN - O
, PUNCT - O
Lichtheimia NNP - B-NORP
ramosa NOUN - O
, PUNCT - O
Mucor NNP - B-ORG
circinelloides VERB - O
, PUNCT - O
Rhizomucor NNP - B-ORG
pusillus NOUN - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
arrhizus NOUN - O
, PUNCT - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
) PUNCT - O
were VERB - O
analysed VERB - O
in ADP - O
a DET - O
targeted VERB - O
metabolomics NOUN - O
fashion NOUN - O
after ADP - O
derivatization NOUN - O
by ADP - O
gas NOUN - O
chromatography NOUN - O
- PUNCT - O
mass NOUN - O
spectrometry NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
regional ADJ - O
standard NOUN - O
for ADP - O
tempeh NOUN - O
established VERB - O
by ADP - O
the DT - B-ORG
Codex NNP - I-ORG
Alimentarius NNP - I-ORG
defines VERB - O
the DET - O
use NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
oligosporus NOUN - O
, PUNCT - O
R. NNP - B-NORP
oryzae VERB - O
, PUNCT - O
and/or CCONJ - O
R. PROPN - O
stolonifer NOUN - O
as ADP - O
soybean NOUN - O
tempeh NOUN - O
starters NOUN - O
. PUNCT - O

However ADV - O
, PUNCT - O
comparative ADJ - O
studies NOUN - O
on ADP - O
the DET - O
functions NOUN - O
of ADP - O
tempeh NOUN - O
prepared VERB - O
with ADP - O
these DET - O
Rhizopus NNP - B-MEDICINE
species NOUN - O
are VERB - O
scarce ADJ - O
. PUNCT - O

In ADP - O
the DET - O
present ADJ - O
study NOUN - O
, PUNCT - O
we PRON - O
examined VERB - O
the DET - O
effects NOUN - O
of ADP - O
dietary ADJ - O
tempeh NOUN - O
prepared VERB - O
with ADP - O
these DET - O
three CD - B-CARDINAL
Rhizopus NNP - B-MEDICINE
species NOUN - O
using VERB - O
rats NOUN - O
fed VERB - O
with ADP - O
a DET - O
high ADJ - O
- PUNCT - O
fat NOUN - O
diet NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

During ADP - O
our ADJ - O
studies NOUN - O
with ADP - O
Piper PROPN - O
essential ADJ - O
oils NOUN - O
, PUNCT - O
we PRON - O
evaluated VERB - O
its ADJ - O
activity NOUN - O
against ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
, PUNCT - O
the DET - O
main ADJ - O
agent NOUN - O
of ADP - O
mucormycosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Piper NOUN - O
Essential ADJ - O
Oils PROPN - O
Inhibit PROPN - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
Growth PROPN - O
, PUNCT - O
Biofilm PROPN - O
Formation PROPN - O
, PUNCT - O
and CCONJ - O
Rhizopuspepsin NNP - B-ORG
Activity NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
quinoa NOUN - O
was VERB - O
fermented VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
oligosporus NOUN - O
( PUNCT - O
R. NNP - B-NORP
oligosporus NOUN - O
) PUNCT - O
up ADP - O
to PART - O
5 CD - B-CARDINAL
  SPACE - O
days NNS - B-DATE
and CCONJ - O
the DET - O
functional ADJ - O
compounds NOUN - O
( PUNCT - O
L NOUN - O
- PUNCT - O
carnitine NOUN - O
, PUNCT - O
GABA NNP - B-ORG
, PUNCT - O
vanillic ADJ - O
acid NOUN - O
and CCONJ - O
gallic ADJ - O
acid NOUN - O
) PUNCT - O
were VERB - O
analyzed VERB - O
by ADP - O
LC NNP - B-ORG
/ SYM - I-ORG
MS NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Characterization NOUN - O
of ADP - O
quinoa NOUN - O
( PUNCT - O
Chenopodium PROPN - O
quinoa NOUN - O
) PUNCT - O
fermented VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
oligosporus NOUN - O
and CCONJ - O
its ADJ - O
bioactive ADJ - O
properties NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tempeh PROPN - O
products NOUN - O
included VERB - O
soybean NOUN - O
fermented VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
, PUNCT - O
soybean NOUN - O
fermented VERB - O
through ADP - O
cocultivation NOUN - O
with ADP - O
Rhizopus NNP - B-MEDICINE
and CC - I-ORG
Lactobacillus PROPN - O
, PUNCT - O
and CCONJ - O
red ADJ - O
bean NOUN - O
fermented VERB - O
through ADP - O
cocultivation NOUN - O
with ADP - O
Rhizopus NNP - B-MEDICINE
and CCONJ - O
Lactobacillus PROPN - O
( PUNCT - O
RT PROPN - O
- PUNCT - O
C PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
review NOUN - O
we PRON - O
summarize VERB - O
recent ADJ - O
advances NOUN - O
in ADP - O
genetic ADJ - O
tools NOUN - O
to PART - O
study VERB - O
the DET - O
two CD - B-CARDINAL
most ADV - O
prevalent ADJ - O
and CCONJ - O
genetically ADV - O
amenable ADJ - O
Mucoralean NNP - B-NORP
fungi NOUN - O
, PUNCT - O
Mucor NNP - B-ORG
circinelloides VERB - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
delemar NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

However ADV - O
, PUNCT - O
only ADV - O
a DET - O
small ADJ - O
amount NOUN - O
of ADP - O
lactic ADJ - O
acid NOUN - O
is VERB - O
produced VERB - O
even ADV - O
though ADP - O
Rhizopus NN - B-MEDICINE
oryzae NOUN - O
can VERB - O
consume VERB - O
glucose NOUN - O
in ADP - O
rice NOUN - O
straw NOUN - O
- PUNCT - O
derived VERB - O
hydrolysates NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Influence NOUN - O
of ADP - O
rice NOUN - O
straw NOUN - O
- PUNCT - O
derived VERB - O
dissolved VERB - O
organic ADJ - O
matter NOUN - O
on ADP - O
lactic ADJ - O
acid NOUN - O
fermentation NOUN - O
by ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Optimization NOUN - O
of ADP - O
biodiesel NOUN - O
synthesis NOUN - O
by ADP - O
esterification NOUN - O
using VERB - O
a DET - O
fermented VERB - O
solid NOUN - O
produced VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
on ADP - O
sugarcane NOUN - O
bagasse NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rhizopus NN - B-MEDICINE
oryzae VERB - O
lipase NOUN - O
( PUNCT - O
ROL NNP - B-ORG
) PUNCT - O
is VERB - O
an DET - O
important ADJ - O
industrial ADJ - O
enzyme ADJ - O
limited VERB - O
in ADP - O
application NOUN - O
due ADP - O
to ADP - O
its ADJ - O
low ADJ - O
production NOUN - O
in ADP - O
native ADJ - O
strains NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rhizopus NN - B-MEDICINE
oligosporus NOUN - O
, PUNCT - O
a DET - O
fungus NOUN - O
in ADP - O
the DET - O
family NOUN - O
Mucoraceae NNP - B-ORG
, PUNCT - O
is VERB - O
widely ADV - O
used VERB - O
as ADP - O
a DET - O
starter NOUN - O
for ADP - O
homemade ADJ - O
tempeh NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Tempeh PROPN - O
Fermentation PROPN - O
with ADP - O
Lactobacillus PROPN - O
plantarum NOUN - O
and CCONJ - O
Rhizopus NN - B-MEDICINE
oligosporus NOUN - O
on ADP - O
Streptozotocin PROPN - O
- PUNCT - O
Induced PROPN - O
Type PROPN - O
II PROPN - O
Diabetes NOUN - O
Mellitus PROPN - O
in ADP - O
Rats PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
aimed VERB - O
to PART - O
investigate VERB - O
the DET - O
antifungal ADJ - O
mechanism NOUN - O
of ADP - O
carvacrol NOUN - O
and CCONJ - O
eugenol NOUN - O
to PART - O
inhibit VERB - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O
and CCONJ - O
the DET - O
control NOUN - O
of ADP - O
postharvest NOUN - O
soft ADJ - O
rot NOUN - O
decay NOUN - O
in ADP - O
peaches NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
metabolite NOUN - O
screening NOUN - O
was VERB - O
conducted VERB - O
by ADP - O
adding VERB - O
ZEN NNP - B-ORG
to ADP - O
liquid NOUN - O
fungi ADJ - O
cultures NOUN - O
of ADP - O
known ADJ - O
ZEN PROPN - O
conjugating VERB - O
Aspergillus NNP - B-PERSON
and CCONJ - O
Rhizopus NNP - B-MEDICINE
strains NOUN - O
. PUNCT - O

In ADP - O
addition NOUN - O
, PUNCT - O
a DET - O
consecutive ADJ - O
biosynthesis NOUN - O
was VERB - O
developed VERB - O
by ADP - O
using VERB - O
Fusarium NNP - B-ORG
graminearum NOUN - O
for ADP - O
ZEN PROPN - O
biosynthesis NOUN - O
with ADP - O
subsequent ADJ - O
conjugation NOUN - O
of ADP - O
the DET - O
toxin NOUN - O
by ADP - O
utilizing VERB - O
Aspergillus NNP - B-PERSON
and CCONJ - O
Rhizopus NNP - B-MEDICINE
species NOUN - O
. PUNCT - O

( PUNCT - O
yield NOUN - O
: PUNCT - O
67 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
and CCONJ - O
ZEN-16-glucoside NNP - B-PERSON
( PUNCT - O
yield NOUN - O
: PUNCT - O
39 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
are VERB - O
formed VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
and CCONJ - O
Rhizopusoligosporus NNP - B-ORG
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

g ADP - O
total ADJ - O
weight NOUN - O
basis NOUN - O
) PUNCT - O
showed VERB - O
antimicrobial ADJ - O
effects NOUN - O
against ADP - O
Bacillus PROPN - O
cereus NOUN - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
sp PROPN - O
. PUNCT - O

Interestingly ADV - O
, PUNCT - O
the DET - O
bread NOUN - O
containing VERB - O
chitooligosaccharides NOUN - O
showed VERB - O
a DET - O
stronger ADJ - O
inhibitory ADJ - O
effect NOUN - O
against ADP - O
B. NNP - B-PERSON
cereus NOUN - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
sp PROPN - O
. PUNCT - O

compared VERB - O
to ADP - O
bread NOUN - O
containing VERB - O
chitosan NOUN - O
and CCONJ - O
control NOUN - O
, PUNCT - O
where ADV - O
B. NNP - B-PERSON
cereus NOUN - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE

-DOCSTART- -X- - O

The DET - O
majority NOUN - O
of ADP - O
fungal ADJ - O
isolates NOUN - O
belonged VERB - O
to ADP - O
Aspergillus PROPN - O
flavus NOUN - O
( PUNCT - O
35 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
followed VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
( PUNCT - O
13 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
and CCONJ - O
Eurotium PROPN - O
amstelodami NOUN - O
( PUNCT - O
9 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Using VERB - O
the DET - O
agar NOUN - O
plate NOUN - O
method NOUN - O
, PUNCT - O
Alternaria NNP - B-PERSON
alternata NOUN - O
was VERB - O
isolated VERB - O
from ADP - O
coriander NOUN - O
seed NOUN - O
lots NOUN - O
together ADV - O
with ADP - O
four CD - B-CARDINAL
other ADJ - O
fungal ADJ - O
genera NOUN - O
, PUNCT - O
which ADJ - O
included VERB - O
Aspergillus NNP - B-ORG
, , - I-ORG
Fusarium NNP - I-ORG
, , - I-ORG
Penicillium NNP - I-ORG
and CC - I-ORG
Rhizopus NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
brown ADJ - O
rot VERB - O
fungus NOUN - O
Rhizopus NNP - B-MEDICINE
delemar NOUN - O
F2 PROPN - O
was VERB - O
shown VERB - O
to PART - O
produce VERB - O
extracellular NOUN - O
thermostable NOUN - O
and CCONJ - O
multiple ADJ - O
carbohydrase NOUN - O
enzymes NOUN - O
. PUNCT - O

The DET - O
potential NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
delemar NOUN - O
F2 NOUN - O
in ADP - O
utilizing VERB - O
apple NOUN - O
pomace NOUN - O
under ADP - O
solid ADJ - O
state NOUN - O
fermentation NOUN - O
( PUNCT - O
SSF NNP - B-ORG
) PUNCT - O
is VERB - O
the DET - O
purpose NOUN - O
of ADP - O
the DET - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Utilization NOUN - O
of ADP - O
horticultural ADJ - O
waste NOUN - O
( PUNCT - O
Apple NNP - B-ORG
Pomace NNP - I-ORG
) PUNCT - O
for ADP - O
multiple ADJ - O
carbohydrase NOUN - O
production NOUN - O
from ADP - O
Rhizopus NNP - B-MEDICINE
delemar NOUN - O
F2 NOUN - O
under ADP - O
solid ADJ - O
state NOUN - O
fermentation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Due ADP - O
to ADP - O
Rhizopus NNP - B-MEDICINE
arrhizus VERB - O
in ADP - O
an DET - O
8-Year CD - B-CARDINAL
- HYPH - I-CARDINAL
Old JJ - I-CARDINAL
Girl NN - I-CARDINAL
. . - I-CARDINAL

-DOCSTART- -X- - O

Peaches NOUN - O
were VERB - O
inoculated VERB - O
with ADP - O
three CD - B-CARDINAL
common ADJ - O
spoilage NOUN - O
fungi NOUN - O
, PUNCT - O
Botrytis NNP - B-ORG
cinerea NOUN - O
, PUNCT - O
Monilinia NNP - B-GPE
fructicola NOUN - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
stolonifer VERB - O
and CCONJ - O
then ADV - O
stored VERB - O
for ADP - O
various ADJ - O
periods NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Therefore ADV - O
, PUNCT - O
the DET - O
changes NOUN - O
in ADP - O
the DET - O
structure NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
chinensis NOUN - O
lipase NOUN - O
( PUNCT - O
RCL NNP - B-ORG
) PUNCT - O
after ADP - O
high ADJ - O
hydrostatic ADJ - O
pressure NOUN - O
treatment NOUN - O
were VERB - O
investigated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Liberation NOUN - O
and CCONJ - O
recovery NOUN - O
of ADP - O
phenolic NOUN - O
antioxidants NOUN - O
and CCONJ - O
lipids NOUN - O
in ADP - O
chokeberry NOUN - O
( PUNCT - O
Aronia NNP - B-GPE
melanocarpa NOUN - O
) PUNCT - O
pomace NOUN - O
by ADP - O
solid ADJ - O
- PUNCT - O
state NOUN - O
bioprocessing NOUN - O
using VERB - O
Aspergillus RB - B-ORG
niger NOUN - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
oligosporus NOUN - O
strains VERB - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
evaluated VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
coatings NOUN - O
comprising VERB - O
gum NOUN - O
arabic NOUN - O
( PUNCT - O
GA NNP - B-ORG
) PUNCT - O
and CCONJ - O
essential ADJ - O
oils NOUN - O
from ADP - O
Origanum NNP - B-GPE
vulgare VERB - O
L. NNP - B-PERSON
( PUNCT - O
OVEO NNP - B-ORG
) PUNCT - O
and CCONJ - O
Rosmarinus NNP - B-ORG
officinalis NOUN - O
L. NNP - B-PERSON
( PUNCT - O
ROEO NNP - B-ORG
) PUNCT - O
to PART - O
control VERB - O
Rhizopus NNP - B-MEDICINE
soft ADJ - O
rot NOUN - O
and CCONJ - O
quality NOUN - O
of ADP - O
plums NOUN - O
( PUNCT - O
Prunus PROPN - O
domestica PROPN - O
L. NNP - B-PERSON
) PUNCT - O
during ADP - O
storage NOUN - O
at ADP - O
room NOUN - O
( PUNCT - O
25Â CD - B-CARDINAL
° PROPN - O
C NOUN - O
; PUNCT - O
12 CD - B-DATE
days NNS - I-DATE
) PUNCT - O
and CCONJ - O
cold ADJ - O
( PUNCT - O
12Â NUM - O
° NNP - B-PERSON
C NNP - I-PERSON
; PUNCT - O
24 CD - B-DATE
days NNS - I-DATE
) PUNCT - O
temperatures NOUN - O
. PUNCT - O

In ADP - O
plums NOUN - O
, PUNCT - O
the DET - O
reduction NOUN - O
of ADP - O
postharvest ADJ - O
quality NOUN - O
losses NOUN - O
resulting VERB - O
from ADP - O
decay NOUN - O
caused VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O
contamination NOUN - O
or CCONJ - O
by ADP - O
the DET - O
ripening NOUN - O
process NOUN - O
is VERB - O
a DET - O
major ADJ - O
goal NOUN - O
of ADP - O
postharvest ADJ - O
technology NOUN - O
, PUNCT - O
which ADJ - O
increase VERB - O
attention NOUN - O
to PART - O
use VERB - O
environmental ADJ - O
friendly ADJ - O
methods NOUN - O
as ADP - O
postharvest ADJ - O
treatment NOUN - O
of ADP - O
fruit NOUN - O
. PUNCT - O

This DET - O
study NOUN - O
evaluated VERB - O
coatings NOUN - O
containing VERB - O
reduced VERB - O
amounts NOUN - O
of ADP - O
oregano NOUN - O
and CCONJ - O
rosemary ADJ - O
essential ADJ - O
oils NOUN - O
in ADP - O
combination NOUN - O
as ADP - O
postharvest ADJ - O
treatment NOUN - O
to PART - O
control VERB - O
Rhizopus NNP - B-MEDICINE
soft ADJ - O
rot NOUN - O
in ADP - O
plums NOUN - O
( PUNCT - O
Prunus PROPN - O
domestica PROPN - O
) PUNCT - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
their ADJ - O
effects NOUN - O
on ADP - O
the DET - O
quality NOUN - O
attributes NOUN - O
of ADP - O
this DET - O
fruit NOUN - O
during ADP - O
storage NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Control NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
soft ADJ - O
rot NOUN - O
and CCONJ - O
quality NOUN - O
responses NOUN - O
in ADP - O
plums NOUN - O
( PUNCT - O
Prunus NNP - B-NORP
domestica PROPN - O
L. NNP - B-PERSON
) PUNCT - O
coated VERB - O
with ADP - O
gum NOUN - O
arabic ADJ - O
, PUNCT - O
oregano NOUN - O
and CCONJ - O
rosemary ADJ - O
essential ADJ - O
oils NOUN - O

-DOCSTART- -X- - O

In ADP - O
order NOUN - O
to PART - O
improve VERB - O
the DET - O
quality NOUN - O
and CCONJ - O
functionality NOUN - O
of ADP - O
Makgeolli NNP - B-ORG
, PUNCT - O
the DET - O
Rhizopus NNP - B-MEDICINE
oligosporus NOUN - O
fermented VERB - O
buckwheat NOUN - O
containing VERB - O
18.7 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
of ADP - O
l NOUN - O
- PUNCT - O
carnitine NOUN - O
were VERB - O
utilized VERB - O
to PART - O
brew VERB - O
l NOUN - O
- PUNCT - O
carnitine NOUN - O
fortified VERB - O
Makgeolli NNP - B-ORG
with ADP - O
rice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
species NOUN - O
isolated VERB - O
in ADP - O
the DET - O
mycological ADJ - O
culture NOUN - O
was VERB - O
Rhizopus NNP - B-MEDICINE
sp PART - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
report VERB - O
a DET - O
case NOUN - O
of ADP - O
rhinocerebral ADJ - O
mucormycosis NOUN - O
caused VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
arrhizus PROPN - O
var NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rhinocerebral ADJ - O
mucormycosis NOUN - O
caused VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
arrhizus PROPN - O
var NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Most ADJ - O
common ADJ - O
fungus NOUN - O
was VERB - O
Aspergillus NNP - B-ORG
species NOUN - O
( PUNCT - O
31.1 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
followed VERB - O
by ADP - O
Fusarium NNP - B-ORG
species NOUN - O
( PUNCT - O
24.5 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
Alternaria NNP - B-ORG
( PUNCT - O
10.5 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
Curvularia NNP - B-PERSON
( PUNCT - O
10.2 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
Helminthosporium PROPN - O
( PUNCT - O
5.7 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
Bipolaris NNP - B-PERSON
( PUNCT - O
5.4 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
Penicillium PROPN - O
( PUNCT - O
4.5 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
Candida NNP - B-GPE
( PUNCT - O
4.4 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
Acremonium PROPN - O
( PUNCT - O
1.2 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
( PUNCT - O
1.0 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
Paecilomyces NOUN - O
( PUNCT - O
0.8 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
Rhodotorula NNP - B-ORG
( PUNCT - O
0.5 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
and CCONJ - O
Mucor NNP - B-ORG
( PUNCT - O
0.2 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Optimization NOUN - O
of ADP - O
the DET - O
CRISPR PROPN - O
/ SYM - O
Cas9 PROPN - O
System PROPN - O
to PART - O
Manipulate PROPN - O
Gene PROPN - O
Function PROPN - O
in ADP - O
Rhizopus NNP - B-MEDICINE
delemar NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Although ADP - O
infections NOUN - O
with ADP - O
fungi NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
Rhizopus NNP - B-MEDICINE
species NOUN - O
, PUNCT - O
usually ADV - O
occur VERB - O
in ADP - O
diabetics NOUN - O
or CCONJ - O
immunocompromised VERB - O
patients NOUN - O
, PUNCT - O
they PRON - O
can VERB - O
also ADV - O
rarely ADV - O
affect VERB - O
immunocompetent ADJ - O
individuals NOUN - O
. PUNCT - O

We PRON - O
present VERB - O
a DET - O
case NOUN - O
of ADP - O
disseminated ADJ - O
infection NOUN - O
with ADP - O
multiple ADJ - O
cold ADJ - O
abscesses NOUN - O
in ADP - O
a DET - O
13-year CD - B-CARDINAL
, PUNCT - O
otherwise ADV - O
healthy ADJ - O
girl NOUN - O
caused VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
arrhizus PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Disseminated VERB - O
Infection PROPN - O
with ADP - O
Multiple PROPN - O
Cold PROPN - O
Abscesses NOUN - O
Caused VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
Arrhizusin PROPN - O
an DET - O
Immunocompetent PROPN - O
Girl PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Enhanced VERB - O
vitamin NOUN - O
B12 PROPN - O
production NOUN - O
in ADP - O
an DET - O
innovative ADJ - O
lupin NOUN - O
tempeh NOUN - O
is VERB - O
due ADJ - O
to ADP - O
synergic ADJ - O
effects NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
and CC - I-ORG
Propionibacterium NNP - I-ORG
in ADP - O
cofermentation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Eight CD - B-CARDINAL
genera NOUN - O
( PUNCT - O
24 CD - B-CARDINAL
species NOUN - O
) PUNCT - O
of ADP - O
Mucorales NNP - B-GPE
organisms NOUN - O
were VERB - O
identified VERB - O
in ADP - O
447/851 NNP - B-DATE
( PUNCT - O
53 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
cases NOUN - O
, PUNCT - O
of ADP - O
which ADJ - O
Rhizopus NNP - B-MEDICINE
spp NOUN - O
. PUNCT - O

Compared VERB - O
with ADP - O
other ADJ - O
genera NOUN - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
spp NOUN - O
. PUNCT - O
was VERB - O
predominantly ADV - O
observed VERB - O
in ADP - O
patients NOUN - O
with ADP - O
rhino NOUN - O
- PUNCT - O
orbital ADJ - O
- PUNCT - O
cerebral ADJ - O
mucormycosis NOUN - O
( PUNCT - O
75/213 NNS - B-ORDINAL
, PUNCT - O
35 CD - B-PERCENT
% NN - I-PERCENT
versus ADP - O
34/234 PROPN - O
, PUNCT - O
15 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
p DET - O
  SPACE - O
< X - O
  SPACE - O
0.001 CD - B-DATE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
measured VERB - O
the DET - O
in X - O
vitro X - O
activity NOUN - O
of ADP - O
VT-1598 NNP - B-ORG
against ADP - O
clinical ADJ - O
isolates NOUN - O
of ADP - O
Candida NNP - B-ORG
and CC - I-ORG
Cryptococcus NNP - I-ORG
species NOUN - O
, PUNCT - O
endemic NOUN - O
fungi NOUN - O
, PUNCT - O
including VERB - O
Coccidioides NNP - B-ORG
, PUNCT - O
Blastomyces NNPS - B-ORG
and CCONJ - O
Histoplasma NNP - B-PERSON
, PUNCT - O
Aspergillus PROPN - O
species NOUN - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
arrhizus PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Coupled ADJ - O
effects NOUN - O
of ADP - O
salt NOUN - O
and CCONJ - O
pressure NOUN - O
on ADP - O
catalytic ADJ - O
ability NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
chinensis NOUN - O
lipase NOUN - O

-DOCSTART- -X- - O

We PRON - O
searched VERB - O
for ADP - O
secreted ADJ - O
or CCONJ - O
membrane ADJ - O
- PUNCT - O
bound VERB - O
proteins NOUN - O
of ADP - O
Rhizopus JJ - B-MEDICINE
oryzae NOUN - O
, PUNCT - O
which ADJ - O
is VERB - O
the DET - O
most ADV - O
common ADJ - O
pathogen NOUN - O
of ADP - O
mucormycosis NOUN - O
, PUNCT - O
using VERB - O
the DET - O
method NOUN - O
of ADP - O
a DET - O
signal ADJ - O
sequence NOUN - O
trap NOUN - O
by ADP - O
retrovirus NOUN - O
- PUNCT - O
mediated VERB - O
expression NOUN - O
( PUNCT - O
SST NNP - B-ORG
- HYPH - I-ORG
REX NNP - I-ORG
) PUNCT - O
. PUNCT - O

Among ADP - O
the DET - O
identified VERB - O
proteins NOUN - O
, PUNCT - O
a DET - O
Rhizopus NN - B-MEDICINE
- PUNCT - O
specific ADJ - O
antigen NOUN - O
was VERB - O
selected VERB - O
as ADP - O
a DET - O
candidate NOUN - O
, PUNCT - O
and CCONJ - O
efficacy NOUN - O
of ADP - O
this DET - O
specific ADJ - O
antigen NOUN - O
was VERB - O
evaluated VERB - O
using VERB - O
R. NNP - B-NORP
oryzae NOUN - O
- PUNCT - O
infected VERB - O
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Identification NOUN - O
of ADP - O
a DET - O
Novel PROPN - O
Rhizopus NNP - B-MEDICINE
- PUNCT - O
specific PROPN - O
Antigen PROPN - O
by ADP - O
Screening VERB - O
with ADP - O
a DT - B-ORG
Signal NNP - I-ORG
Sequence NNP - I-ORG
Trap NNP - I-ORG
and CC - I-ORG
Evaluation NNP - I-ORG
as ADP - O
a DET - O
Possible PROPN - O
Diagnostic PROPN - O
Marker PROPN - O
of ADP - O
Mucormycosis NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
six CD - B-CARDINAL
isolates NOUN - O
( PUNCT - O
Pseudomonas NNP - B-GPE
hibiscicola NOUN - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O
, PUNCT - O
Fusarium PROPN - O
solani NOUN - O
, PUNCT - O
Actinomucor NNP - B-ORG
elegans NOUN - O
, PUNCT - O
Enterobacter NOUN - O
aerogenes NOUN - O
and CCONJ - O
Aspergillus NNP - B-PRODUCT
tubingensis NOUN - O
) PUNCT - O
from ADP - O
rotten ADJ - O
roots NOUN - O
were VERB - O
confirmed VERB - O
to PART - O
be VERB - O
pathogens NOUN - O
for ADP - O
root NOUN - O
decay NOUN - O
of ADP - O
R. NNP - B-NORP
glutinosa NOUN - O
in ADP - O
pot NOUN - O
experiments NOUN - O
with ADP - O
different ADJ - O
pathogenicities NOUN - O
of ADP - O
33.33%–100 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
suggesting VERB - O
the DET - O
potential ADJ - O
synergy NOUN - O
of ADP - O
several ADJ - O
pathogens NOUN - O
in ADP - O
causing VERB - O
root NOUN - O
rot NOUN - O
in ADP - O
R. NNP - B-NORP
glutinosa NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
was VERB - O
conducted VERB - O
to PART - O
determine VERB - O
if ADP - O
topical ADJ - O
application NOUN - O
of ADP - O
Moringa NNP - B-GPE
oleifera NOUN - O
extracts NOUN - O
and CCONJ - O
its ADJ - O
bioconversion NOUN - O
product NOUN - O
fermented VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
oligosporus NOUN - O
has VERB - O
therapeutic ADJ - O
properties NOUN - O
enhancement NOUN - O
for ADP - O
treatment NOUN - O
of ADP - O
atopic ADJ - O
dermatitis NOUN - O
. PUNCT - O

Rhizopus NN - B-MEDICINE
oligosporus NOUN - O
( PUNCT - O
KCCM NNP - B-ORG
11232P PROPN - O
) PUNCT - O
was VERB - O
used VERB - O
to PART - O
ferment VERB - O
Moringa NNP - B-GPE
leaves NOUN - O
' PART - O
extracts NOUN - O
in ADP - O
this DET - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Advanced PROPN - O
Effect PROPN - O
of ADP - O
Moringa PROPN - O
oleifera NOUN - O
Bioconversion PROPN - O
by ADP - O
Rhizopus NNP - B-MEDICINE
oligosporus NOUN - O
on ADP - O
the DET - O
Treatment PROPN - O
of ADP - O
Atopic PROPN - O
Dermatitis NOUN - O
: PUNCT - O
Preliminary PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
study NOUN - O
was VERB - O
aimed VERB - O
at ADP - O
production NOUN - O
of ADP - O
different ADJ - O
organic ADJ - O
acids NOUN - O
( PUNCT - O
OA PROPN - O
) PUNCT - O
( PUNCT - O
lactic ADJ - O
, PUNCT - O
fumaric ADJ - O
, PUNCT - O
or CCONJ - O
succinic ADJ - O
) PUNCT - O
by ADP - O
various ADJ - O
microbial ADJ - O
cells NOUN - O
( PUNCT - O
filamentous ADJ - O
fungi NOUN - O
Rhizopus NN - B-MEDICINE
oryzae NOUN - O
( PUNCT - O
F-814 NNP - B-ORG
, PUNCT - O
F-1127 NOUN - O
) PUNCT - O
and CCONJ - O
bacteria NOUN - O
Actinobacillus PROPN - O
succinogenes NOUN - O
B-10111 NNP - B-PERSON
) PUNCT - O
immobilized VERB - O
into ADP - O
poly(vinyl SYM - O
alcohol NOUN - O
) PUNCT - O

-DOCSTART- -X- - O

, PUNCT - O
Rhizopus NNP - B-MEDICINE
spp NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
Propionibacterium NOUN - O
freudenreichii VERB - O
, PUNCT - O
a DET - O
food NOUN - O
- PUNCT - O
grade NOUN - O
, PUNCT - O
vitamin NOUN - O
B12 PROPN - O
producing VERB - O
bacterium NOUN - O
, PUNCT - O
was VERB - O
used VERB - O
in ADP - O
co NOUN - O
- NOUN - O
culture NOUN - O
with ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
to PART - O
produce VERB - O
B12-enriched PROPN - O
lupin NOUN - O
tempeh NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Hepatic ADJ - O
mucormycosis NOUN - O
due ADP - O
to ADP - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Backbone PROPN - O
and CCONJ - O
Ile PROPN - O
- PUNCT - O
δ1 PROPN - O
, PUNCT - O
Leu NNP - B-ORG
, PUNCT - O
Val PROPN - O
methyl NOUN - O
1H NNP - B-DATE
, PUNCT - O
15N CD - B-CARDINAL
, PUNCT - O
and CCONJ - O
13C CD - B-CARDINAL
, PUNCT - O
chemical NOUN - O
shift NOUN - O
assignments NOUN - O
for ADP - O
Rhizopus NN - B-MEDICINE
chinensis NOUN - O
lipase NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
potential NOUN - O
of ADP - O
six CD - B-CARDINAL
microorganisms NOUN - O
( PUNCT - O
Pseudomonas NNP - B-GPE
aeruginosa NOUN - O
, PUNCT - O
Micrococcus NNP - B-PERSON
sp X - O
, PUNCT - O
Flavobacterium NNP - B-LOC
sp X - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
sp PROPN - O
, PUNCT - O
Penicillium PROPN - O
sp PROPN - O
and CCONJ - O
Fusarium NNP - B-ORG
sp X - O
) PUNCT - O
isolated VERB - O
from ADP - O
hydrocarbon NOUN - O
contaminated VERB - O
site NOUN - O
were VERB - O
evaluated VERB - O
for ADP - O
their ADJ - O
biodegradation NOUN - O
ability NOUN - O
. PUNCT - O

P. PROPN - O
aeruginosa NOUN - O
had VERB - O
the DET - O
highest ADJ - O
level NOUN - O
of ADP - O
degradation NOUN - O
( PUNCT - O
89.2 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
while ADP - O
Micrococcus NNP - B-PERSON
sp PART - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
sp PROPN - O
had VERB - O
the DET - O
least ADJ - O
degradation NOUN - O
at ADP - O
79.9 CD - B-PERCENT
% NN - I-PERCENT
. PUNCT - O

-DOCSTART- -X- - O

Oats PROPN - O
were VERB - O
fermented VERB - O
by ADP - O
Lactobacillus NNP - B-ORG
plantarum NOUN - O
B1 NNP - B-DATE
- HYPH - I-DATE
6 CD - I-DATE
, PUNCT - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
, PUNCT - O
or CCONJ - O
a DET - O
combination NOUN - O
of ADP - O
L. NNP - B-PERSON
plantarum NOUN - O
B1 NNP - B-CARDINAL
- PUNCT - O
6 NUM - O
and CCONJ - O
R. NNP - B-NORP
oryzae NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Bacteria NOUN - O
such ADJ - O
as ADP - O
Lysobacter NNP - B-ORG
, , - I-ORG
Spingomonas NNP - I-ORG
and CC - I-ORG
Haliangium NNP - I-ORG
of IN - I-ORG
Proteobacteria NNP - I-ORG
; PUNCT - O
Actinomadura NNP - B-GPE
and CCONJ - O
Lamia NNP - B-GPE
of ADP - O
Actinobacteria NNP - B-GPE
; PUNCT - O
and CCONJ - O
unidentified ADJ - O
Acidobacteria NNP - B-GPE
of ADP - O
Acidobacteria NNP - B-GPE
as ADV - O
well ADV - O
as ADP - O
fungi ADV - O
such ADJ - O
as ADP - O
Talaromyces NNP - B-GPE
and CCONJ - O
Fusarium PROPN - O
of ADP - O
Ascomycota PROPN - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
of ADP - O
Zygomycota NNP - B-GPE
were VERB - O
dominant ADJ - O
in ADP - O
the DET - O
rhizosphere NOUN - O
soil NOUN - O
of ADP - O
maize NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Our ADJ - O
previous ADJ - O
studies NOUN - O
demonstrated VERB - O
that ADP - O
the DET - O
N NOUN - O
- PUNCT - O
glycans NOUN - O
in ADP - O
Rhizopus NN - B-MEDICINE
chinensis NOUN - O
lipase NOUN - O
( PUNCT - O
RCL NNP - B-ORG
) PUNCT - O
was VERB - O
important ADJ - O
for ADP - O
its ADJ - O
secretion NOUN - O
. PUNCT - O

In ADP - O
order NOUN - O
to PART - O
improve VERB - O
the DET - O
secretion NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
lipase NOUN - O
( PUNCT - O
ROL NNP - B-ORG
) PUNCT - O
under ADP - O
the DET - O
control NOUN - O
of ADP - O
the DET - O
GAP NNP - B-ORG
promoter NOUN - O
in ADP - O
Komagataella NNP - B-GPE
phaffii NOUN - O
, PUNCT - O
two CD - B-CARDINAL
extra ADJ - O
N NOUN - O
- PUNCT - O
glycosylation NOUN - O
sites NOUN - O
were VERB - O
introduced VERB - O
in ADP - O
ROL NNP - B-ORG
according VERB - O
to ADP - O
the DET - O
position NOUN - O
of ADP - O
the DET - O
N CD - B-ORG
- PUNCT - O
glycosylation NOUN - O
sites NOUN - O
of ADP - O
RCL NNP - B-ORG
by ADP - O
sequence NOUN - O
alignment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
efficiently ADV - O
produce VERB - O
xylitol NOUN - O
from ADP - O
xylose NOUN - O
by ADP - O
xylose ADJ - O
reductase NOUN - O
in ADP - O
a DET - O
single ADJ - O
step NOUN - O
, PUNCT - O
the DET - O
coupled ADJ - O
system NOUN - O
and CCONJ - O
the DET - O
coexpression NOUN - O
system NOUN - O
using VERB - O
xylose NOUN - O
reductase NOUN - O
( PUNCT - O
XR PROPN - O
) PUNCT - O
from ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
and CCONJ - O
glucose NOUN - O
dehydrogenase NOUN - O
( PUNCT - O
GDH PROPN - O
) PUNCT - O
from ADP - O
Exiguobacterium NNP - B-GPE
sibiricum NOUN - O
were VERB - O
constructed VERB - O
, PUNCT - O
the DET - O
latter ADJ - O
of ADP - O
which ADJ - O
was VERB - O
used VERB - O
for ADP - O
cofactor NOUN - O
regeneration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Soursop PROPN - O
( PUNCT - O
Annona NNP - B-GPE
muricata NOUN - O
) PUNCT - O
is VERB - O
a DET - O
tropical ADJ - O
fruit NOUN - O
that ADJ - O
can VERB - O
be VERB - O
infected VERB - O
by ADP - O
Colletotrichum NNP - B-NORP
gloeosporioides NOUN - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O
. PUNCT - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
Colletotrichum NNP - B-NORP
was VERB - O
reactivated VERB - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
was VERB - O
identified VERB - O
using VERB - O
morphological ADJ - O
features NOUN - O
and CCONJ - O
molecular ADJ - O
tools NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Use PROPN - O
of ADP - O
inductors NOUN - O
in ADP - O
the DET - O
control NOUN - O
of ADP - O
Colletotrichum NNP - B-NORP
gloeosporioides NOUN - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
stolonifer VERB - O
isolated VERB - O
from ADP - O
soursop NOUN - O
fruits NOUN - O
: PUNCT - O
in ADP - O
vitro NOUN - O
tests NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
goals NOUN - O
get VERB - O
on ADP - O
heterologous ADJ - O
Candida NNP - B-GPE
antarctica NOUN - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
, PUNCT - O
and CCONJ - O
Candida NNP - B-GPE
rugosa NOUN - O
lipases VERB - O
, PUNCT - O
three CD - B-CARDINAL
of ADP - O
the DET - O
most ADV - O
common ADJ - O
lipases NOUN - O
used VERB - O
in ADP - O
biocatalysis NOUN - O
, PUNCT - O
are VERB - O
showed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
evaluate VERB - O
the DET - O
antifungal ADJ - O
activity NOUN - O
( PUNCT - O
in ADP - O
vitro X - O
) PUNCT - O
of ADP - O
thymol NOUN - O
and CCONJ - O
carvacrol NOUN - O
alone ADV - O
or CCONJ - O
in ADP - O
mixtures NOUN - O
against ADP - O
Fusarium NNP - B-ORG
verticillioides NOUN - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
stolonifer VERB - O
, PUNCT - O
and CCONJ - O
to PART - O
obtain VERB - O
primary ADJ - O
growth NOUN - O
models NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fusarium NOUN - O
verticillioides NOUN - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
stolonifer VERB - O
with ADP - O
thymol NOUN - O
and CCONJ - O
carvacrol NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

One CD - B-CARDINAL
steroid NOUN - O
- PUNCT - O
treated VERB - O
patient NOUN - O
with ADP - O
diabetes NOUN - O
died VERB - O
6 CD - B-DATE
weeks NNS - I-DATE
after ADP - O
biopsy NOUN - O
, PUNCT - O
with ADP - O
invasive ADJ - O
rhinoorbital ADJ - O
Rhizopus NNP - B-MEDICINE
infection NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

, PUNCT - O
Rhizopus NNP - B-MEDICINE
nigricans NOUN - O
( PUNCT - O
3 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
Fusarium NOUN - O
solani NOUN - O
( PUNCT - O
2 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
were VERB - O
found VERB - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
2009 CD - B-DATE
this DET - O
tomb NOUN - O
was VERB - O
deteriorated VERB - O
by ADP - O
" PUNCT - O
Aspergillus ADV - O
niger ADV - O
, PUNCT - O
A. NOUN - O
flavus NOUN - O
, PUNCT - O
Fusarium NN - B-PRODUCT
moniliforme NOUN - O
, PUNCT - O
Alternaria NNP - B-PERSON
alternate NOUN - O
, PUNCT - O
Rhizopus NN - B-MEDICINE
stolonifera NOUN - O
, PUNCT - O
Bacillus NOUN - O
subtilis NOUN - O
, PUNCT - O
Bacillus NOUN - O
cereus NOUN - O
, PUNCT - O
and CCONJ - O
micrococcus NOUN - O
iuteus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rhizopus NN - B-MEDICINE
was VERB - O
the DET - O
predominant ADJ - O
species NOUN - O
of ADP - O
pathogen NOUN - O
( PUNCT - O
66.7 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Intravenous PROPN - O
Olanzapine NNP - B-MEDICINE
for ADP - O
the DET - O
Management PROPN - O
of ADP - O
Agitation PROPN - O
: PUNCT - O
Review NOUN - O
of ADP - O
the DET - O
Literature PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
is VERB - O
a DET - O
second JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
anti ADJ - O
- ADJ - O
psychotic ADJ - O
drug NOUN - O
used VERB - O
to PART - O
prevent VERB - O
neuroinflammation NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
schizophrenia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
Induced VERB - O
Dysmetabolic PROPN - O
Changes PROPN - O
Involving PROPN - O
Tissue PROPN - O
Chromium PROPN - O
Mobilization NOUN - O
in ADP - O
Female PROPN - O
Rats PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
pamoate NOUN - O
is VERB - O
one NUM - O
of ADP - O
the DET - O
recently ADV - O
approved VERB - O
long ADV - O
- PUNCT - O
acting VERB - O
depot NOUN - O
psychotropic ADJ - O
preparations NOUN - O
that ADJ - O
have VERB - O
shown VERB - O
its ADJ - O
efficacy NOUN - O
both CCONJ - O
in ADP - O
clinical ADJ - O
trials NOUN - O
and CCONJ - O
in ADP - O
clinical ADJ - O
uses NOUN - O
against ADP - O
the DET - O
illness NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

After ADP - O
31st ADJ - O
Long PROPN - O
- PUNCT - O
Acting PROPN - O
Olanzapine NNP - B-MEDICINE
Depot PROPN - O
Injection PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
- PUNCT - O
induced VERB - O
weight NOUN - O
gain NOUN - O
and CCONJ - O
fourteen CD - B-CARDINAL
genera NOUN - O
of ADP - O
intestinal ADJ - O
bacteria NOUN - O
, PUNCT - O
were VERB - O
not ADV - O
influenced VERB - O
by ADP - O
sodium NOUN - O
acetate NOUN - O
intake NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Case NOUN - O
of ADP - O
Schizophrenia PROPN - O
With ADP - O
Catatonia PROPN - O
Resistant PROPN - O
to ADP - O
Lorazepam NNP - B-PERSON
and CCONJ - O
Olanzapine NNP - B-MEDICINE
Monotherapy NNP - I-PERSON

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
pamoate NOUN - O
has VERB - O
a DET - O
higher ADJ - O
cost NOUN - O
of ADP - O
treatment NOUN - O
than ADP - O
the DET - O
oral ADJ - O
form NOUN - O
and CCONJ - O
requires VERB - O
administration NOUN - O
in ADP - O
a DET - O
hospital NOUN - O
setting NOUN - O
( PUNCT - O
unlike ADP - O
other ADJ - O
long ADV - O
- PUNCT - O
acting VERB - O
antipsychotics NOUN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
the DET - O
cost NOUN - O
- PUNCT - O
effectiveness NOUN - O
of ADP - O
this DET - O
treatment NOUN - O
may VERB - O
be VERB - O
questioned VERB - O
. PUNCT - O

Olanzapine NN - B-MEDICINE
pamoate VERB - O
significantly ADV - O
reduced VERB - O
the DET - O
number NOUN - O
of ADP - O
hospitalizations NOUN - O
compared VERB - O
to ADP - O
the DET - O
previous ADJ - O
management NOUN - O
strategy NOUN - O
( PUNCT - O
1 CD - B-CARDINAL
less ADJ - O
hospitalization NOUN - O
, PUNCT - O
P<0.001 NNP - B-PERSON
in ADP - O
patients NOUN - O
treated VERB - O
more JJR - B-DATE
than IN - I-DATE
one CD - I-DATE
year NN - I-DATE
and CCONJ - O
in ADP - O
the DET - O
general ADJ - O
cohort NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Age NOUN - O
Impacts VERB - O
Olanzapine NN - B-MEDICINE
Exposure NOUN - O

-DOCSTART- -X- - O

Development PROPN - O
and CCONJ - O
Characterization PROPN - O
of ADP - O
Olanzapine NNP - B-MEDICINE
Loaded PROPN - O
Poly(lactide NNP - B-GPE
- PUNCT - O
co NOUN - O
- ADJ - O
glycolide ADJ - O
) PUNCT - O
Microspheres NNS - B-ORG
for IN - I-ORG
Depot NNP - I-ORG
Injection NNP - I-ORG
: PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
( PUNCT - O
100 CD - B-CARDINAL
  SPACE - O
uM DET - O
) PUNCT - O
and CCONJ - O
clozapine VERB - O
( PUNCT - O
100 CD - B-CARDINAL
, PUNCT - O
20 CD - B-CARDINAL
  SPACE - O
uM INTJ - O
) PUNCT - O

Olanzapine NNP - B-MEDICINE
( PUNCT - O
100 CD - B-CARDINAL
  SPACE - O
uM DET - O
) PUNCT - O
and CCONJ - O
aripiprazole NOUN - O
( PUNCT - O
20 CD - B-CARDINAL
  SPACE - O
uM INTJ - O
) PUNCT - O
increased VERB - O
BDNF ADJ - O
expression NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
dose NOUN - O
was VERB - O
inversely ADV - O
correlated VERB - O
with ADP - O
the DET - O
drug NOUN - O
efficacy NOUN - O
( PUNCT - O
p VERB - O
  SPACE - O

Olanzapine NN - B-MEDICINE
treatment NOUN - O
outcome NOUN - O
is VERB - O
also ADV - O
affected VERB - O
by ADP - O
dose NOUN - O
, PUNCT - O
sex NOUN - O
, PUNCT - O
age NOUN - O
and CCONJ - O
CYP2D6 NN - B-PERSON
metabolizer NOUN - O
status NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
- PUNCT - O
Induced PROPN - O
Fever PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Reference PROPN - O
Brain PROPN - O
and CCONJ - O
Blood PROPN - O
Concentrations PROPN - O
of ADP - O
Olanzapine NNP - B-MEDICINE
in ADP - O
Postmortem PROPN - O
Cases PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
is VERB - O
commonly ADV - O
used VERB - O
for ADP - O
the DET - O
management NOUN - O
of ADP - O
psychotic ADJ - O
symptoms NOUN - O
as ADV - O
well ADV - O
as ADP - O
for ADP - O
the DET - O
management NOUN - O
of ADP - O
behavioural ADJ - O
and CCONJ - O
psychological ADJ - O
problems NOUN - O
with ADP - O
dementia NOUN - O
in ADP - O
the DET - O
elderly ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
is VERB - O
commonly ADV - O
utilized VERB - O
in ADP - O
palliative ADJ - O
care NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
nausea NOUN - O
, PUNCT - O
and CCONJ - O
a DET - O
known VERB - O
side NOUN - O
effect NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
is VERB - O
increased VERB - O
appetite NOUN - O
. PUNCT - O

Olanzapine NNP - B-MEDICINE
is VERB - O
also ADV - O
known VERB - O
to PART - O
cause VERB - O
re NOUN - O
- NOUN - O
emergence NOUN - O
of ADP - O
eating VERB - O
disorders NOUN - O
( PUNCT - O
EDs NOUN - O
) PUNCT - O
in ADP - O
patients NOUN - O
utilizing VERB - O
olanzapine NN - B-MEDICINE
for ADP - O
its ADJ - O
antipsychotic ADJ - O
effects NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Atypical PROPN - O
Antipsychotic PROPN - O
Drug PROPN - O
Olanzapine NNP - B-MEDICINE
Deregulates VERB - O
Hepatic PROPN - O
Lipid PROPN - O
Metabolism PROPN - O
and CCONJ - O
Aortic PROPN - O
Inflammation PROPN - O
and CCONJ - O
Aggravates PROPN - O
Atherosclerosis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

CONCLUSION NOUN - O
: PUNCT - O
Olanzapine NN - B-MEDICINE
, PUNCT - O
haloperidol NOUN - O
plus CCONJ - O
promethazine NOUN - O
or CCONJ - O
droperidol NOUN - O
are VERB - O
most ADV - O
effective ADJ - O
and CCONJ - O
safe ADJ - O
for ADP - O
use NOUN - O
as ADP - O
rapid ADJ - O
tranquilisation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
for ADP - O
the DET - O
prevention NOUN - O
and CCONJ - O
treatment NOUN - O
of ADP - O
cancer NOUN - O
- PUNCT - O
related VERB - O
nausea NOUN - O
and CCONJ - O
vomiting VERB - O
in ADP - O
adults NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Call VERB - O
for ADP - O
" `` - B-WORK_OF_ART
High JJ - I-WORK_OF_ART
- HYPH - I-WORK_OF_ART
Dose NNP - I-WORK_OF_ART
" '' - I-WORK_OF_ART
Olanzapine NNP - I-MEDICINE
Research NNP - I-WORK_OF_ART
in IN - I-WORK_OF_ART
Treatment NNP - I-WORK_OF_ART
- HYPH - I-WORK_OF_ART
Resistant NNP - I-WORK_OF_ART
Psychosis NNP - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
is VERB - O
associated VERB - O
with ADP - O
somnolence NOUN - O
, PUNCT - O
and CCONJ - O
we PRON - O
have VERB - O
previously ADV - O
conducted VERB - O
a DET - O
randomized VERB - O
Phase NNP - B-PRODUCT
II NNP - I-PRODUCT
study NOUN - O
to PART - O
evaluate VERB - O
the DET - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
10 CD - B-CARDINAL
mg NOUN - O
and CCONJ - O
5 CD - B-CARDINAL
mg PRON - O
olanzapine RB - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
for ADP - O
the DET - O
Prevention PROPN - O
of ADP - O
Chemotherapy PROPN - O
- PUNCT - O
Induced VERB - O
Nausea PROPN - O
and CCONJ - O
Vomiting NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
is VERB - O
an DET - O
atypical ADJ - O
antipsychotic ADJ - O
that ADJ - O
has VERB - O
shown VERB - O
efficacy NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
nausea NOUN - O
, PUNCT - O
anxiety NOUN - O
, PUNCT - O
and CCONJ - O
insomnia NOUN - O
. PUNCT - O

This DET - O
study NOUN - O
was VERB - O
conducted VERB - O
to PART - O
evaluate VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
( PUNCT - O
5 CD - B-CARDINAL
  _SP - I-CARDINAL
mg NOUN - O
) PUNCT - O
combined VERB - O
with ADP - O
5-HT3 ADJ - O
receptor NOUN - O
antagonists NOUN - O
and CCONJ - O
dexamethasone NOUN - O
for ADP - O
the DET - O
prevention NOUN - O
of ADP - O
chemotherapy NOUN - O
- PUNCT - O
induced VERB - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
( PUNCT - O
CINV PROPN - O
) PUNCT - O
in ADP - O
lung NOUN - O
patients NOUN - O
receiving VERB - O
cisplatin ADV - O
- PUNCT - O
based VERB - O
( PUNCT - O
25 CD - B-CARDINAL
  _SP - I-CARDINAL
mg NOUN - O
/ SYM - O
m2 ADJ - O
d1 NOUN - O
- SYM - O
3 NUM - O
) PUNCT - O
highly ADV - O
emetogenic ADJ - O
chemotherapy NOUN - O
( PUNCT - O
HEC).Olanzapine PROPN - O
( PUNCT - O
5 CD - B-CARDINAL
  _SP - I-CARDINAL
mg PRON - O
) PUNCT - O
was VERB - O
administered VERB - O
a DT - B-DATE
day NN - I-DATE
prior ADV - O
to ADP - O
cisplatin ADJ - O
administration NOUN - O
and CCONJ - O
continued VERB - O
on ADP - O
days NNS - B-DATE
1 CD - I-DATE
to IN - I-DATE
5 CD - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
plus CCONJ - O
aprepitant NOUN - O
, PUNCT - O
palonosetron NOUN - O
, PUNCT - O
and CCONJ - O
dexamethasone VERB - O
for ADP - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
breast NOUN - O
cancer NOUN - O
receiving VERB - O
anthracycline NOUN - O
: PUNCT - O
A DET - O
retrospective ADJ - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
is VERB - O
an DET - O
atypical ADJ - O
antipsychotic ADJ - O
drug NOUN - O
commonly ADV - O
used VERB - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
schizophrenia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
( PUNCT - O
Olz NOUN - O
) PUNCT - O
is VERB - O
an DET - O
atypical ADJ - O
antipsychotic NOUN - O
used VERB - O
to PART - O
treat VERB - O
depression NOUN - O
, PUNCT - O
anxiety NOUN - O
and CCONJ - O
schizophrenia NOUN - O
, PUNCT - O
which ADJ - O
can VERB - O
be VERB - O
caused VERB - O
by ADP - O
chronic ADJ - O
psychosocial ADJ - O
stress NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Intraindividual ADJ - O
and CCONJ - O
Interindividual JJ - B-ORG
Variability NNP - I-ORG
of IN - I-ORG
Olanzapine NNP - I-MEDICINE
Trough NNP - I-ORG
Concentrations NNP - I-ORG
in ADP - O
Patients NOUN - O
Treated VERB - O
With ADP - O
the DET - O
Long PROPN - O
- PUNCT - O
Acting PROPN - O
Injectable PROPN - O
Formulation PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
significantly ADV - O
increased VERB - O
the DET - O
phosphorylated VERB - O
levels NOUN - O
of ADP - O
mTORC1 NOUN - O
, PUNCT - O
its ADJ - O
downstream ADJ - O
effectors NOUN - O
, PUNCT - O
and CCONJ - O
its ADJ - O
upstream ADJ - O
activators NOUN - O
. PUNCT - O

Olanzapine NNP - B-MEDICINE
also ADV - O
increased VERB - O
dendritic ADJ - O
outgrowth NOUN - O
and CCONJ - O
synaptic ADJ - O
proteins NOUN - O
levels NOUN - O
; PUNCT - O
all DET - O
of ADP - O
these DET - O
effects NOUN - O
were VERB - O
blocked VERB - O
by ADP - O
rapamycin NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
, PUNCT - O
a DET - O
second JJ - B-ORDINAL
generation NOUN - O
antipsychotic ADJ - O
, PUNCT - O
has VERB - O
previously ADV - O
been VERB - O
associated VERB - O
with ADP - O
an DET - O
increased VERB - O
risk NOUN - O
of ADP - O
venous ADJ - O
thromboembolism NOUN - O
( PUNCT - O
VTE PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
treatment NOUN - O
reduced VERB - O
RER NNP - B-ORG
in ADP - O
the DET - O
dark ADJ - O
and CCONJ - O
light ADJ - O
phases NOUN - O
( PUNCT - O
most ADV - O
consistently ADV - O
in ADP - O
the DET - O
4-hours CD - B-ORDINAL
post ADJ - O
- ADJ - O
treatment ADJ - O
) PUNCT - O
, PUNCT - O
while ADP - O
ICV NNP - B-ORG
insulin NOUN - O
reduced VERB - O
average ADJ - O
RER NNP - B-ORG
predominantly ADV - O
in ADP - O
the DET - O
dark ADJ - O
phase NOUN - O
, PUNCT - O
but CCONJ - O
also ADV - O
at ADP - O
the DET - O
end NOUN - O
of ADP - O
the DET - O
light ADJ - O
cycle NOUN - O
. PUNCT - O

Olanzapine NN - B-MEDICINE
treatment NOUN - O
, PUNCT - O
alone ADV - O
or CCONJ - O
in ADP - O
combination NOUN - O
with ADP - O
ICV PROPN - O
- PUNCT - O
insulin NOUN - O
, PUNCT - O
significantly ADV - O
reduced VERB - O
VCO2 PROPN - O
at ADP - O
regular ADJ - O
intervals NOUN - O
in ADP - O
the DET - O
dark ADJ - O
phase NOUN - O
( PUNCT - O
specifically ADV - O
3 CD - B-CARDINAL
  SPACE - O
h PRON - O
post ADJ - O
- ADJ - O
treatment ADJ - O
) PUNCT - O
, PUNCT - O
while ADP - O
VO2 NNP - B-PERSON
was VERB - O
not ADV - O
significantly ADV - O
altered VERB - O
by ADP - O
either DET - O
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Reply VERB - O
to ADP - O
: PUNCT - O
Comment VERB - O
on ADP - O
: PUNCT - O
Olanzapine NN - B-MEDICINE
for ADP - O
chemotherapy NOUN - O
- PUNCT - O
induced VERB - O
nausea NOUN - O
: PUNCT - O
Lessons NOUN - O
learned VERB - O
from ADP - O
child NOUN - O
and CCONJ - O
adolescent NOUN - O
psychiatry NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
is VERB - O
more ADV - O
commonly ADV - O
prescribed VERB - O
to ADP - O
people NOUN - O
with ADP - O
lower ADJ - O
weight NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine RB - B-MEDICINE
, PUNCT - O
clozapine NOUN - O
and CCONJ - O
risperidone NOUN - O
showed VERB - O
superiority NOUN - O
for ADP - O
symptom NOUN - O
reduction NOUN - O
compared VERB - O
to ADP - O
some DET - O
other ADJ - O
drugs NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
10 CD - B-QUANTITY
mg NNS - I-QUANTITY
or CCONJ - O
matching VERB - O
placebo NOUN - O
were VERB - O
given VERB - O
on ADP - O
each DT - B-DATE
chemotherapy NN - I-DATE
day NN - I-DATE
and CCONJ - O
3 CD - B-DATE
days NNS - I-DATE
after RB - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Versus PROPN - O
FOND PROPN - O
Plus CCONJ - O
Olanzapine NNP - B-MEDICINE
( PUNCT - O
FOND PROPN - O
- PUNCT - O
O PROPN - O
) PUNCT - O
for ADP - O
the DET - O
Prevention PROPN - O
of ADP - O
Chemotherapy PROPN - O
- PUNCT - O
Induced VERB - O
Nausea PROPN - O
and CCONJ - O
Vomiting PROPN - O
in ADP - O
Patients PROPN - O
with ADP - O
Hematologic PROPN - O
Malignancies PROPN - O
Receiving VERB - O
Highly ADV - O
Emetogenic ADJ - O
Chemotherapy PROPN - O
and CCONJ - O
Hematopoietic NNP - B-ORG
Cell NNP - I-ORG

-DOCSTART- -X- - O

Butyl NNP - B-ORG
Methacrylate NNP - I-ORG
- HYPH - I-ORG
Co NNP - I-ORG
- HYPH - I-ORG
Ethylene NNP - I-ORG
Glycol NNP - I-ORG
Dimethacrylate NNP - I-ORG
Monolith NNP - I-ORG
for IN - I-ORG
Online NNP - I-ORG
in IN - I-ORG
- HYPH - I-ORG
Tube NNP - I-ORG
SPME NNP - I-ORG
- HYPH - I-ORG
UHPLC NNP - I-ORG
- HYPH - I-ORG
MS NNP - I-ORG
/ SYM - I-ORG
MS NNP - I-ORG
to PART - O
Determine VB - B-ORG
Chlopromazine NNP - I-ORG
, PUNCT - O
Clozapine NNP - B-ORG
, PUNCT - O
Quetiapine NNP - B-GPE
, PUNCT - O
Olanzapine NNP - B-MEDICINE
, PUNCT - O
and CCONJ - O
Their PRP$ - B-WORK_OF_ART
Metabolites NNS - I-WORK_OF_ART
in IN - I-WORK_OF_ART
Plasma NNP - I-WORK_OF_ART
Samples NNPS - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

Metabolic NNP - B-ORG
Changes NNP - I-ORG
in ADP - O
Patients NNPS - B-GPE
with ADP - O
Schizophrenia PROPN - O
Switched VERB - O
From ADP - O
Olanzapine NNP - B-MEDICINE
to ADP - O
Asenapine NNP - B-GPE
or CCONJ - O
Clozapine NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
was VERB - O
superior ADJ - O
to PART - O
haloperidol VERB - O
in ADP - O
overall ADJ - O
symptoms NOUN - O
, PUNCT - O
negative ADJ - O
symptoms NOUN - O
and CCONJ - O
response NOUN - O
, PUNCT - O
and CCONJ - O
it PRON - O
was VERB - O
associated VERB - O
with ADP - O
fewer ADJ - O
dropouts NOUN - O
than ADP - O
risperidone NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
resulted VERB - O
in ADP - O
a DET - O
greater ADJ - O
proportion NOUN - O
of ADP - O
patients NOUN - O
adequately ADV - O
sedated VERB - O
at ADP - O
15 CD - B-TIME
minutes NNS - I-TIME
compared VERB - O
with ADP - O
haloperidol NOUN - O
5 CD - B-CARDINAL
mg PRON - O
( PUNCT - O
difference NOUN - O
20 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
10 CD - B-PERCENT
% NN - I-PERCENT
to TO - I-PERCENT
31 CD - I-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
haloperidol NOUN - O
10 CD - B-QUANTITY
mg NNS - I-QUANTITY
( PUNCT - O
difference NOUN - O
18 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
7 CD - B-PERCENT
% NN - I-PERCENT
to TO - I-PERCENT
29 CD - I-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
and CCONJ - O
ziprasidone NOUN - O
( PUNCT - O
difference NOUN - O
8 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-PERCENT
-3 NN - I-PERCENT
% NN - I-PERCENT
to TO - I-PERCENT
19 CD - I-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

Olanzapine NNP - B-MEDICINE
provided VERB - O
more ADV - O
effective ADJ - O
sedation NOUN - O
than ADP - O
haloperidol NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Intramuscular NNP - B-PERSON
Midazolam NNP - I-PERSON
, PUNCT - O
Olanzapine NNP - B-MEDICINE
, PUNCT - O
Ziprasidone NNP - B-GPE
, PUNCT - O
or CCONJ - O
Haloperidol NNP - B-ORG
for IN - I-ORG
Treating NNP - I-ORG
Acute NNP - I-ORG
Agitation NNP - I-ORG
in IN - I-ORG
the DT - I-ORG
Emergency NNP - I-ORG
Department NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
of ADP - O
this DET - O
study NOUN - O
is VERB - O
to PART - O
explore VERB - O
the DET - O
influence NOUN - O
of ADP - O
the DET - O
most ADV - O
commonly ADV - O
used VERB - O
antipsychotics NOUN - O
in ADP - O
this DET - O
population NOUN - O
( PUNCT - O
Olanzapine NNP - B-MEDICINE
and CCONJ - O
Risperidone PROPN - O
) PUNCT - O
on ADP - O
physical ADJ - O
activity NOUN - O
and CCONJ - O
the DET - O
physical ADJ - O
fitness NOUN - O
of ADP - O
people NOUN - O
with ADP - O
severe ADJ - O
mental ADJ - O
illness NOUN - O
. PUNCT - O

The DET - O
doses NOUN - O
of ADP - O
Risperidone NNP - B-PERSON
and CCONJ - O
Olanzapine NNP - B-MEDICINE
were VERB - O
also ADV - O
evaluated VERB - O
in ADP - O
all DET - O
participants NOUN - O
. PUNCT - O

Regarding VERB - O
physical ADJ - O
fitness NOUN - O
, PUNCT - O
significant ADJ - O
differences NOUN - O
were VERB - O
only ADV - O
found VERB - O
for ADP - O
the DET - O
consumption NOUN - O
of ADP - O
Risperidone NNP - B-GPE
, PUNCT - O
with ADP - O
better ADJ - O
physical ADJ - O
fitness NOUN - O
levels NOUN - O
seen VERB - O
in ADP - O
patients NOUN - O
who NOUN - O
did VERB - O
not ADV - O
consume VERB - O
this DET - O
medication NOUN - O
; PUNCT - O
on ADP - O
the DET - O
other ADJ - O
hand NOUN - O
, PUNCT - O
for ADP - O
the DET - O
consumption NOUN - O
of ADP - O
Olanzapine NNP - B-MEDICINE
, PUNCT - O
differences NOUN - O
were VERB - O
found VERB - O
in ADP - O
muscular ADJ - O
strength NOUN - O
, PUNCT - O
balance NOUN - O
and CCONJ - O
aerobic ADJ - O
condition NOUN - O
with ADP - O
better ADJ - O
values NOUN - O
in ADP - O
non JJ - B-NORP
- JJ - I-NORP
Olanzapine JJ - I-MEDICINE
consumers NOUN - O
compared VERB - O
with ADP - O
Olanzapine NNP - B-MEDICINE
consumers NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
was VERB - O
used VERB - O
in ADP - O
five CD - B-CARDINAL
and CCONJ - O
risperidone NOUN - O
in ADP - O
six CD - B-CARDINAL
experiments NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Comparison NNP - I-ORG
of IN - I-ORG
Olanzapine NNP - I-MEDICINE
and CC - I-ORG
Risperidone NNP - I-ORG
Treatment NNP - I-ORG
in IN - I-ORG
Male NNP - I-ORG
Schizophrenic NNP - I-ORG
Patients NNPS - I-ORG
using VERB - O
Positive PROPN - O
and CCONJ - O
Negative PROPN - O
Syndromes PROPN - O
Scale PROPN - O
( PUNCT - O
PANSS PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
- PUNCT - O
induced VERB - O
Cataract NNP - B-ORG
in ADP - O
a DET - O
Teenage NNP - B-FAC
Girl NNP - I-FAC
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
has VERB - O
rapidly ADV - O
become VERB - O
the DET - O
first JJ - B-ORDINAL
choice NOUN - O
of ADP - O
intramuscular ADJ - O
medication NOUN - O
in ADP - O
psychiatric ADJ - O
emergency NOUN - O
situations NOUN - O
since ADP - O
it PRON - O
became VERB - O
available ADJ - O
in ADP - O
Japan NNP - B-GPE
, PUNCT - O
probably ADV - O
due ADP - O
to ADP - O
the DET - O
advantages NOUN - O
in ADP - O
both DET - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comment NOUN - O
on ADP - O
: PUNCT - O
Olanzapine NN - B-MEDICINE
for ADP - O
chemotherapy NOUN - O
- PUNCT - O
induced VERB - O
nausea NOUN - O
: PUNCT - O
Lessons NOUN - O
learned VERB - O
from ADP - O
child NOUN - O
and CCONJ - O
adolescent NOUN - O
psychiatry NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Randomized VBN - B-ORG
, , - I-ORG
Double JJ - I-ORG
- HYPH - I-ORG
Blind JJ - I-ORG
, PUNCT - O
Placebo NNP - B-GPE
- PUNCT - O
Controlled PROPN - O
Study PROPN - O
of ADP - O
the DET - O
Safety PROPN - O
and CCONJ - O
Efficacy PROPN - O
of ADP - O
Olanzapine NNP - B-MEDICINE
for ADP - O
the DET - O
Prevention PROPN - O
of ADP - O
Chemotherapy PROPN - O
- PUNCT - O
Induced VERB - O
Nausea PROPN - O
and CCONJ - O
Vomiting PROPN - O
in ADP - O
Patients PROPN - O
Receiving VERB - O
Moderately PROPN - O
Emetogenic PROPN - O
Chemotherapy NOUN - O
: PUNCT - O
Results NOUN - O
of ADP - O
the DT - B-LOC
Korean NNP - I-LOC
South NNP - I-LOC
West NNP - I-LOC
Oncology NNP - I-LOC
Group NNP - I-LOC

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
is VERB - O
an DET - O
effective ADJ - O
antinausea NOUN - O
agent NOUN - O
, PUNCT - O
but CCONJ - O
sedation NOUN - O
can VERB - O
be VERB - O
a DET - O
problem NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Eryt NNP - B-PERSON
and CCONJ - O
Olanzapine NNP - B-MEDICINE
reduced VERB - O
MDA NNP - B-ORG
concentration NOUN - O
in ADP - O
ST NNP - B-ORG
when ADV - O
compared VERB - O
to ADP - O
KET PROPN - O
group NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
systematic ADJ - O
search NOUN - O
of ADP - O
the DET - O
literature NOUN - O
published VERB - O
before ADP - O
April NNP - B-DATE
2018 CD - I-DATE
was VERB - O
performed VERB - O
on ADP - O
PubMed NNP - B-ORG
using VERB - O
the DET - O
following VERB - O
search NOUN - O
strings NOUN - O
: PUNCT - O
" PUNCT - O
Delirium NNP - B-WORK_OF_ART
" PUNCT - O
and CCONJ - O
" PUNCT - O
Atypical ADJ - O
antipsychotics NOUN - O
" PUNCT - O
, PUNCT - O
" PUNCT - O
Novel ADJ - O
antipsychotics NOUN - O
" PUNCT - O
, PUNCT - O
" PUNCT - O
New ADJ - O
antipsychotics NOUN - O
" PUNCT - O
, PUNCT - O
" PUNCT - O
Quetiapine NNP - B-GPE
" PUNCT - O
, PUNCT - O
" PUNCT - O
Olanzapine NNP - B-MEDICINE
" PUNCT - O
, PUNCT - O
" PUNCT - O
Aripiprazole NNP - B-PRODUCT
" PUNCT - O
, PUNCT - O
" PUNCT - O
Risperidone PROPN - O
" PUNCT - O
, PUNCT - O
" PUNCT - O
Paliperidone PROPN - O
" PUNCT - O
, PUNCT - O
" PUNCT - O
Clozapine PROPN - O
" PUNCT - O
, PUNCT - O
" PUNCT - O
Asenapine NNP - B-WORK_OF_ART
" PUNCT - O
, PUNCT - O
" PUNCT - O
Iloperidone NOUN - O
" PUNCT - O
, PUNCT - O
" PUNCT - O
Amisulpiride PROPN - O
" PUNCT - O
, PUNCT - O
" PUNCT - O
Ziprasidone NNP - B-ORG
" '' - I-ORG
, PUNCT - O
" PUNCT - O
Zotepine NNP - B-WORK_OF_ART
" PUNCT - O
, PUNCT - O
" PUNCT - O
Sertindole PROPN - O
" PUNCT - O
, PUNCT - O
" PUNCT - O
Lurasidone NOUN - O
" PUNCT - O
or CCONJ - O
" PUNCT - O
Perospirone NNP - B-WORK_OF_ART
" PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Exercise NOUN - O
Protects VERB - O
Against ADP - O
Olanzapine NNP - B-MEDICINE
- PUNCT - O
Induced PROPN - O
Hyperglycemia PROPN - O
in ADP - O
Male PROPN - O
C57BL/6J PROPN - O
Mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Olanzapine NNP - B-MEDICINE
on ADP - O
Clinical PROPN - O
and CCONJ - O
Polysomnography PROPN - O
Profiles PROPN - O
in ADP - O
Patients NNS - B-GPE
with ADP - O
Schizophrenia NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
and CCONJ - O
haloperidol NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
acute ADJ - O
symptoms NOUN - O
of ADP - O
mental ADJ - O
disorders NOUN - O
induced VERB - O
by ADP - O
amphetamine ADJ - O
- PUNCT - O
type NOUN - O
stimulants NOUN - O
: PUNCT - O
A DET - O
randomized ADJ - O
controlled VERB - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

ResultsThe PROPN - O
most ADV - O
frequently ADV - O
used VERB - O
drugs NOUN - O
were VERB - O
Risperidone NNP - B-ORG
, PUNCT - O
Aripiprazole NNP - B-GPE
, PUNCT - O
Olanzapine NNP - B-MEDICINE
in ADP - O
the DET - O
antipsychotic ADJ - O
drug NOUN - O
, PUNCT - O
Valproate NNP - B-ORG
, , - I-ORG
Lamotrigine NNP - I-ORG
, , - I-ORG
Topiramate NN - I-ORG
in ADP - O
the DET - O
anticonvulsant ADJ - O
agents NOUN - O
, PUNCT - O
Escitalopram NNP - B-ORG
, PUNCT - O
Sertraline NNP - B-ORG
, PUNCT - O
Milnacipran NNP - B-ORG
in ADP - O
antidepressants NOUN - O
, PUNCT - O
Lorazepam NNP - B-PERSON
, PUNCT - O
Clonazepam NNP - B-PERSON
, PUNCT - O
Zolpidem NNP - B-ORG
in ADP - O
anxiolytics NOUN - O
or CCONJ - O
sedatives NOUN - O
, PUNCT - O
Propranolol NNP - B-PERSON
, PUNCT - O
Benztropine NNP - B-PERSON
, PUNCT - O
Trihexyphenidyl NNP - B-PERSON
in ADP - O
antiparkinson NOUN - O
drugs NOUN - O
. PUNCT - O

Aripiprazole PROPN - O
also ADV - O
showed VERB - O
a DET - O
lower ADJ - O
incidence NOUN - O
of ADP - O
discontinuation NOUN - O
except ADP - O
for ADP - O
Clozapine NNP - B-ORG
and CCONJ - O
Olanzapine NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Comparison NOUN - O
of ADP - O
the DET - O
Effects NOUN - O
of ADP - O
Piroxicam PROPN - O
and CCONJ - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
as ADP - O
Treatments NNP - B-ORG
for IN - I-ORG
Primary NNP - I-ORG
Dysmenorrhea NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
Vitro PROPN - O
Evaluation NOUN - O
of ADP - O
2D PROPN - O
- PUNCT - O
Printed VERB - O
Edible PROPN - O
Films NOUN - O
for ADP - O
the DET - O
Buccal ADJ - O
Delivery NOUN - O
of ADP - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Influence NN - I-ORG
of IN - I-ORG
Simulated NNP - I-ORG
Fasted NNP - I-ORG
Gastrointestinal NNP - I-ORG
pH XX - I-ORG
Profiles NNS - I-ORG
on IN - I-ORG
Diclofenac NNP - I-ORG
Sodium NNP - I-ORG
Dissolution NNP - I-ORG
in ADP - O
a DET - O
Glass NNP - B-FAC
- HYPH - I-FAC
Bead NNP - I-FAC
Flow NNP - I-FAC
- HYPH - I-FAC
Through NNP - I-FAC
System NNP - I-FAC
. PUNCT - O

-DOCSTART- -X- - O

Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
3 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O

-DOCSTART- -X- - O

Oral NNP - B-ORG
Versus NNP - I-ORG
Topical NNP - I-ORG
Diclofenac NNP - I-ORG
Sodium NNP - I-ORG
in ADP - O
the DT - B-ORG
Treatment NNP - I-ORG
of IN - I-ORG
Osteoarthritis NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
case NOUN - O
study NOUN - O
of ADP - O
Diclofenac NNP - B-ORG
Sodium NN - I-ORG
Extended ADJ - O
Release PROPN - O
Matrix PROPN - O
Tablets NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pharmacological ADJ - O
effects NOUN - O
of ADP - O
Vitamin NNP - B-ORG
C NNP - I-ORG
& CC - I-ORG
E NNP - I-ORG
on ADP - O
Diclofenac NNP - B-ORG
Sodium NNP - I-ORG
intoxicated VERB - O
Rats NNPS - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Diclofenac NNP - B-ORG
Sodium NNP - I-ORG
Bolus NNP - I-ORG
Injection NNP - I-ORG
( PUNCT - O
Dyloject(TM PROPN - O
) PUNCT - O
) PUNCT - O
: PUNCT - O

-DOCSTART- -X- - O

pH NOUN - O
- PUNCT - O
Responsive ADJ - O
PLGA PROPN - O
Nanoparticle PROPN - O
for ADP - O
Controlled PROPN - O
Payload PROPN - O
Delivery NOUN - O
of ADP - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Characterization NOUN - O
of ADP - O
the DT - B-ORG
Effect NNP - I-ORG
of IN - I-ORG
Drug NNP - I-ORG
- HYPH - I-ORG
Drug NN - I-ORG
Interaction NNP - I-ORG
on IN - I-ORG
Protein NNP - I-ORG
Binding NNP - I-ORG
in IN - I-ORG
Concurrent NNP - I-ORG
Administration NNP - I-ORG
of IN - I-ORG
Sulfamethoxazol NNP - I-ORG
and CC - I-ORG
Diclofenac NNP - I-ORG
Sodium NNP - I-ORG

-DOCSTART- -X- - O

Topical PROPN - O
Colchicine PROPN - O
Gel PROPN - O
versus ADP - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
Gel PROPN - O
for ADP - O
the DET - O
Treatment PROPN - O
of ADP - O
Actinic PROPN - O
Keratoses PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Development PROPN - O
of ADP - O
Oral PROPN - O
Dissolvable PROPN - O
Films PROPN - O
of ADP - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
for ADP - O
Osteoarthritis PROPN - O
Using PROPN - O
Albizia PROPN - O
and CCONJ - O
Khaya NNP - B-ORG
Gums NNP - I-ORG
as ADP - O
Hydrophilic NNP - B-ORG
Film NNP - I-ORG
Formers NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
Situ PROPN - O
Hydrogels NOUN - O
Combined VERB - O
With ADP - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
- PUNCT - O
Loaded PROPN - O
Alginate PROPN - O
Microspheres PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison NOUN - O
of ADP - O
the DET - O
Effects NOUN - O
of ADP - O
Daily PROPN - O
Single PROPN - O
- PUNCT - O
Dose PROPN - O
Use PROPN - O
of ADP - O
Flurbiprofen NNP - B-ORG
, , - I-ORG
Diclofenac NNP - I-ORG
Sodium NNP - I-ORG
, PUNCT - O
and CCONJ - O
Tenoxicam NNP - B-ORG
on IN - I-ORG
Postoperative NNP - I-ORG
Pain NNP - I-ORG
, , - I-ORG
Swelling NN - I-ORG
, PUNCT - O
and CCONJ - O
Trismus NNP - B-PERSON
: PUNCT - O
A DET - O
Randomized VERB - O
Double ADJ - O
- PUNCT - O
Blind PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison NOUN - O
of ADP - O
the DT - B-ORG
Analgesic NNP - I-ORG
Effect NNP - I-ORG
of IN - I-ORG
Diclofenac NNP - I-ORG
Sodium NNP - I-ORG
- HYPH - I-ORG
Eudragit NNP - I-ORG
( PUNCT - O
® NOUN - O
) PUNCT - O

-DOCSTART- -X- - O

In ADP - O
the DET - O
present ADJ - O
study NOUN - O
, PUNCT - O
Diclofenac NNP - B-PERSON
Sodium NNP - I-PERSON
( PUNCT - O
DS NNP - B-PERSON
) PUNCT - O
matrix NOUN - O
tablets NOUN - O
were VERB - O
prepared VERB - O
by ADP - O
direct ADJ - O
compression NOUN - O
method NOUN - O
under ADP - O
different ADJ - O
compression NOUN - O
forces NOUN - O
( PUNCT - O
5 CD - B-CARDINAL
, PUNCT - O
10 CD - B-CARDINAL
, PUNCT - O
15 CD - B-DATE
and CCONJ - O
20 CD - B-CARDINAL
KN NNP - B-ORG
) PUNCT - O
, PUNCT - O
using VERB - O
ethylcellulose NOUN - O
as ADP - O
matrix NOUN - O
forming VERB - O
material NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-ORG
is VERB - O
a DET - O
frequently ADV - O
prescribed VERB - O
antibacterial ADJ - O
agent NOUN - O
with ADP - O
Diclofenac NNP - B-ORG
Sodium NNP - I-ORG
for ADP - O
pain NOUN - O
management NOUN - O
in ADP - O
infectious ADJ - O
conditions NOUN - O
. PUNCT - O

The DET - O
objective NOUN - O
of ADP - O
the DET - O
present ADJ - O
work NOUN - O
is VERB - O
to PART - O
evaluate VERB - O
the DET - O
level NOUN - O
of ADP - O
interaction NOUN - O
between ADP - O
Levofloxacin NNP - B-ORG
and CCONJ - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
. PUNCT - O

However ADV - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
showed VERB - O
adherence NOUN - O
with ADP - O
( PUNCT - O
first JJ - B-ORDINAL
order NOUN - O
, PUNCT - O
Hixson NNP - B-PERSON
Crowell NNP - I-PERSON
and CCONJ - O
Weibull NNP - B-PERSON
) PUNCT - O
at ADP - O
pH PROPN - O
( PUNCT - O
1.2 CD - B-CARDINAL
, PUNCT - O
4.5 CD - B-CARDINAL
and CCONJ - O
6.8 CD - B-DATE
) PUNCT - O
but CCONJ - O
following VERB - O
Higuchi NNP - B-GPE
at ADP - O
pH PROPN - O
1.2 CD - B-CARDINAL
and CCONJ - O
4.5 CD - B-CARDINAL
only ADV - O
. PUNCT - O

The DET - O
studies NOUN - O
showed VERB - O
that ADP - O
the DET - O
percent NOUN - O
availability NOUN - O
of ADP - O
Levofloxacin NNP - B-ORG
was VERB - O
increased VERB - O
significantly ADV - O
in ADP - O
FaSSIF NNP - B-ORG
i.e. X - O
129.173±0.323 NUM - O
at ADP - O
45 CD - B-TIME
minutes NNS - I-TIME
in ADP - O
the DET - O
presence NOUN - O
of ADP - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Catalytic ADJ - O
Degradation PROPN - O
of ADP - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
over ADP - O
the DT - B-ORG
Catalyst NNP - I-ORG
of IN - I-ORG
3D NNP - I-ORG
Flower NNP - I-ORG
- PUNCT - O
like PROPN - O
alpha NOUN - O
- PUNCT - O
FeOOH NOUN - O
Synergized VERB - O
with ADP - O
H2O2 NOUN - O
Under ADP - O
Visible JJ - B-PRODUCT
Light NN - I-PRODUCT
Irradiation]. NNP - I-PRODUCT

-DOCSTART- -X- - O

Nephroprotective ADJ - O
Effect PROPN - O
of ADP - O
the DET - O
Leaves PROPN - O
of ADP - O
Aloe PROPN - O
barbadensis NOUN - O
( PUNCT - O
Aloe NNP - B-PERSON
Vera NNP - I-PERSON
) PUNCT - O
against ADP - O
Toxicity PROPN - O
Induced VERB - O
by ADP - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
in ADP - O
Albino NNP - B-GPE
Rabbits NNP - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

Influence NOUN - O
of ADP - O
the DET - O
Vehicle PROPN - O
and CCONJ - O
Antibiotic NNP - B-ORG
Formulation NNP - I-ORG
on IN - I-ORG
Cytotoxicity NNP - I-ORG
of IN - I-ORG
Triple NNP - I-ORG
Antibiotic NNP - I-ORG
Paste NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Infection NNP - B-ORG
Control NNP - I-ORG
in ADP - O
Teeth NNP - B-GPE
with ADP - O
Apical NNP - B-ORG
Periodontitis NNP - I-ORG
Using VERB - O
a DET - O
Triple NNP - B-MEDICINE
Antibiotic NNP - I-MEDICINE
Solution PROPN - O
or CCONJ - O
Calcium PROPN - O
Hydroxide PROPN - O
with ADP - O
Chlorhexidine NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

A DET - O
Review NOUN - O
on ADP - O
Triple NNP - B-MEDICINE
Antibiotic NNP - I-MEDICINE
Paste PROPN - O
as ADP - O
a DET - O
Suitable PROPN - O
Material PROPN - O
Used VERB - O
in ADP - O
Regenerative PROPN - O
Endodontics PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Efficacy NOUN - O
of ADP - O
Vancomycin NNP - B-GPE
- PUNCT - O
based VERB - O
Continuous NNP - B-ORG
Triple NNP - I-ORG
Antibiotic NNP - I-ORG
Irrigation NNP - I-ORG
in ADP - O
Immediate NNP - B-NORP
, PUNCT - O
Implant PROPN - O
- PUNCT - O
based VERB - O
Breast NNP - B-GPE
Reconstruction NNP - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

Comparison NN - B-ORG
of IN - I-ORG
Antimicrobial NNP - I-ORG
Effects NNPS - I-ORG
of IN - I-ORG
Triple NNP - I-ORG
Antibiotic NNP - I-ORG
Paste NNP - I-ORG
and CCONJ - O
Calcium PROPN - O
Hydroxide PROPN - O
Mixed VERB - O
with ADP - O
2 CD - B-PERCENT
% NN - I-PERCENT
Chlorhexidine PROPN - O
as ADP - O
Intracanal ADJ - O
Medicaments PROPN - O

-DOCSTART- -X- - O

To PART - O
observe VERB - O
the DET - O
potential NOUN - O
of ADP - O
combinations NOUN - O
[ PUNCT - O
( PUNCT - O
Amoxicillin+ NNP - B-ORG
Metronidazole NNP - I-ORG
, PUNCT - O
Amoxicillin PROPN - O
Clavulanic PROPN - O
Acid PROPN - O
+ CCONJ - O
Metronidazole PROPN - O
; PUNCT - O
Amoxicillin NNP - B-GPE
and CCONJ - O
Cloxacillin NNP - B-ORG
+ CC - I-ORG
Metronidazole NNP - I-ORG
) PUNCT - O
] PUNCT - O
over ADP - O
Triple NNP - B-ORG
Antibiotic NNP - I-ORG
Paste NNP - I-ORG
. PUNCT - O

The DET - O
largest ADJ - O
inhibition NOUN - O
zones NOUN - O
were VERB - O
observed VERB - O
for ADP - O
the DT - B-ORG
Triple NNP - I-ORG
Antibiotic NNP - I-ORG
Paste NNP - I-ORG
, PUNCT - O
followed VERB - O
by ADP - O
Amoxicillin NNP - B-GPE
and CCONJ - O
Clavulanic NNP - B-ORG
acid NOUN - O
+ CCONJ - O
Metronidazole PROPN - O
group NOUN - O
however ADV - O
, PUNCT - O
the DET - O
clearest ADJ - O
zones NOUN - O
were VERB - O
achieved VERB - O
with ADP - O
Amoxicillin NNP - B-ORG
and CCONJ - O
Clavlunic NNP - B-ORG
acid NOUN - O
+ CCONJ - O
Metronidazole PROPN - O
group NOUN - O
and CCONJ - O
the DET - O
smallest ADJ - O
for ADP - O
Amoxicillin NNP - B-ORG
and CCONJ - O
Metronidazole NNP - B-PRODUCT
group NOUN - O
. PUNCT - O

Key ADJ - O
words NOUN - O
: PUNCT - O
Enterococcus NOUN - O
faecalis NOUN - O
, PUNCT - O
Triple NNP - B-ORG
Antibiotic NNP - I-ORG
Paste NNP - I-ORG
, PUNCT - O
Amoxcillin NNP - B-GPE
, PUNCT - O
Clavulanic JJ - B-ORG
acid NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
a DET - O
Low PROPN - O
Surface PROPN - O
Tension PROPN - O
Vehicle PROPN - O
on ADP - O
the DT - B-EVENT
Dentinal NNP - I-EVENT
Tubule NNP - I-EVENT
Penetration NNP - I-EVENT
of IN - I-EVENT
Calcium NNP - I-EVENT
Hydroxide NNP - I-EVENT
and CCONJ - O
Triple NNP - B-ORG
Antibiotic NNP - I-ORG
Paste NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Novel ADJ - O
Microdilution NOUN - O
Method PROPN - O
to ADP - O
Assess NNP - B-ORG
Double JJ - I-ORG
and CCONJ - O
Triple NNP - B-ORG
Antibiotic NNP - I-ORG
Combination NNP - I-ORG
Therapy NNP - I-ORG

-DOCSTART- -X- - O

Triple JJ - B-MEDICINE
Antibiotic NNP - I-MEDICINE
Polymer PROPN - O
Nanofibers PROPN - O
for ADP - O
Intracanal ADJ - O
Drug PROPN - O
Delivery PROPN - O
: PUNCT - O
Effects NOUN - O
on ADP - O
Dual PROPN - O
Species PROPN - O
Biofilm PROPN - O
and CCONJ - O
Cell NNP - B-ORG
Function NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Laser NNP - B-ORG
- HYPH - I-ORG
Activated NNP - I-ORG
Irrigation NNP - I-ORG
with ADP - O
Ethylene NNP - B-PERSON
Diaminetetraacetic NNP - I-PERSON
Acid NNP - I-PERSON
and CCONJ - O
Phytic ADJ - O
Acid NOUN - O
on ADP - O
the DET - O
Removal PROPN - O
of ADP - O
Calcium PROPN - O
Hydroxide PROPN - O
and CCONJ - O
Triple NNP - B-ORG
Antibiotic NNP - I-ORG
Paste NNP - I-ORG
from ADP - O
Root NNP - B-PERSON
Dentin NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial ADJ - O
Effects NOUN - O
of ADP - O
Novel PROPN - O
Triple JJ - B-MEDICINE
Antibiotic JJ - I-MEDICINE
Paste PROPN - O
- PUNCT - O
Mimic PROPN - O
Scaffolds PROPN - O
on ADP - O
Actinomyces PROPN - O
naeslundii VERB - O
Biofilm PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Revisiting VERB - O
Triple NNP - B-MEDICINE
Antibiotic NNP - I-MEDICINE
Irrigation PROPN - O
of ADP - O
Breast PROPN - O
Implant PROPN - O
Pockets PROPN - O
: PUNCT - O
A DET - O
Placebo NN - B-GPE
- PUNCT - O
controlled VERB - O
Single PROPN - O
Practice PROPN - O
Cohort PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Human PROPN - O
APC NNP - B-ORG
were VERB - O
tested VERB - O
for ADP - O
in ADP - O
vitro X - O
cytotoxicity NOUN - O
of ADP - O
modified VERB - O
Triple PROPN - O
Antibiotic NNP - B-PERSON
Paste NNP - I-PERSON
( PUNCT - O
mTAP PROPN - O
- PUNCT - O
Ciprofloxacin PROPN - O
, PUNCT - O
Metronidazole NNP - B-PERSON
and CCONJ - O
Cefaclor PROPN - O
at ADP - O
1:1:1 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
of ADP - O
a DET - O
paste NOUN - O
of ADP - O
Ciprofloxacin NNP - B-ORG
, PUNCT - O
Metronidazole NNP - B-PRODUCT
and CCONJ - O
Calcium NNP - B-ORG
hydroxide NOUN - O
( PUNCT - O
CMC PROPN - O
- PUNCT - O
1:1:2 NUM - O
) PUNCT - O
and CCONJ - O
modified VERB - O
CMC NNP - B-ORG
( PUNCT - O
mCMC PROPN - O
- PUNCT - O
2:2:1 NUM - O
) PUNCT - O
by ADP - O
using VERB - O
MTT NNP - B-ORG
assay NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Dual ADJ - O
versus ADP - O
Triple NNP - B-ORG
Antibiotics NNP - I-ORG
Regimen NNP - I-ORG
in IN - I-ORG
Children NNPS - I-ORG
with IN - I-ORG
Perforated NNP - I-ORG
Acute NNP - I-ORG
Appendicitis NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

With ADP - O
Calcium NNP - B-MEDICINE
Gluconate NNP - I-MEDICINE
: PUNCT - O

-DOCSTART- -X- - O

Lesions NOUN - O
Associated VERB - O
With ADP - O
Calcium NNP - B-MEDICINE
Gluconate NNP - I-MEDICINE
Extravasation NOUN - O
: PUNCT - O
Presentation NOUN - O
of ADP - O
5 CD - B-CARDINAL
Clinical NNP - B-WORK_OF_ART
Cases NNPS - I-WORK_OF_ART
and CC - I-WORK_OF_ART
Analysis NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Cases NNPS - I-WORK_OF_ART
Published VBN - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aluminum NOUN - O
concentration NOUN - O
in ADP - O
a DET - O
recently ADV - O
released VERB - O
Calcium NNP - B-ORG
Gluconate NNP - I-ORG
Injection NNP - I-ORG
USP NNP - I-ORG
was VERB - O
approximately ADV - O
320 NUM - O
μg PROPN - O
/ SYM - O
L. PROPN - O
Phthalates PROPN - O
were VERB - O
not ADV - O
detected VERB - O
in ADP - O
any DET - O
calcium NN - B-MEDICINE
gluconate NN - I-MEDICINE
solutions NOUN - O
or CCONJ - O
leachates NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Hydrofluoric PROPN - O
Acid NOUN - O
Burn VERB - O
on ADP - O
a DET - O
Fingertip PROPN - O
Treated VERB - O
Successfully ADV - O
with ADP - O
Single PROPN - O
Session PROPN - O
of ADP - O
Subcutaneous PROPN - O
Injection PROPN - O
of ADP - O
6.7 CD - B-PERCENT
% NN - I-PERCENT
Calcium NNP - B-MEDICINE
Gluconate NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Results NOUN - O
from ADP - O
a DET - O
Natural PROPN - O
Experiment PROPN - O
Created VERB - O
by ADP - O
a DET - O
Calcium NNP - B-MEDICINE
Gluconate NNP - I-MEDICINE
Shortage PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Effect NNP - I-ORG
of IN - I-ORG
Thyroid NNP - I-ORG
Hormone NNP - I-ORG
, PUNCT - O
Prostaglandin NNP - B-ORG
E2 NNP - I-ORG
, PUNCT - O
and CCONJ - O
Calcium NNP - B-ORG
Gluconate NNP - I-ORG
on IN - I-ORG
Orthodontic NNP - I-ORG
Tooth NNP - I-ORG
Movement NNP - I-ORG
and CC - I-ORG
Root NNP - I-ORG
Resorption NNP - I-ORG
in IN - I-ORG
Rats NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
Is VERB - O
an DET - O
Effective ADJ - O
Alternative NOUN - O
to ADP - O
Decrease PROPN - O
the DT - B-ORG
Incidence NNP - I-ORG
of IN - I-ORG
Postspinal NNP - I-ORG
Hypotension NNP - I-ORG
in ADP - O
Healthy PROPN - O
Subjects PROPN - O
Undergoing PROPN - O
Infra NNP - B-ORG
- HYPH - I-ORG
Umbilical NNP - I-ORG
Surgeries NNPS - I-ORG

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Intraoperative NNP - B-ORG
Dexamethasone NNP - I-ORG
and CCONJ - O
Ondansetron NNP - B-MEDICINE
on ADP - O
Postoperative NNP - B-ORG
Nausea NNP - I-ORG
and CC - I-ORG
Vomiting NNP - I-ORG
in ADP - O
Microvascular PROPN - O
Decompression PROPN - O
Surgery PROPN - O
: PUNCT - O
A DET - O
Randomized VERB - O
Controlled PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Helping VERB - O
Pregnant PROPN - O
Women PROPN - O
and CCONJ - O
Clinicians NNPS - B-NORP
Understand VERB - O
the DET - O
Risk NOUN - O
of ADP - O
Ondansetron NNP - B-MEDICINE
for ADP - O
Nausea PROPN - O
and CCONJ - O
Vomiting PROPN - O
During ADP - O
Pregnancy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
is VERB - O
one NUM - O
of ADP - O
the DET - O
most ADV - O
widely ADV - O
used VERB - O
drugs NOUN - O
in ADP - O
the DET - O
prophylaxis NOUN - O
of ADP - O
PONV PROPN - O
and CCONJ - O
is VERB - O
extensively ADV - O
metabolized VERB - O
in ADP - O
humans NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
is VERB - O
the DET - O
first JJ - B-ORDINAL
reported VERB - O
fluorescence NOUN - O
study NOUN - O
of ADP - O
Ondansetron NNP - B-MEDICINE
in ADP - O
Triton NNP - B-GPE
X NOUN - O
100 CD - B-CARDINAL
system NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Determination NOUN - O
of ADP - O
Ondansetron NNP - B-MEDICINE
by ADP - O
Spectrofluorimetry PROPN - O
: PUNCT - O
Application NOUN - O
to ADP - O
Forced PROPN - O
Degradation PROPN - O
Study PROPN - O
, PUNCT - O
Pharmaceuticals PROPN - O
and CCONJ - O
Human PROPN - O
Plasma PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison NOUN - O
of ADP - O
Ondansetron NNP - B-MEDICINE
versus ADP - O
Clonidine NNP - B-ORG
efficacy NOUN - O
for ADP - O
prevention NOUN - O
of ADP - O
postoperative ADJ - O
pain NOUN - O
, PUNCT - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
after ADP - O
orthognathic ADJ - O
surgeries NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
dispensing VERB - O
during ADP - O
the DET - O
first JJ - B-ORDINAL
trimester NOUN - O
, PUNCT - O
the DET - O
period NOUN - O
of ADP - O
organogenesis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Association NNP - B-ORG
of IN - I-ORG
Maternal NNP - I-ORG
First NNP - I-ORG
- HYPH - I-ORG
Trimester NN - I-ORG
Ondansetron NNP - B-MEDICINE
Use PROPN - O
With ADP - O
Cardiac NNP - B-ORG
Malformations NNPS - I-ORG
and CCONJ - O
Oral NNP - B-FAC
Clefts NNP - I-FAC
in ADP - O
Offspring NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Oral NNP - B-ORG
Ondansetron NNP - I-MEDICINE
Administration NNP - I-ORG
to IN - I-ORG
Nondehydrated NNP - I-ORG
Children NNS - I-ORG

-DOCSTART- -X- - O

Investigation NOUN - O
of ADP - O
Ondansetron NNP - B-MEDICINE
, PUNCT - O
Haloperidol NNP - B-PERSON
, PUNCT - O
and CCONJ - O
Dexmedetomidine NNP - B-PERSON
Efficacy NNP - I-PERSON
for ADP - O
Prevention PROPN - O
of ADP - O
Postoperative PROPN - O
Nausea PROPN - O
and CCONJ - O
Vomiting PROPN - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
offers VERB - O
symptomatic ADJ - O
relief NOUN - O
in ADP - O
the DET - O
majority NOUN - O
of ADP - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Medical PROPN - O
and CCONJ - O
Nursing PROPN - O
Staff PROPN - O
Education PROPN - O
Reduces PROPN - O
Use PROPN - O
of ADP - O
Prophylactic PROPN - O
Ondansetron NNP - B-MEDICINE
With ADP - O
Opioids NNPS - B-GPE
in ADP - O
the DT - B-ORG
Emergency NNP - I-ORG
Department NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
, PUNCT - O
a DET - O
potent ADJ - O
and CCONJ - O
highly ADV - O
sensitive ADJ - O
5-hydroxytryptamine NUM - O
type NOUN - O
3 CD - B-CARDINAL
( PUNCT - O
5-HT3 PROPN - O
) PUNCT - O
receptor NOUN - O
antagonist NOUN - O
, PUNCT - O
has VERB - O
been VERB - O
used VERB - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
chemotherapy- NOUN - O
and CCONJ - O
radiotherapy NOUN - O
- PUNCT - O
induced VERB - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
the DT - B-ORG
Dexamethasone NNP - I-ORG
- HYPH - I-ORG
Ondansetron NNP - I-MEDICINE
Combination NNP - I-ORG
Versus NNP - I-ORG
Dexamethasone NNP - I-ORG
- HYPH - I-ORG
Aprepitant NNP - I-ORG
Combination NNP - I-ORG
to IN - I-ORG
Prevent VB - I-ORG
Postoperative NNP - I-ORG
Nausea NNP - I-ORG
and CC - I-ORG
Vomiting NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
total NOUN - O
of ADP - O
102 CD - B-CARDINAL
patients NOUN - O
who NOUN - O
underwent VERB - O
laparoscopic ADJ - O
cholecystectomy NOUN - O
under ADP - O
general ADJ - O
anesthesia NOUN - O
, PUNCT - O
out ADP - O
of ADP - O
which ADJ - O
patients NOUN - O
who NOUN - O
received VERB - O
Palonosetron NNP - B-ORG
were VERB - O
in ADP - O
Group NNP - B-ORG
A NNP - I-ORG
( PUNCT - O
n=34 NOUN - O
) PUNCT - O
, PUNCT - O
patients NOUN - O
who NOUN - O
received VERB - O
Ondansetron NNP - B-MEDICINE
were VERB - O
in ADP - O
group NOUN - O
B PROPN - O
( PUNCT - O
n=34 NOUN - O
) PUNCT - O
and CCONJ - O
patients NOUN - O
who NOUN - O
received VERB - O
Granisetron NNP - B-PERSON
were VERB - O
in ADP - O
group NOUN - O
C NOUN - O
( PUNCT - O
n=34 PROPN - O
) PUNCT - O
and CCONJ - O
also ADV - O
the DET - O
patients NOUN - O
were VERB - O
selected VERB - O
randomly ADV - O
by ADP - O
lottery NOUN - O
method NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comment NOUN - O
on ADP - O
: PUNCT - O
Ondansetron NNP - B-MEDICINE
in ADP - O
Pregnancy NNP - B-GPE
and CCONJ - O
the DT - B-WORK_OF_ART
Risk NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Congenital JJ - I-WORK_OF_ART
Malformations NNS - I-WORK_OF_ART
: PUNCT - O
A PROPN - O
Systematic PROPN - O
Review PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
was VERB - O
unable ADJ - O
to PART - O
rescue VERB - O
the DET - O
reduction NOUN - O
in ADP - O
duration NOUN - O
of ADP - O
anesthesia NOUN - O
induced VERB - O
by ADP - O
either DET - O
rolipram NOUN - O
or CCONJ - O
yohimbine NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron UH - B-MEDICINE
, PUNCT - O
a DET - O
selective ADJ - O
5-HT3 ADJ - O
receptor NOUN - O
antagonist NOUN - O
; PUNCT - O
L NNP - B-ORG
- HYPH - I-ORG
NAME NNP - I-ORG
, PUNCT - O
a DET - O
NOS NNP - B-ORG
inhibitor NOUN - O
; PUNCT - O
and CCONJ - O
naloxone NOUN - O
, PUNCT - O
an DET - O
opioid ADJ - O
antagonist NOUN - O
were VERB - O
injected VERB - O
to PART - O
determine VERB - O
the DET - O
mechanisms NOUN - O
of ADP - O
antinociception NOUN - O
and CCONJ - O
anti ADJ - O
- ADJ - O
inflammation ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron UH - B-MEDICINE
, PUNCT - O
not ADV - O
approved VERB - O
for ADP - O
use NOUN - O
in ADP - O
pregnancy NOUN - O
, PUNCT - O
is VERB - O
increasingly ADV - O
being VERB - O
prescribed VERB - O
for ADP - O
nausea NOUN - O
and CCONJ - O
vomiting VERB - O
in ADP - O
pregnancy NOUN - O
and CCONJ - O
hyperemesis NOUN - O
gravidarum NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
in ADP - O
Pregnancy NNP - B-GPE
and CCONJ - O
the DT - B-WORK_OF_ART
Risk NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Congenital JJ - I-WORK_OF_ART
Malformations NNS - I-WORK_OF_ART
: PUNCT - O
A PROPN - O
Systematic PROPN - O
Review PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Adding VERB - O
Ondansetron NNP - B-MEDICINE
in ADP - O
Morphine NNP - B-ORG
Intravenous NNP - I-ORG
Analgesia NNP - I-ORG
Pump NNP - B-ORG
for IN - I-ORG
Prevention NNP - I-ORG
of IN - I-ORG
Postoperative NNP - I-ORG
Nausea NNP - I-ORG
and CC - I-ORG
Vomiting NNP - I-ORG
in ADP - O
Women]. NNP - B-GPE

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
, PUNCT - O
an DET - O
antiemetic NOUN - O
is VERB - O
a DET - O
serotonin ADJ - O
receptor NOUN - O
antagonist NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Plus CCONJ - O
Ondansetron NNP - B-MEDICINE
Infusion PROPN - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
use NOUN - O
increased VERB - O
from ADP - O
36 CD - B-PERCENT
% NN - I-PERCENT
to PART - O
75 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
P NOUN - O
< X - O
0.001 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
blocks VERB - O
wild ADJ - O
- PUNCT - O
type NOUN - O
and CCONJ - O
p NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Aromatherapy NN - B-ORG
Versus NNP - I-ORG
Oral NNP - I-ORG
Ondansetron NNP - I-MEDICINE
for ADP - O
  SPACE - O
Antiemetic PROPN - O
Therapy PROPN - O

-DOCSTART- -X- - O

A DET - O
Comparison NNP - B-ORG
of IN - I-ORG
Fosaprepitant NNP - I-ORG
and CCONJ - O
Ondansetron NNP - B-MEDICINE
for ADP - O
Preventing VERB - O
Postoperative ADJ - O
Nausea PROPN - O
and CCONJ - O
Vomiting PROPN - O
in ADP - O
Moderate PROPN - O
to ADP - O
High ADJ - O
Risk NOUN - O
Patients NOUN - O
: PUNCT - O
A DET - O
Retrospective PROPN - O
Database PROPN - O
Analysis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Prophylactic PROPN - O
Effects PROPN - O
of ADP - O
Ephedrine PROPN - O
, PUNCT - O
Ondansetron NNP - B-MEDICINE
and CCONJ - O
Ringer NNP - B-PERSON
on ADP - O
Hemodynamic PROPN - O
Changes PROPN - O
during ADP - O
Cesarean PROPN - O
Section PROPN - O
under ADP - O
Spinal NNP - B-PERSON
Anesthesia NNP - I-PERSON
- PUNCT - O
a DET - O
randomized VERB - O
clinical ADJ - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Randomized VERB - O
, PUNCT - O
Placebo PROPN - O
- PUNCT - O
Controlled PROPN - O
, PUNCT - O
Phase PROPN - O
III PROPN - O
Trial PROPN - O
of ADP - O
Fosaprepitant NNP - B-GPE
, PUNCT - O
Ondansetron NNP - B-MEDICINE
, PUNCT - O
Dexamethasone NNP - B-GPE
( PUNCT - O
FOND NNP - B-ORG
) PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
hydrochloride NOUN - O
OR=7.12 PROPN - O
( PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
, PUNCT - O
1.59 CD - B-CARDINAL
– NOUN - O
31.9 CD - B-CARDINAL
) PUNCT - O
resulted VERB - O
in ADP - O
the DET - O
highest ADJ - O
odds NOUN - O
of ADP - O
pneumothorax NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Furthermore ADV - O
, PUNCT - O
ondansetron NN - B-MEDICINE
reduced VERB - O
diarrhea NOUN - O
episodes NOUN - O
, PUNCT - O
most ADV - O
pronounced VERB - O
in ADP - O
children NOUN - O
that ADJ - O
had VERB - O
been VERB - O
sick ADJ - O
for ADP - O
more JJR - B-DATE
than IN - I-DATE
3 CD - I-DATE
days NNS - I-DATE
before ADP - O
treatment NOUN - O
( PUNCT - O
p VERB - O
= SYM - O
0.028).Ondansetron NUM - O
may VERB - O
be VERB - O
a DET - O
beneficial ADJ - O
treatment NOUN - O
for ADP - O
children NOUN - O
with ADP - O
rotavirus NOUN - O
gastroenteritis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
use VERB - O
during ADP - O
an DET - O
initial ADJ - O
emergency NOUN - O
department NOUN - O
visit NOUN - O
for ADP - O
head NOUN - O
trauma NOUN - O
in ADP - O
children NOUN - O
not ADV - O
requiring VERB - O
neuroimaging NOUN - O
is VERB - O
associated VERB - O
with ADP - O
a DET - O
higher ADJ - O
likelihood NOUN - O
of ADP - O
return NOUN - O
within ADP - O
72 CD - B-TIME
hours NNS - I-TIME
and CCONJ - O
subsequent ADJ - O
admission NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Use PROPN - O
of ADP - O
Ondansetron NNP - B-MEDICINE
for ADP - O
Vomiting NOUN - O
After ADP - O
Head PROPN - O
Trauma PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Use PROPN - O
of ADP - O
Prophylactic NNP - B-GPE
Ondansetron NNP - I-MEDICINE
with ADP - O
Intravenous NNP - B-ORG
Opioids NNP - I-ORG
in IN - I-ORG
Emergency NNP - I-ORG
Department NNP - I-ORG
Patients NNPS - I-ORG
: PUNCT - O
A DET - O
Prospective ADJ - O
Observational PROPN - O
Pilot PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Torsades NNS - B-ORG
de NNP - I-ORG
Pointes NNPS - I-ORG
after ADP - O
Ondansetron NNP - B-MEDICINE
Infusion NNP - I-ORG
in ADP - O
2 CD - B-CARDINAL
Patients PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison NNP - B-ORG
of IN - I-ORG
Dexamethasone NNP - I-ORG
- HYPH - I-ORG
Dimenhydrinate NNP - I-ORG
and CCONJ - O
Dexamethasone PROPN - O
- PUNCT - O
Ondansetron NNP - B-MEDICINE
in ADP - O
Prevention PROPN - O
of ADP - O
Nausea PROPN - O
and CCONJ - O
Vomiting PROPN - O
in ADP - O
Postoperative PROPN - O
Patients PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Rare PROPN - O
Case PROPN - O
of ADP - O
Fixed PROPN - O
Drug PROPN - O
Eruption PROPN - O
due ADP - O
to ADP - O
Ondansetron NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Prevention PROPN - O
of ADP - O
Shivering PROPN - O
during ADP - O
Spinal NNP - B-LAW
Anesthesia NNP - I-LAW
: : - I-LAW
Comparison NN - I-LAW
between ADP - O
Tramadol NNP - B-GPE
, PUNCT - O
Ketamine NNP - B-GPE
and CCONJ - O
Ondansetron NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
does VERB - O
not ADV - O
prevent VERB - O
physical ADJ - O
dependence NOUN - O
in ADP - O
patients NOUN - O
taking VERB - O
opioid ADJ - O
medications NOUN - O
chronically ADV - O
for ADP - O
pain NOUN - O
control NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
5-HT3 PROPN - O
Receptor PROPN - O
Antagonist PROPN - O
Ondansetron NNP - B-MEDICINE
Attenuates VERB - O
Pancreatic PROPN - O
Injury PROPN - O
in ADP - O
Cerulein NNP - B-GPE
- HYPH - I-GPE
Induced NNP - I-GPE
Acute PROPN - O
Pancreatitis PROPN - O
Model PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Effect NN - I-ORG
of IN - I-ORG
Ondansetron NNP - I-MEDICINE
on IN - I-ORG
Acute NNP - I-ORG
Opioid NNP - I-ORG
Tolerance NNP - I-ORG
in IN - I-ORG
Patients NNP - I-ORG
Receiving VBG - I-ORG
Intrathecal NNP - I-ORG
Opioids NNPS - I-ORG

-DOCSTART- -X- - O

Ondansetron NN - B-MEDICINE
and CCONJ - O
trazodone NOUN - O
were VERB - O
prescribed VERB - O
as ADP - O
needed VERB - O
for ADP - O
symptom NOUN - O
control NOUN - O
. PUNCT - O

Ondansetron NN - B-MEDICINE
and CCONJ - O
trazodone NOUN - O
have VERB - O
both DET - O
been VERB - O
associated VERB - O
with ADP - O

-DOCSTART- -X- - O

We PRON - O
present VERB - O
the DET - O
case NOUN - O
of ADP - O
a DET - O
26-year CD - B-CARDINAL
- PUNCT - O
old ADJ - O
woman NOUN - O
who NOUN - O
suffered VERB - O
from ADP - O
suspected ADJ - O
AFE PROPN - O
and CCONJ - O
was VERB - O
successfully ADV - O
treated VERB - O
with ADP - O
the DET - O
novel ADJ - O
regimen NOUN - O
of ADP - O
Atropine NNP - B-GPE
, PUNCT - O
Ondansetron NNP - B-MEDICINE
, PUNCT - O
and CCONJ - O
Ketorolac NNP - B-PERSON
( PUNCT - O
A PROPN - O
- PUNCT - O
OK INTJ - O
) PUNCT - O
. PUNCT - O

We PRON - O
hope VERB - O
this DET - O
case NOUN - O
report NOUN - O
will VERB - O
prompt VERB - O
further ADJ - O
research NOUN - O
into ADP - O
this DET - O
novel ADJ - O
approach NOUN - O
to ADP - O
treating VERB - O
AFE PROPN - O
with ADP - O
Atropine NNP - B-ORG
, PUNCT - O
Ondansetron NNP - B-MEDICINE
, PUNCT - O
and CCONJ - O
Ketorolac NNP - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NN - B-MEDICINE
and CCONJ - O
maropitant NOUN - O
reduced VERB - O
overall ADV - O
the DET - O
area NOUN - O
under ADP - O
the DET - O
curve NOUN - O
of ADP - O
nausea NOUN - O
behaviour NOUN - O
score NOUN - O
by ADP - O
90 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
25 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Arrhythmic NNP - B-PERSON
Side NNP - I-PERSON
of ADP - O
Ondansetron NNP - B-MEDICINE
Alongside PROPN - O
Antiemetic PROPN - O
Effect PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Co NOUN - O
- NOUN - O
administration NOUN - O
of ADP - O
Cyclosporin NNP - B-ORG
A NNP - I-ORG
and CCONJ - O
Ondansetron NNP - B-MEDICINE
decreases VERB - O
transient ADJ - O
local ADJ - O
cerebral ADJ - O
ischemic ADJ - O
injury NOUN - O
in ADP - O
the DET - O
mouse NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NN - B-MEDICINE
for ADP - O
neuraxial ADJ - O
morphine NOUN - O
- PUNCT - O
induced VERB - O
pruritus NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Comparison NOUN - O
of ADP - O
Antiemetic PROPN - O
Effectiveness PROPN - O
of ADP - O
Palonosetron PROPN - O
Versus NNP - B-PERSON
Ondansetron NNP - I-MEDICINE
in ADP - O
Patients NNPS - B-GPE
on ADP - O
Cancer PROPN - O
Chemotherapy NNP - B-PERSON
: PUNCT - O
A DET - O
Prospective ADJ - O
Observational PROPN - O
Study PROPN - O
in ADP - O
South NNP - B-NORP
Indians NNPS - I-NORP
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-LAW
Comparative NNP - I-LAW
Study NNP - I-LAW
of IN - I-LAW
Ondansetron NNP - I-MEDICINE
and CC - I-LAW
Metoclopramide NNP - I-LAW
Effects NNPS - I-LAW
in IN - I-LAW
Reducing VBG - I-LAW
Nausea NNP - I-LAW
and CC - I-LAW
Vomiting NNP - I-LAW
After IN - I-LAW
Laparoscopic NNP - I-LAW
Cholecystectomy NNP - I-LAW
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
has VERB - O

 SPACE - O
been VERB - O
studied VERB - O
in ADP - O
the DET - O
attenuation NOUN - O
of ADP - O
spinal ADJ - O
anesthesia– NOUN - O

 SPACE - O
induced VERB - O
hypotension NOUN - O
( PUNCT - O
SIH PROPN - O
) PUNCT - O
and CCONJ - O
bradycardia NOUN - O
because ADP - O
of ADP - O

 SPACE - O
its ADJ - O
antagonistic ADJ - O
effect NOUN - O
on ADP - O
the DET - O
Bezold PROPN - O
- PUNCT - O
Jarisch PROPN - O
reflex NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Ondansetron NNP - B-MEDICINE
on ADP - O
Attenuating PROPN - O
Spinal PROPN - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
hydrochloride NOUN - O
OR=7.12 PROPN - O
( PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
, PUNCT - O
1.59 CD - B-CARDINAL
- SYM - O
31.9 NUM - O
) PUNCT - O
resulted VERB - O
in ADP - O
the DET - O
highest ADJ - O
odds NOUN - O
of ADP - O
pneumothorax NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison NN - B-ORG
on IN - I-ORG
Anticoagulation NNP - I-ORG
and CC - I-ORG
Antiplatelet NNP - I-ORG
Aggregation NNP - I-ORG
Effects NNPS - I-ORG
of IN - I-ORG
Puerarin NNP - I-ORG
with ADP - O
Heparin NNP - B-PERSON
Sodium NNP - I-PERSON
and CCONJ - O
Tirofiban NNP - B-PERSON
Hydrochloride NNP - I-PERSON
: PUNCT - O

-DOCSTART- -X- - O

Raw ADJ - O
Material PROPN - O
Specification PROPN - O
, PUNCT - O
Heparin NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
Injection PROPN - O
, PUNCT - O
USP NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Study VERB - O
on ADP - O
Technology PROPN - O
for ADP - O
Purification PROPN - O
of ADP - O
Heparin NNP - B-MEDICINE
Sodium NNP - I-MEDICINE

-DOCSTART- -X- - O

Turgor PROPN - O
Pressure PROPN - O
Effects NOUN - O
on ADP - O
Textural PROPN - O
Behavior PROPN - O
of ADP - O
Honeydew NNP - B-MEDICINE
Melon NNP - I-MEDICINE

-DOCSTART- -X- - O

Improved NNP - B-PERSON
Morphine NNP - I-PERSON
- HYPH - I-PERSON
Loaded VBN - I-PERSON
Hydrogels NNS - B-ORG
for IN - I-ORG
Wound NNP - I-ORG
- HYPH - I-ORG
Related VBN - I-ORG
Pain NNP - I-ORG
Relief NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Cochrane PROPN - O
Review PROPN - O
Summary NOUN - O
: PUNCT - O
Epidural ADJ - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
Versus PROPN - O
Systemic PROPN - O
Opioid PROPN - O
- PUNCT - O
Based VERB - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
for ADP - O
Abdominal PROPN - O
Aortic PROPN - O
Surgery PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Phenomenological ADJ - O
Study PROPN - O
of ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
by ADP - O
Cannabis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Lancet NNP - I-ORG
Commission NNP - I-ORG
on ADP - O
Global PROPN - O
Access PROPN - O
to ADP - O
Palliative PROPN - O
Care PROPN - O
and CCONJ - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
developed VERB - O
a DET - O
framework NOUN - O
to PART - O
measure VERB - O
the DET - O
global ADJ - O
burden NOUN - O
of ADP - O
serious ADJ - O
health NOUN - O
- PUNCT - O
related VERB - O
suffering NOUN - O
and CCONJ - O
generated VERB - O
the DET - O
evidence NOUN - O
base NOUN - O
to PART - O
address VERB - O
this DET - O
burden NOUN - O
. PUNCT - O

We PRON - O
present VERB - O
the DET - O
inequities NOUN - O
in ADP - O
access NOUN - O
to ADP - O
pain NN - B-MEDICINE
relief NN - I-MEDICINE
and CCONJ - O
highlight VERB - O
key ADJ - O
points NOUN - O
from ADP - O
country NOUN - O
responses NOUN - O
, PUNCT - O
drawing VERB - O
from ADP - O
and CCONJ - O
building VERB - O
on ADP - O
recommendations NOUN - O
of ADP - O
the DET - O
Lancet NNP - B-ORG
Commission NNP - I-ORG
report NOUN - O
" PUNCT - O
Alleviating VBG - B-WORK_OF_ART
the DT - I-WORK_OF_ART
Access NNP - I-WORK_OF_ART
Abyss NNP - I-WORK_OF_ART
in IN - I-WORK_OF_ART
Palliative NNP - I-WORK_OF_ART
Care NNP - I-WORK_OF_ART
and CC - I-WORK_OF_ART
Pain NNP - I-WORK_OF_ART
Relief NNP - I-WORK_OF_ART
- : - I-WORK_OF_ART
An DT - I-WORK_OF_ART
Imperative NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Universal NNP - I-WORK_OF_ART
Health NNP - I-WORK_OF_ART
Coverage NNP - I-WORK_OF_ART
" PUNCT - O
to PART - O
close VERB - O
the DET - O
access NOUN - O
abyss NOUN - O
in ADP - O
relief NOUN - O
of ADP - O
pain NOUN - O
and CCONJ - O
other ADJ - O
types NOUN - O
of ADP - O
serious ADJ - O
health NOUN - O
- PUNCT - O
related VERB - O
suffering NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pain JJ - B-MEDICINE
Relief NNP - I-MEDICINE
by ADP - O
Parecoxib PROPN - O
for ADP - O
Laparoscopic PROPN - O
Cholecystectomy PROPN - O
: PUNCT - O
A PROPN - O
Meta PROPN - O
- PUNCT - O
Analysis PROPN - O
of ADP - O
Randomized PROPN - O
Controlled PROPN - O
Trials PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Two CD - B-CARDINAL
- PUNCT - O
Point PROPN - O
Discrimination PROPN - O
Predicts PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
after ADP - O
Lower PROPN - O
Limb PROPN - O
Nerve PROPN - O
Decompression PROPN - O
for ADP - O
Painful ADJ - O
Diabetic PROPN - O
Peripheral PROPN - O
Neuropathy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Reply NOUN - O
: PUNCT - O
Two CD - B-CARDINAL
- PUNCT - O
Point PROPN - O
Discrimination PROPN - O
Predicts PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
after ADP - O
Lower PROPN - O
Limb PROPN - O
Nerve PROPN - O
Decompression PROPN - O
for ADP - O
Painful ADJ - O
Diabetic PROPN - O
Peripheral PROPN - O
Neuropathy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
as ADP - O
an DET - O
Integral PROPN - O
Part PROPN - O
of ADP - O
the DET - O
Palliative PROPN - O
Care PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Non ADJ - O
- ADJ - O
pharmacologic ADJ - O
Measures NOUN - O
for ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
in ADP - O
Preterm PROPN - O
Neonates PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Does VERB - O
Immediate PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
After ADP - O
an DET - O
Injection NOUN - O
into ADP - O
the DET - O
Sacroiliac PROPN - O
Joint PROPN - O
with ADP - O
Anesthetic PROPN - O
and CCONJ - O
Corticosteroid PROPN - O
Predict PROPN - O
Subsequent PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
? PUNCT - O

-DOCSTART- -X- - O

Pleasant PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
and CCONJ - O
Inhibitory PROPN - O
Conditioned VERB - O
Pain PROPN - O
Modulation PROPN - O
: PUNCT - O
A DET - O
Psychophysical PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Effect PROPN - O
of ADP - O
Normal PROPN - O
Physiologic PROPN - O
Childbirth PROPN - O
on ADP - O
Labor PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
: PUNCT - O
an DET - O
Interventional PROPN - O
Study PROPN - O
in ADP - O
Mother PROPN - O
- PUNCT - O
Friendly PROPN - O
Hospitals PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Minimal JJ - B-PERSON
Use NNP - I-PERSON
of ADP - O
Opioids NNP - B-GPE
for ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
in ADP - O
an DET - O
Internal PROPN - O
Medicine PROPN - O
Department PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluoroscopically RB - B-ORG
Guided VBN - I-ORG
Facet NNP - I-ORG
Injections NNPS - I-ORG
: PUNCT - O
Comparison NNP - B-ORG
of IN - I-ORG
Intra NNP - I-ORG
- HYPH - I-ORG
Articular NNP - I-ORG
and CCONJ - O
Periarticular NNP - B-ORG
Steroid NNP - I-ORG
and CC - I-ORG
Anesthetic NNP - I-ORG
Injection NNP - I-ORG
on IN - I-ORG
Immediate NNP - I-ORG
and CC - I-ORG
Short NNP - I-ORG
- HYPH - I-ORG
Term NNP - I-ORG
Pain NNP - I-ORG
Relief NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

NF NNP - B-GPE
- PUNCT - O
KappaB NOUN - O
Pathway NOUN - O
Is VERB - O
Involved VERB - O
in ADP - O
Bone PROPN - O
Marrow PROPN - O
Stromal PROPN - O
Cell PROPN - O
- PUNCT - O
Produced VERB - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Efficacy NOUN - O
of ADP - O
Lidocaine PROPN - O
Spray PROPN - O
in ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
during ADP - O
Outpatient PROPN - O
- PUNCT - O
Based VERB - O
Endometrial PROPN - O
Sampling NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Comparison NOUN - O
of ADP - O
the DET - O
Effects NOUN - O
of ADP - O
Epidural PROPN - O
Analgesia PROPN - O
and CCONJ - O
Patient PROPN - O
- PUNCT - O
controlled VERB - O
Intravenous NNP - B-ORG
Analgesia NNP - I-ORG
on ADP - O
Postoperative PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
and CCONJ - O
Recovery PROPN - O
After ADP - O
Laparoscopic PROPN - O
Gastrectomy PROPN - O
for ADP - O
Gastric PROPN - O
Cancer PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Randomized VERB - O
Controlled PROPN - O
Trial PROPN - O
on ADP - O
Efficacy PROPN - O
and CCONJ - O
Safety PROPN - O
of ADP - O
Trocar PROPN - O
- PUNCT - O
Site NOUN - O
Infiltration NOUN - O
with ADP - O
Lidocaine PROPN - O
for ADP - O
Postoperative PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
after ADP - O
Diagnostic NNP - B-PERSON
Laparoscopy NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Effectiveness NOUN - O
of ADP - O
Sucrose PROPN - O
Used VERB - O
Routinely ADV - O
for ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
and CCONJ - O
Neonatal PROPN - O
Clinical PROPN - O
Risk PROPN - O
in ADP - O
Preterm PROPN - O
Infants PROPN - O
: PUNCT - O
A DET - O
Nonrandomized PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Transcutaneous ADJ - O
Electrical PROPN - O
Nerve NOUN - O
Stimulation NOUN - O
( PUNCT - O
TENS NOUN - O
) PUNCT - O
in ADP - O
the DT - B-ORG
Emergency NNP - I-ORG
Department NNP - I-ORG
for IN - I-ORG
Pain NNP - I-ORG
Relief NNP - I-ORG
: : - I-ORG
A DT - I-ORG
Preliminary NNP - I-ORG
Study NNP - I-ORG
of IN - I-ORG
Feasibility NNP - I-ORG
and CC - I-ORG
Efficacy NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Pranoprofen NNP - B-ORG
on ADP - O
Aqueous PROPN - O
Humor PROPN - O
Monocyte PROPN - O
Chemoattractant PROPN - O
Protein-1 PROPN - O
Level PROPN - O
and CCONJ - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE

-DOCSTART- -X- - O

Pethidine PROPN - O
in ADP - O
Low PROPN - O
Doses PROPN - O
versus ADP - O
Dipyrone NOUN - O
for ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
in ADP - O
Labor PROPN - O
: PUNCT - O
A DET - O
Randomized VERB - O
Controlled PROPN - O
Trial PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Efficacy NOUN - O
of ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
in ADP - O
Different PROPN - O
Postherpetic PROPN - O
Neuralgia PROPN - O
Therapies PROPN - O
: PUNCT - O
A DET - O
Network PROPN - O
Meta PROPN - O
- PUNCT - O
Analysis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Identification NOUN - O
of ADP - O
the DET - O
First PROPN - O
Synthetic PROPN - O
Allosteric PROPN - O
Modulator PROPN - O
of ADP - O
the DET - O
CB2 PROPN - O
Receptors PROPN - O
and CCONJ - O
Evidence PROPN - O
of ADP - O
Its ADJ - O
Efficacy NOUN - O
for ADP - O
Neuropathic PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Effect NNP - I-ORG
of IN - I-ORG
Flat NNP - I-ORG
Dual NNP - I-ORG
- HYPH - I-ORG
Cure NN - I-ORG
Stabilizer NN - I-ORG
Occlusal NNP - I-ORG
Splint NNP - I-ORG
in IN - I-ORG
Pain NNP - I-ORG
Relief NNP - I-ORG
of IN - I-ORG
Individuals NNPS - I-ORG
Suffering NNP - I-ORG
from ADP - O
Migraine NNP - B-GPE
Headaches NNS - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
Postoperative PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Comparison NN - B-ORG
of IN - I-ORG
Postoperative NNP - I-ORG
Quality NNP - I-ORG
of IN - I-ORG
Recovery NNP - I-ORG
and CC - I-ORG
Pain NNP - I-ORG
Relief NNP - I-ORG
with IN - I-ORG
Preoperative JJ - I-ORG
Single NNP - I-ORG
- HYPH - I-ORG
Dose NNP - I-ORG
Dexamethasone NNP - I-ORG
and CCONJ - O
Lignocaine NNP - B-GPE
after ADP - O
Laparoscopic NNP - B-ORG
Cholecystectomy NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Different ADJ - O
Volumes PROPN - O
on ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
in ADP - O
Patient PROPN - O
Receiving VERB - O
Fluoroscopic PROPN - O
Guided VERB - O
Interlaminar PROPN - O
Lumbar PROPN - O
Epidural PROPN - O
Steroid PROPN - O
Injection PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Serratus PROPN - O
Anterior PROPN - O
Plane PROPN - O
Block PROPN - O
Versus PROPN - O
Thoracic PROPN - O
Epidural PROPN - O
Analgesia PROPN - O
for ADP - O
Post NNP - B-ORG
- NNP - I-ORG
Thoracotomy NNP - I-ORG
Pain NNP - I-ORG
Relief NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Following VERB - O
Esophagectomy NOUN - O
for ADP - O
Acute PROPN - O
Postoperative PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
in ADP - O
the DT - B-ORG
Postanesthesia NNP - I-ORG
Care NNP - I-ORG
Unit NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Effect NNP - I-ORG
of IN - I-ORG
Pain NNP - I-ORG
Relief NNP - I-ORG
on IN - I-ORG
Daily NNP - I-ORG
Physical NNP - I-ORG
Activity NNP - I-ORG
: PUNCT - O
In ADP - O
- PUNCT - O
Home NOUN - O
Objective PROPN - O
Physical PROPN - O
Activity PROPN - O
Assessment PROPN - O
in ADP - O
Chronic PROPN - O
Low PROPN - O
Back PROPN - O
Pain NOUN - O
Patients PROPN - O
after ADP - O
Paravertebral NNP - B-ORG
Spinal NNP - I-ORG
Block NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Effect NNP - I-ORG
of IN - I-ORG
Pain NNP - I-ORG
Relief NNP - I-ORG
on IN - I-ORG
Daily NNP - I-ORG
Physical NNP - I-ORG
Activity NNP - I-ORG
: PUNCT - O
in ADP - O
- PUNCT - O
Home NOUN - O
Objective PROPN - O
Physical PROPN - O
Activity PROPN - O
Assessment PROPN - O
in ADP - O
Chronic PROPN - O
Low PROPN - O
Back PROPN - O
Pain NOUN - O
Patients PROPN - O
after ADP - O
Paravertebral PROPN - O
Spinal PROPN - O
Block PROPN - O

-DOCSTART- -X- - O

Nerve PROPN - O
Safety PROPN - O
, PUNCT - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
, PUNCT - O
and CCONJ - O
Patient PROPN - O
Satisfaction PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Two CD - B-CARDINAL
- PUNCT - O
Point PROPN - O
Discrimination PROPN - O
Predicts PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
after ADP - O
Lower PROPN - O
Limb PROPN - O
Nerve PROPN - O
Decompression PROPN - O
for ADP - O
Painful ADJ - O
Diabetic PROPN - O
Peripheral PROPN - O
Neuropathy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison NN - B-ORG
of IN - I-ORG
Epidural NNP - I-ORG
Bupivacaine NNP - I-ORG
and CCONJ - O
Dexmedetomidine PROPN - O
with ADP - O
Bupivacaine NNP - B-GPE
and CCONJ - O
Fentanyl NNP - B-GPE
for ADP - O
Postoperative PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
in ADP - O
Lower PROPN - O
Limb PROPN - O
Orthopedic PROPN - O
Surgery PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Ibuprofen NNP - B-ORG
and CCONJ - O
Morphine NNP - B-ORG
Provide NNP - I-ORG
Similar NNP - I-ORG
Post NNP - I-ORG
- , - I-ORG
op NN - I-ORG
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
in ADP - O
Kids NNP - B-PERSON
; PUNCT - O
Ibuprofen NNP - B-PERSON
Has VBZ - I-PERSON
Fewer JJR - B-PERSON
Harms NNPS - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

What NOUN - O
Is VERB - O
the DET - O
Role NOUN - O
of ADP - O
the DET - O
Placebo PROPN - O
Effect PROPN - O
for ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
in ADP - O
Neurorehabilitation PROPN - O
? PUNCT - O

-DOCSTART- -X- - O

Initial ADJ - O
colonization NOUN - O
occurred VERB - O
by ADP - O
AD NOUN - O
1246 NUM - O
, PUNCT - O
but CCONJ - O
expansion NOUN - O
was VERB - O
forestalled VERB - O
by ADP - O
catastrophic ADJ - O
drought NOUN - O
( PUNCT - O
1250 CD - B-DATE
- SYM - I-DATE
1288 CD - I-DATE
) PUNCT - O
, PUNCT - O
which ADJ - O
we PRON - O
speculate VERB - O
produced VERB - O
extensive ADJ - O
mortality NOUN - O
of ADP - O
Utah NNP - B-ORG
Juniper NNP - I-ORG
( PUNCT - O
Juniperus NNP - B-FAC
osteosperma ADV - O
( PUNCT - O
Torr ADJ - O
. PUNCT - O
) PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
, PUNCT - O
a DET - O
fluoroquinolone NOUN - O
, PUNCT - O
is VERB - O
used VERB - O
therapeutically ADV - O
in ADP - O
numerous ADJ - O
countries NOUN - O
; PUNCT - O
however ADV - O
, PUNCT - O
it PRON - O
can VERB - O
cause VERB - O
an DET - O
increase NOUN - O
in ADP - O
liver NOUN - O
function NOUN - O
tests NOUN - O
and CCONJ - O
liver NOUN - O
dysfunction NOUN - O
. PUNCT - O

The DET - O
current ADJ - O
study NOUN - O
was VERB - O
designed VERB - O
to PART - O
determine VERB - O
the DET - O
effect NOUN - O
of ADP - O
Levofloxacin NNP - B-MEDICINE
( PUNCT - O
40 CD - B-CARDINAL
  SPACE - O
mg PROPN - O
/ SYM - O
kg VERB - O
body NOUN - O
weight NOUN - O
( PUNCT - O
b.wt NOUN - O
. PUNCT - O
) PUNCT - O

M. PROPN - O
oleifera NOUN - O
leaf NOUN - O
extract NOUN - O
was VERB - O
found VERB - O
to PART - O
improve VERB - O
the DET - O
hepatic ADJ - O
dysfunction NOUN - O
induced VERB - O
by ADP - O
Levofloxacin NNP - B-MEDICINE
by ADP - O
recovering VERB - O
liver NOUN - O
enzymatic ADJ - O
activities NOUN - O
( PUNCT - O
alanine NOUN - O
aminotransferase NOUN - O
[ PUNCT - O
ALT NNP - B-ORG
] PUNCT - O
, PUNCT - O
aspartate NOUN - O
aminotransferase NOUN - O
[ PUNCT - O
AST PROPN - O
] PUNCT - O
and CCONJ - O
gamma NOUN - O
- PUNCT - O
glutamyl NOUN - O
transferase NOUN - O
[ PUNCT - O
GGT NNP - B-ORG
] PUNCT - O
) PUNCT - O
to ADP - O
normal ADJ - O
levels NOUN - O
. PUNCT - O

Additionally ADV - O
, PUNCT - O
its ADJ - O
presence NOUN - O
attenuated VERB - O
the DET - O
downregulation NOUN - O
of ADP - O
IL-1 PROPN - O
induced VERB - O
by ADP - O
Levofloxacin NNP - B-MEDICINE
alone ADV - O
from ADP - O
hepatic ADJ - O
tissue NOUN - O
. PUNCT - O

It PRON - O
can VERB - O
be VERB - O
concluded VERB - O
that ADP - O
M. NNP - B-ORG
oleifera NOUN - O
extract NOUN - O
can VERB - O
help VERB - O
reduce VERB - O
the DET - O
side NOUN - O
effects NOUN - O
caused VERB - O
by ADP - O
Levofloxacin NNP - B-MEDICINE
administration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Evaluation NOUN - O
of ADP - O
Ciprofloxacin NNP - B-ORG
and CCONJ - O
Levofloxacin NNP - B-MEDICINE
Disk PROPN - O
Diffusion PROPN - O
and CCONJ - O
Etest NNP - B-ORG
Using VBG - I-ORG
the DET - O
2019 CD - B-DATE
Enterobacteriaceae NNP - B-FAC
CLSI NNP - I-FAC
Breakpoints NNS - I-FAC
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
is VERB - O
used VERB - O
to PART - O
treat VERB - O
and CCONJ - O
prevent VERB - O
drug NOUN - O
- PUNCT - O
resistant ADJ - O
tuberculosis NOUN - O
in ADP - O
children NOUN - O
. PUNCT - O

Levofloxacin NN - B-MEDICINE
dosing VERB - O
recommendations NOUN - O
may VERB - O
require VERB - O
reevaluation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
, PUNCT - O
pefloxacin NOUN - O
, PUNCT - O
ciprofloxacin NOUN - O
and CCONJ - O
moxifloxacin NOUN - O
are VERB - O
four CD - B-CARDINAL
fluoroquinolones NOUN - O
used VERB - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
serious ADJ - O
bacterial ADJ - O
infections NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Therapeutic JJ - B-ORG
Effect NN - I-ORG
of IN - I-ORG
the DT - I-ORG
Quinolone NNP - I-ORG
Levofloxacin NNP - I-MEDICINE
on IN - I-ORG
Inflammatory NNP - I-ORG
Fibroblast NNP - I-ORG
- HYPH - I-ORG
like JJ - I-ORG
Synoviocytes NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

AbstractBackgroundLevofloxacin NOUN - O
given VERB - O
at ADP - O
a DET - O
standard ADJ - O
dose NOUN - O
of ADP - O
500 CD - B-CARDINAL
mg NOUN - O
daily RB - B-DATE
is VERB - O
recommended VERB - O
for ADP - O
antibacterial ADJ - O
prophylaxis NOUN - O
in ADP - O
patients NOUN - O
receiving VERB - O
myelosuppressive ADJ - O
chemotherapy NOUN - O
. PUNCT - O

Levofloxacin NNP - B-MEDICINE
AUC NNP - B-ORG
was VERB - O
estimated VERB - O
from ADP - O
CrCL NNP - B-ORG
using VERB - O
the DET - O
method NOUN - O
of ADP - O
Pai NNP - B-PERSON
et NNP - I-PERSON
al NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Population NNP - B-ORG
Pharmacokinetic NNP - I-ORG
Analysis NNP - I-ORG
of IN - I-ORG
Ciprofloxacin PROPN - O
and CCONJ - O
Levofloxacin NNP - B-MEDICINE
in ADP - O
Critically ADV - O
Ill PROPN - O
Trauma PROPN - O
, PUNCT - O
Surgical PROPN - O
, PUNCT - O
and CCONJ - O
Burn NNP - B-ORG
Patients NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Impact NOUN - O
of ADP - O
Levofloxacin NNP - B-MEDICINE
for ADP - O
the DT - B-ORG
Prophylaxis NNP - I-ORG
of IN - I-ORG
Bloodstream NNP - I-ORG
Infection NNP - I-ORG
on ADP - O
the DET - O
Gut PROPN - O
Microbiome PROPN - O
in ADP - O
Patients PROPN - O
with ADP - O
Hematologic PROPN - O
Malignancy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
( PUNCT - O
Reference PROPN - O
) PUNCT - O
was VERB - O
tested VERB - O
against ADP - O
E.coli PROPN - O
standard NOUN - O
( PUNCT - O
American NNP - B-ORG
Type NNP - I-ORG
Culture NNP - I-ORG
Collection NNP - I-ORG
) PUNCT - O
( PUNCT - O
ATCC=25922 NN - B-NORP
) PUNCT - O
with ADP - O
( PUNCT - O
MIC90 NNP - B-GPE
; PUNCT - O
0.03μg NNP - B-ORG
/ SYM - I-ORG
ml NN - I-ORG
) PUNCT - O
and CCONJ - O
compared VERB - O
with ADP - O
different ADJ - O
eleven CD - B-CARDINAL
brands NOUN - O
of ADP - O
levofloxacin NN - B-MEDICINE
tablets NOUN - O
250 CD - B-QUANTITY
mg NN - I-QUANTITY
( PUNCT - O
MIC90 NNP - B-GPE
; PUNCT - O
0.5μg NN - B-CARDINAL
/ SYM - O
ml PROPN - O
-16.0μg PUNCT - O
/ SYM - O
ml PROPN - O
) PUNCT - O
. PUNCT - O

Levofloxacin NNP - B-MEDICINE
( PUNCT - O
Reference PROPN - O
) PUNCT - O
sensitivity NOUN - O
against ADP - O
S. PROPN - O
aureus NOUN - O
standard NOUN - O
( PUNCT - O
ATCC=25923 PROPN - O
) PUNCT - O
is VERB - O
( PUNCT - O
MIC90 NNP - B-GPE
; PUNCT - O
0.12μg NNP - B-ORG
/ SYM - I-ORG
ml NN - I-ORG
) PUNCT - O
and CCONJ - O
similarly ADV - O
when ADV - O
it PRON - O
was VERB - O
compared VERB - O
with ADP - O
same ADJ - O
levofloxacin NN - B-MEDICINE
tablets NOUN - O
( PUNCT - O
MIC90 NNP - B-GPE
; PUNCT - O
0.5 CD - B-CARDINAL
- PUNCT - O
16.0μg NUM - O
/ SYM - O
ml PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
was VERB - O
administered VERB - O
from ADP - O
autologous ADJ - O
SCT NNP - B-GPE
( PUNCT - O
day NN - B-DATE
0 CD - I-DATE
) PUNCT - O
until ADP - O
day NN - B-DATE
13 CD - I-DATE
, PUNCT - O
absolute ADJ - O
neutrophil NOUN - O
count NOUN - O
> X - O
500/mm3 CD - B-CARDINAL
, PUNCT - O
or CCONJ - O
neutropenic ADJ - O
fever NOUN - O
, PUNCT - O
whichever ADJ - O
occurred VERB - O
first ADV - O
. PUNCT - O

Levofloxacin NN - B-MEDICINE
prophylaxis NOUN - O
was VERB - O
effective ADJ - O
in ADP - O
reducing VERB - O
CLABSIs NOUN - O
and CCONJ - O
neutropenic ADJ - O
fever NOUN - O
in ADP - O
patients NOUN - O
undergoing VERB - O
autologous ADJ - O
SCT NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
Vitro PROPN - O
Study PROPN - O
of ADP - O
the DET - O
Modulatory PROPN - O
Effects PROPN - O
of ADP - O
Levofloxacin NNP - B-MEDICINE
and CCONJ - O
BCG PROPN - O
on ADP - O
Secretion NOUN - O
of ADP - O
Proinflammatory PROPN - O
Cytokines PROPN - O
in ADP - O
Infiltrative PROPN - O
Pulmonary PROPN - O
Tuberculosis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Oral ADJ - O
Step NOUN - O
Down ADV - O
Therapy NOUN - O
With ADP - O
Levofloxacin NNP - B-MEDICINE
for ADP - O
Low PROPN - O
- PUNCT - O
Risk NOUN - O
Febrile PROPN - O
Neutropenia PROPN - O
in ADP - O
Children PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Optimized VBN - B-ORG
Preparation NNP - I-ORG
of IN - I-ORG
Levofloxacin NNP - I-MEDICINE
Loaded NNP - I-ORG
Polymeric NNP - I-ORG
Nanoparticles NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

P NOUN - O
- PUNCT - O
ValueAminoglycosides PROPN - O
Amikacin66 PROPN - O
% NOUN - O
( PUNCT - O
8)86 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
16)55 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
4)<0.001 NUM - O
Gentamicin21 NN - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
2)31 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
4)21 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
2)<0.001 NUM - O
Tobramycin15 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
2)18 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
4)14 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
1)0.063Cyclines NUM - O
Minocycline–16 PROPN - O
% NOUN - O
( PUNCT - O
4)1 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
1)<0.001 NUM - O
Tigecycline43 NOUN - O
% NOUN - O
( PUNCT - O
1)84 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
2)43 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
1)<0.001Fluoroquinolones PROPN - O
Levofloxacin6 PROPN - O
% NOUN - O
( PUNCT - O
0.5)15 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
2)6 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
0.5)0.001 NUM - O
P NOUN - O
< NOUN - O
0.05 CD - B-CARDINAL
are VERB - O
significant ADJ - O
and CCONJ - O
indicate VERB - O
differences NOUN - O
between ADP - O
CLSI NNP - B-ORG
/ SYM - I-ORG
FDA NNP - I-ORG
and CCONJ - O
USCAST NNP - B-ORG
susceptibility NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mesoporous ADJ - O
Bioactive NOUN - O
Glasses PROPN - O
Equipped VERB - O
with ADP - O
Stimuli NNP - B-ORG
- HYPH - I-ORG
Responsive NNP - I-ORG
Molecular NNP - I-ORG
Gates NNP - I-ORG
for ADP - O
Controlled PROPN - O
Delivery PROPN - O
of ADP - O
Levofloxacin NNP - B-MEDICINE
against ADP - O
Bacteria NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
pharmacokinetics NOUN - O
and CCONJ - O
pharmacodynamics NOUN - O
and CCONJ - O
outcome NOUN - O
in ADP - O
MDR PROPN - O
- PUNCT - O
TB PROPN - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
based VERB - O
alternate ADJ - O
therapy NOUN - O
is VERB - O
safer ADJ - O
to ADP - O
the DET - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Microarray ADV - O
- PUNCT - O
Based VERB - O
Detection PROPN - O
and CCONJ - O
Clinical PROPN - O
Evaluation PROPN - O
for ADP - O
Helicobacter PROPN - O
pylori NOUN - O
Resistance NOUN - O
to ADP - O
Clarithromycin PROPN - O
or CCONJ - O
Levofloxacin NNP - B-MEDICINE
and CCONJ - O
the DET - O
Genotype NNP - B-PERSON
of ADP - O
CYP2C19 PROPN - O
in ADP - O
1083 CD - B-DATE
Patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
and CCONJ - O
moxifloxacin NOUN - O
were VERB - O
associated VERB - O
with ADP - O
a DET - O
lower ADJ - O
risk NOUN - O
of ADP - O
heart NOUN - O
failure NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Increased PROPN - O
Doses VERB - O
Lead VERB - O
to ADP - O
Higher PROPN - O
Drug PROPN - O
Exposures PROPN - O
of ADP - O
Levofloxacin NNP - B-MEDICINE
for ADP - O
Treatment PROPN - O
of ADP - O
Tuberculosis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
( PUNCT - O
LV PROPN - O
) PUNCT - O
given VERB - O
once ADV - O
neutropenia NOUN - O
develops VERB - O
. PUNCT - O

-DOCSTART- -X- - O

High ADJ - O
- PUNCT - O
Performance NOUN - O
Photocatalytic PROPN - O
Hydrogen PROPN - O
Production PROPN - O
and CCONJ - O
Degradation PROPN - O
of ADP - O
Levofloxacin NNP - B-MEDICINE
by ADP - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
resistance NOUN - O
increased VERB - O
between IN - B-DATE
2000 CD - I-DATE
and CC - I-DATE
2016 CD - I-DATE
( PUNCT - O
P<0.001 NNP - B-PERSON
) PUNCT - O
, PUNCT - O
but CCONJ - O
resistance NOUN - O
to ADP - O
other ADJ - O
antimicrobials NOUN - O
did VERB - O
not ADV - O
change VERB - O
over ADP - O
time NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
loaded ADJ - O
samples NOUN - O
also ADV - O
presented VERB - O
bacteria NOUN - O
growth NOUN - O
inhibition NOUN - O
ability NOUN - O
, PUNCT - O
proving VERB - O
that DET - O
antibiotic NOUN - O
was VERB - O
not ADV - O
degraded VERB - O
during ADP - O
the DET - O
fabrication NOUN - O
process NOUN - O
and CCONJ - O
its ADJ - O
bactericidal NOUN - O
efficacy NOUN - O
was VERB - O
preserved VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
was VERB - O
most ADV - O
commonly ADV - O
requested VERB - O
( PUNCT - O
36.76 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
1,297 CD - B-CARDINAL
of ADP - O
3,528 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
followed VERB - O
by ADP - O
meropenem NOUN - O
, PUNCT - O
caspofungin NOUN - O
, PUNCT - O
and CCONJ - O
fluconazole NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NN - B-MEDICINE
- PUNCT - O
induced VERB - O
Achilles NNP - B-PERSON
Tendon NNP - I-PERSON
Rupture NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Risk NN - B-ORG
Factors NNS - I-ORG
for IN - I-ORG
Community NNP - I-ORG
- HYPH - I-ORG
Onset NNP - I-ORG
Pneumonia NNP - I-ORG
Caused VERB - O
by ADP - O
Levofloxacin NNP - B-MEDICINE
- HYPH - I-ORG
Nonsusceptible NNP - I-ORG
Streptococcus NNP - I-ORG
pneumoniae VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Formal NNP - B-PERSON
Synthesis NNP - I-PERSON
of ADP - O
Levofloxacin NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
, PUNCT - O
which ADJ - O
A. NN - B-PERSON
  _SP - I-PERSON
actinomycetemcomitans NOUN - O
is VERB - O
usually ADV - O
susceptible ADJ - O
to PART - O
, PUNCT - O
can VERB - O
be VERB - O
an DET - O
effective ADJ - O
alternative ADJ - O
oral ADJ - O
antimicrobial ADJ - O
agent NOUN - O
in ADP - O
such ADJ - O
cases NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NN - B-MEDICINE
- PUNCT - O
Loaded VERB - O
Nanoparticles NNP - B-ORG
Decrease NNP - I-ORG
Emergence NNP - I-ORG
of ADP - O
Fluoroquinolone PROPN - O
Resistance PROPN - O
in ADP - O
Escherichia NNP - B-GPE
coli NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Compared VERB - O
with ADP - O
Levofloxacin NNP - B-MEDICINE
in ADP - O
the DET - O
Treatment PROPN - O
of ADP - O
Complicated PROPN - O
Urinary PROPN - O
Tract PROPN - O
Infection PROPN - O
and CCONJ - O
Acute PROPN - O
Pyelonephritis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine NN - B-MEDICINE
exerts NOUN - O
anti ADJ - O
- ADJ - O
nociceptive ADJ - O
effects NOUN - O
in ADP - O
spared VERB - O
nerve NOUN - O
injury NOUN - O
model NOUN - O
of ADP - O
neuropathic ADJ - O
pain NOUN - O
through ADP - O
inhibition NOUN - O
of ADP - O
TLR4/NF NNP - B-GPE
- HYPH - I-GPE
κB NNP - I-GPE
pathway NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine VB - B-MEDICINE
, PUNCT - O
a DET - O
widely ADV - O
used VERB - O
muscle NOUN - O
relaxant NOUN - O
that ADJ - O
can VERB - O
lower VERB - O
blood NOUN - O
pressure NOUN - O
, PUNCT - O
is VERB - O
metabolized VERB - O
by ADP - O
the DET - O
cytochrome ADJ - O
P450 PROPN - O
1A2 NUM - O
( PUNCT - O
CYP1A2 NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Co PROPN - O
- NOUN - O
Prescription NOUN - O
of ADP - O
Strong PROPN - O
CYP1A2 PROPN - O
Inhibitors PROPN - O
and CCONJ - O
the DET - O
Risk PROPN - O
of ADP - O
Tizanidine NNP - B-MEDICINE
- PUNCT - O
Associated VERB - O
Hypotension PROPN - O
: PUNCT - O
A DET - O
Retrospective PROPN - O
Cohort PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine NNP - B-MEDICINE
is VERB - O
an DET - O
alpha-2 ADJ - O
agonist NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison PROPN - O
the DET - O
Effects NOUN - O
of ADP - O
Oral PROPN - O
Tizanidine NNP - B-MEDICINE
and CCONJ - O
Tramadol NNP - B-GPE
on ADP - O
Intra- PROPN - O
and CCONJ - O
Post NNP - B-ORG
- ADJ - O
operative ADJ - O
Shivering PROPN - O
in ADP - O
Patients PROPN - O
Underwent PROPN - O
Spinal PROPN - O
Anesthesia PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Clinically NNP - B-PERSON
Significant JJ - I-PERSON
Bradycardia NNP - I-PERSON
From ADP - O
Tizanidine NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Simultaneous ADJ - O
Determination PROPN - O
of ADP - O
Tizanidine NNP - B-MEDICINE
, PUNCT - O
Nimesulide NNP - B-ORG
, PUNCT - O
Aceclofenac NNP - B-WORK_OF_ART
and CC - I-WORK_OF_ART
Paracetamol NNP - I-WORK_OF_ART
in IN - I-WORK_OF_ART
Tablets NNPS - I-WORK_OF_ART
and CC - I-WORK_OF_ART
Biological NNP - I-WORK_OF_ART
Fluids NNPS - I-WORK_OF_ART
Using VBG - I-WORK_OF_ART
Micellar NNP - I-WORK_OF_ART
Liquid NNP - I-WORK_OF_ART
Chromatography NNP - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

Development PROPN - O
and CCONJ - O
Validation PROPN - O
of ADP - O
a DET - O
Versatile PROPN - O
UPLC PROPN - O
- PUNCT - O
PDA PROPN - O
Method PROPN - O
for ADP - O
Simultaneous PROPN - O
Determination PROPN - O
of ADP - O
Paracetamol PROPN - O
, PUNCT - O
Tizanidine NNP - B-MEDICINE
, PUNCT - O
Aceclofenac NNP - B-GPE
, PUNCT - O
and CCONJ - O
Nimesulide NN - B-ORG
in ADP - O
Their ADJ - O
New PROPN - O
Combinations PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Importance NOUN - O
of ADP - O
Medication PROPN - O
Reconciliation PROPN - O
: PUNCT - O
Tizanidine NN - B-MEDICINE
- PUNCT - O
Induced PROPN - O
Hepatitis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Synthesized ADJ - O
TAX PROPN - O
was VERB - O
utilized VERB - O
to PART - O
prepare VERB - O
Tizanidine JJ - B-MEDICINE
HCl NOUN - O
( PUNCT - O
TZN PROPN - O
HCl NOUN - O
) PUNCT - O
loaded VERB - O
sustained ADJ - O
release NOUN - O
( PUNCT - O
SR NOUN - O
) PUNCT - O
mucoadhesive ADJ - O
buccal ADJ - O
films NOUN - O
using VERB - O
a DET - O
solvent NOUN - O
casting NOUN - O
technique NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Poster NOUN - O
257 CD - B-CARDINAL
Tizanidine NNP - B-MEDICINE
Reduces PROPN - O
Night PROPN - O
Sweats PROPN - O
due ADP - O
to ADP - O
Dysautonomia NNP - B-GPE
in ADP - O
Syringomyelia NNP - B-GPE
: PUNCT - O
A DET - O
Case PROPN - O
Report PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
UHPLC NN - B-ORG
- PUNCT - O
UV NOUN - O
Method PROPN - O
to ADP - O
Quantify NNP - B-ORG
Skin NNP - I-ORG
Deposition NNP - I-ORG
and CC - I-ORG
Transdermal NNP - I-ORG
Permeation NNP - I-ORG
of IN - I-ORG
Tizanidine NNP - I-MEDICINE
Hydrochloride NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine NNP - B-MEDICINE
is VERB - O
a DET - O
centrally ADV - O
acting VERB - O
α2-agonist NOUN - O
with ADP - O
muscle NOUN - O
relaxant ADJ - O
properties NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Magnetic ADJ - O
molecularly ADJ - O
imprinted VERB - O
polymer NOUN - O
nanoparticles NOUN - O
for ADP - O
selective ADJ - O
solid ADJ - O
phase NOUN - O
extraction NOUN - O
and CCONJ - O
pre ADJ - O
- ADJ - O
concentration NOUN - O
of ADP - O
Tizanidine NNP - B-MEDICINE
in ADP - O
human ADJ - O
urine NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine JJ - B-MEDICINE
hydrochloride NOUN - O
, PUNCT - O
α2-receptor NOUN - O
stimulant NOUN - O
, PUNCT - O
is VERB - O
a DET - O
central ADJ - O
muscle NOUN - O
relaxant NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine NN - B-MEDICINE
- PUNCT - O
induced VERB - O
acute ADJ - O
severe ADJ - O
cystitis NOUN - O
in ADP - O
a DET - O
female ADJ - O
taking VERB - O
famotidine NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison PROPN - O
of ADP - O
Efficacy PROPN - O
and CCONJ - O
Side PROPN - O
Effects PROPN - O
of ADP - O
Oral PROPN - O
Baclofen PROPN - O
Versus PROPN - O
Tizanidine NNP - B-MEDICINE
Therapy NOUN - O
with ADP - O
Adjuvant PROPN - O
Botulinum PROPN - O
Toxin PROPN - O
Type PROPN - O
A PROPN - O
in ADP - O
Children NNP - B-ORG
With IN - I-ORG
Cerebral NNP - I-ORG
Palsy NNP - I-ORG
and CCONJ - O
Spastic PROPN - O
Equinus PROPN - O
Foot PROPN - O
Deformity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine JJ - B-MEDICINE
withdrawal NOUN - O
should VERB - O
be VERB - O
considered VERB - O
in ADP - O
patients NOUN - O
who NOUN - O
manifest VERB - O
signs NOUN - O
and CCONJ - O
symptoms NOUN - O
of ADP - O
withdrawal NOUN - O
from ADP - O
medications NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Tizanidine VB - B-MEDICINE
withdrawal NOUN - O
symptoms NOUN - O
in ADP - O
stress NOUN - O
cardiomyopathy]. ADJ - O

-DOCSTART- -X- - O

Successful ADJ - O
Rituximab PROPN - O
and CCONJ - O
Tizanidine NNP - B-MEDICINE
Therapy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
investigate VERB - O
whether ADP - O
an DET - O
anti ADJ - O
- ADJ - O
spasticity ADJ - O
medication NOUN - O
can VERB - O
facilitate VERB - O
the DET - O
effects NOUN - O
of ADP - O
robotic ADJ - O
locomotor NOUN - O
treadmill NOUN - O
training NOUN - O
( PUNCT - O
LTT NNP - B-ORG
) PUNCT - O
to PART - O
improve VERB - O
gait ADJ - O
function NOUN - O
in ADP - O
people NOUN - O
with ADP - O
incomplete ADJ - O
spinal ADJ - O
cord NOUN - O
injury NOUN - O
( PUNCT - O
SCI).Individuals NOUN - O
with ADP - O
chronic ADJ - O
incomplete ADJ - O
SCI NNP - B-ORG
were VERB - O
recruited VERB - O
and CCONJ - O
carried VERB - O
out PART - O
a DET - O
4 CD - B-CARDINAL
  SPACE - O
week NOUN - O
intervention NOUN - O
of ADP - O
either DET - O
locomotor NOUN - O
treadmill NOUN - O
training NOUN - O
( PUNCT - O
LTT NN - B-ORG
) PUNCT - O
alone ADV - O
( PUNCT - O
n CCONJ - O
  SPACE - O
= SYM - O
  SPACE - O
26 CD - B-CARDINAL
) PUNCT - O
or CCONJ - O
LTT NNP - B-ORG
combined VERB - O
with ADP - O
Tizanidine NNP - B-MEDICINE
( PUNCT - O
TizLTT NN - B-ORG
) PUNCT - O
, PUNCT - O
an DET - O
anti ADJ - O
- ADJ - O
spasticity ADJ - O
medication NOUN - O
( PUNCT - O
n NOUN - O
  SPACE - O
= PUNCT - O
  SPACE - O
22 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

0.40 CD - B-CARDINAL
; PUNCT - O
P NOUN - O
  SPACE - O
< X - O
  SPACE - O
0.05).Tizanidine NUM - O
appears VERB - O
to PART - O
facilitate VERB - O
the DET - O
effects NOUN - O
of ADP - O
LTT NNP - B-ORG
on ADP - O
gait ADJ - O
function NOUN - O
in ADP - O
individuals NOUN - O
with ADP - O
chronic ADJ - O
SCI NNP - B-ORG
that ADJ - O
are VERB - O
higher ADJ - O
functioning VERB - O
at ADP - O
baseline NOUN - O
. PUNCT - O

We PRON - O
speculate VERB - O
that ADP - O
this DET - O
may VERB - O
be VERB - O
due ADP - O
to ADP - O
restoration NOUN - O
of ADP - O
inhibitory ADJ - O
mechanisms NOUN - O
by ADP - O
Tizanidine NNP - B-MEDICINE
, PUNCT - O
resulting VERB - O
in ADP - O
greater ADJ - O
stretch NOUN - O
in ADP - O
the DET - O
planterflexor ADJ - O
muscles NOUN - O
during ADP - O
the DET - O
LTT NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Intermittent ADJ - O
use NOUN - O
of ADP - O
oral ADJ - O
muscle NOUN - O
relaxant ADJ - O
drugs NOUN - O
, PUNCT - O
for ADP - O
example NOUN - O
, PUNCT - O
Tizanidine NNP - B-MEDICINE
( -LRB- - I-ORG
Ternelin NNP - I-ORG
) PUNCT - O
, PUNCT - O
which ADJ - O
is VERB - O
a DET - O
fast ADV - O
- PUNCT - O
acting VERB - O
muscle NOUN - O
relaxant NOUN - O
, PUNCT - O
can VERB - O
provide VERB - O
relief NOUN - O
from ADP - O
the DET - O
severe ADJ - O
hypertonia NOUN - O
in ADP - O
these DET - O
patients NOUN - O
, PUNCT - O
but CCONJ - O
only ADV - O
for ADP - O
short ADJ - O
durations NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine NNP - B-MEDICINE
( PUNCT - O
EC50 PROPN - O
  SPACE - O
= SYM - O
  SPACE - O

-DOCSTART- -X- - O

Tizanidine NNP - B-MEDICINE
( PUNCT - O
2 CD - B-CARDINAL
mg NOUN - O
) PUNCT - O
was VERB - O
administered VERB - O
( PUNCT - O
4\day CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
for ADP - O
4 CD - B-DATE
weeks NNS - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
spectroscopic ADJ - O
techniques NOUN - O
and CCONJ - O
semi ADJ - O
- ADJ - O
empirical ADJ - O
molecular ADJ - O
calculations NOUN - O
have VERB - O
been VERB - O
utilized VERB - O
to PART - O
analyze VERB - O
the DET - O
drug NOUN - O
Tizanidine NNP - B-MEDICINE
( PUNCT - O
5CDIBTA PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Normal ADJ - O
co NOUN - O
- ADJ - O
ordinate ADJ - O
analysis NOUN - O
, PUNCT - O
molecular ADJ - O
structural ADJ - O
, PUNCT - O
non ADJ - O
- ADJ - O
linear ADJ - O
optical ADJ - O
, PUNCT - O
second JJ - B-ORDINAL
order NOUN - O
perturbation NOUN - O
studies NOUN - O
of ADP - O
Tizanidine NNP - B-MEDICINE
by ADP - O
density NOUN - O
functional ADJ - O
theory NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine JJ - B-MEDICINE
HCl NOUN - O
is VERB - O
a DET - O
skeletal ADJ - O
muscle NOUN - O
relaxant NOUN - O
that ADJ - O
suffers VERB - O
from ADP - O
extensive ADJ - O
hepatic ADJ - O
metabolism NOUN - O
resulting VERB - O
in ADP - O
34 CD - B-PERCENT
- SYM - I-PERCENT
40 CD - I-PERCENT
% NN - I-PERCENT
oral ADJ - O
bioavailability NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Among ADP - O
others NOUN - O
, PUNCT - O
two CD - B-CARDINAL
substances NOUN - O
that ADJ - O
never ADV - O
had VERB - O
been VERB - O
detected VERB - O
before ADV - O
in ADP - O
this DET - O
river NOUN - O
, PUNCT - O
namely ADV - O
, PUNCT - O
the DET - O
muscle NOUN - O
relaxant NOUN - O
Tizanidine NNP - B-MEDICINE
and CCONJ - O
the DET - O
solvent NOUN - O
1,3-Dimethyl-2-imidazolidinone NUM - O
( PUNCT - O
DMI NNP - B-ORG
) PUNCT - O
, PUNCT - O
were VERB - O
identified VERB - O
and CCONJ - O
confirmed VERB - O
, PUNCT - O
and CCONJ - O
their ADJ - O
loads NOUN - O
were VERB - O
roughly ADV - O
estimated VERB - O
along ADP - O
the DET - O
river NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine NN - B-MEDICINE
, PUNCT - O
baclofen ADJ - O
, PUNCT - O
and CCONJ - O
placebo NOUN - O
were VERB - O
tested VERB - O
in ADP - O
this DET - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine NNP - B-MEDICINE
is VERB - O
α2-receptor NOUN - O
agonists NOUN - O
that ADJ - O
suppresses VERB - O
central ADJ - O
sympathetic ADJ - O
system NOUN - O
. PUNCT - O

This DET - O
study NOUN - O
evaluates VERB - O
the DET - O
effects NOUN - O
of ADP - O
oral ADJ - O
Tizanidine NNP - B-MEDICINE
on ADP - O
hemodynamic ADJ - O
responses NOUN - O
during ADP - O
operations NOUN - O
and CCONJ - O
aims VERB - O
to PART - O
determine VERB - O
the DET - O
appropriate ADJ - O
Propofol JJ - B-PERSON
dosage NOUN - O
to PART - O
maintain VERB - O
anesthesia NOUN - O
under ADP - O
BIS NNP - B-ORG
monitoring NOUN - O
. PUNCT - O

35 CD - B-CARDINAL
randomly ADV - O
selected VERB - O
patients NOUN - O
( PUNCT - O
the DET - O
case NOUN - O
group NOUN - O
) PUNCT - O
were VERB - O
given VERB - O
4 CD - B-QUANTITY
mg NN - I-QUANTITY
of ADP - O
oral ADJ - O
Tizanidine NNP - B-MEDICINE
90 CD - I-TIME
minutes NNS - I-TIME
before ADP - O
the DET - O
induction NOUN - O
of ADP - O
anesthesia NOUN - O
whereas ADP - O
the DET - O
remaining VERB - O
subjects NOUN - O
( PUNCT - O
the DET - O
control NOUN - O
group NOUN - O
) PUNCT - O
were VERB - O
given VERB - O
placebo NOUN - O
. PUNCT - O

Data NOUN - O
analysis NOUN - O
was VERB - O
done VERB - O
with ADP - O
T NOUN - O
- PUNCT - O
test NOUN - O
and CCONJ - O
Chi NNP - B-PERSON
- PUNCT - O
squared ADJ - O
test NOUN - O
, PUNCT - O
using VERB - O
SPSS NOUN - O
software NOUN - O
version NOUN - O
16.Variations NOUN - O
of ADP - O
blood NOUN - O
pressure NOUN - O
and CCONJ - O
heart NOUN - O
rate NOUN - O
after ADP - O
anesthesia NOUN - O
induction NOUN - O
, PUNCT - O
intubation NOUN - O
and CCONJ - O
extubation NOUN - O
were VERB - O
less ADJ - O
in ADP - O
Tizanidine NNP - B-MEDICINE
group NOUN - O
generally ADV - O
. PUNCT - O

Using VERB - O
oral ADJ - O
Tizanidine NNP - B-MEDICINE
as ADP - O
a DET - O
premedication NOUN - O
, PUNCT - O
yielded VERB - O
stability NOUN - O
in ADP - O
blood NOUN - O
pressure NOUN - O
and CCONJ - O
heart NOUN - O
rate NOUN - O
during ADP - O
surgery NOUN - O
and CCONJ - O
decreased VERB - O
required VERB - O
Propofol NNP - B-PERSON
. PUNCT - O

Considering VERB - O
its ADJ - O
short ADJ - O
duration NOUN - O
of ADP - O
action NOUN - O
, PUNCT - O
Tizanidine NNP - B-MEDICINE
use NOUN - O
as ADP - O
a DET - O
premedication NOUN - O
is VERB - O
recommended VERB - O
for ADP - O
sedation NOUN - O
and CCONJ - O
stabilization NOUN - O
of ADP - O
hemodynamic ADJ - O
responses NOUN - O
during ADP - O
the DET - O
operations NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine VB - B-MEDICINE
and CCONJ - O
tizanidine VB - B-MEDICINE
hydrochloride NOUN - O
: PUNCT - O
on ADP - O
the DET - O
correct ADJ - O
tautomeric ADJ - O
form NOUN - O
of ADP - O
tizanidine NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine NN - B-MEDICINE
could VERB - O
be VERB - O
a DET - O
safe ADJ - O
and CCONJ - O
effective ADJ - O
treatment NOUN - O
of ADP - O
children NOUN - O
with ADP - O
dysfunctional ADJ - O
voiding NOUN - O
due ADP - O
to ADP - O
pelvic ADJ - O
floor NOUN - O
/ SYM - O
skeletal ADJ - O
sphincter NOUN - O
dysfunction NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine JJ - B-MEDICINE
hydrochloride NOUN - O
( PUNCT - O
TIZ NNP - B-ORG
) PUNCT - O
was VERB - O
used VERB - O
as ADP - O
a DET - O
model NOUN - O
drug NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine NNP - B-MEDICINE
( PUNCT - O
Zanaflex NNP - B-PERSON
) PUNCT - O
is VERB - O
a DET - O
centrally ADV - O
acting VERB - O
imidazoline ADJ - O
muscle NOUN - O
relaxant NOUN - O
that ADJ - O
is VERB - O
structurally ADV - O
similar ADJ - O
to ADP - O
clonidine VERB - O
( PUNCT - O
α(2)-adrenergic ADJ - O
agonist NOUN - O
) PUNCT - O
but CCONJ - O
not ADV - O
to ADP - O
other ADJ - O
myorelaxants NOUN - O
such ADJ - O
as ADP - O
baclofen NOUN - O
or CCONJ - O
benzodiazepines NOUN - O
. PUNCT - O

( PUNCT - O
3 LS - B-CARDINAL
) PUNCT - O
Tizanidine VB - B-MEDICINE
0.25 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
kg NNS - I-QUANTITY
ip NOUN - O
caused VERB - O
a DET - O
maximal ADJ - O
11.93 CD - B-CARDINAL
± PUNCT - O
1.49 CD - B-QUANTITY
ms DT - I-QUANTITY
prolongation NOUN - O
of ADP - O
corrected VERB - O
QT NNP - B-ORG
interval NOUN - O
( PUNCT - O
QTc PROPN - O
) PUNCT - O
, PUNCT - O
90 CD - B-TIME
minutes NNS - I-TIME
after ADP - O
injection NOUN - O
. PUNCT - O

Tizanidine NN - B-MEDICINE
prolongs NOUN - O
the DET - O
QT NNP - B-ORG
interval NOUN - O
by ADP - O
blocking VERB - O
I(Kr PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine NNP - B-MEDICINE
( PUNCT - O
Zanaflex NNP - B-PERSON
) PUNCT - O
: PUNCT - O
a DET - O
muscle NOUN - O
relaxant NOUN - O
that ADJ - O
may VERB - O
prolong VERB - O
the DET - O
QT NNP - B-ORG
interval NOUN - O
by ADP - O
blocking VERB - O
IKr NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine NN - B-MEDICINE
can VERB - O
play VERB - O
a DET - O
role NOUN - O
in ADP - O
alcohol NOUN - O
withdrawal NOUN - O
since ADP - O
it PRON - O
interferes VERB - O
with ADP - O
the DET - O
noradrenergic ADJ - O
system NOUN - O
neurotransmission NOUN - O
. PUNCT - O

Tizanidine NNP - B-MEDICINE
is VERB - O
an DET - O
α2-adrenoreceptor NOUN - O
agonist NOUN - O
that ADJ - O
inhibits VERB - O
noradrenaline ADJ - O
release NOUN - O
and CCONJ - O
binds VERB - O
to PART - O
imidazoline ADJ - O
receptors NOUN - O
. PUNCT - O

Although ADP - O
Tizanidine NNP - B-MEDICINE
has VERB - O
been VERB - O
tested VERB - O
as ADP - O
a DET - O
treatment NOUN - O
for ADP - O
opioid ADJ - O
withdrawal NOUN - O
it PRON - O
has VERB - O
not ADV - O
been VERB - O
tried VERB - O
in ADP - O
alcohol NOUN - O
withdrawal NOUN - O
yet ADV - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
PLGA PROPN - O
- PUNCT - O
PEG PROPN - O
- PUNCT - O
PLGA NOUN - O
Thermosensitive PROPN - O
Gel PROPN - O
Enabling PROPN - O
Sustained PROPN - O
Delivery NOUN - O
of ADP - O
Ropivacaine NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
for ADP - O
Postoperative PROPN - O
Pain PROPN - O
Relief PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison NN - B-ORG
Between IN - I-ORG
Lignocaine PROPN - O
Hydrochloride PROPN - O
and CCONJ - O
Ropivacaine NNP - B-PERSON
Hydrochloride NNP - I-PERSON
as ADP - O
Lumbosacral PROPN - O
Epidural PROPN - O
Anaesthetic PROPN - O
Agents PROPN - O
in ADP - O
Goats PROPN - O

-DOCSTART- -X- - O

Comparison NNP - B-ORG
of IN - I-ORG
Two NNP - I-ORG
Doses NNPS - I-ORG
of IN - I-ORG
Ropivacaine NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
for ADP - O
Lumbosacral PROPN - O
Epidural PROPN - O
Anaesthesia PROPN - O
in ADP - O
Goats PROPN - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
relaxes VERB - O
BALB PROPN - O
/ SYM - O
c NOUN - O
mouse NOUN - O
airway ADJ - O
smooth ADJ - O
muscle NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
is VERB - O
necessary ADJ - O
in ADP - O
medical ADJ - O
treatment NOUN - O
and CCONJ - O
known VERB - O
to PART - O
be VERB - O
biosynthesized VERB - O
with ADP - O
propionyl NOUN - O
- PUNCT - O
CoA NOUN - O
as ADP - O
direct ADJ - O
precursor NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
A PROPN - O
( PUNCT - O
Er PROPN - O
- PUNCT - O
A PROPN - O
) PUNCT - O
produced VERB - O
by ADP - O
the DET - O
actinomycete ADJ - O
Saccharopolyspora NNP - B-ORG
erythraea NOUN - O
is VERB - O
an DET - O
important ADJ - O
antibiotic ADJ - O
extensively ADV - O
used VERB - O
in ADP - O
human ADJ - O
medicine NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NN - B-MEDICINE
and CCONJ - O
florfenicol ADJ - O
treatment NOUN - O
of ADP - O
rainbow NOUN - O
trout NOUN - O

-DOCSTART- -X- - O

Metabolic NNP - B-ORG
Engineering NNP - I-ORG
Strategies NNPS - I-ORG
Based VBN - I-ORG
on IN - I-ORG
Secondary PROPN - O
Messengers NOUN - O
( PUNCT - O
p)ppGpp NOUN - O
and CCONJ - O
C PROPN - O
- PUNCT - O
di PROPN - O
- PUNCT - O
GMP NOUN - O
To PART - O
Increase VERB - O
Erythromycin NNP - B-MEDICINE
Yield PROPN - O
in ADP - O
Saccharopolyspora NNP - B-GPE
erythraea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

BACKGROUND NNP - B-ORG
Erythromycin NNP - I-MEDICINE
and CCONJ - O
its ADJ - O
derivatives NOUN - O
have VERB - O
been VERB - O
used VERB - O
to PART - O
treat VERB - O
nasal NOUN - O
polyposis NOUN - O
and CCONJ - O
reduce VERB - O
inflammation NOUN - O
, PUNCT - O
but CCONJ - O
the DET - O
mechanism NOUN - O
of ADP - O
action NOUN - O
remains VERB - O
unclear ADJ - O
. PUNCT - O

Erythromycin NN - B-MEDICINE
treatment NOUN - O
significantly ADV - O
decreased VERB - O
cell NOUN - O
proliferation NOUN - O
and CCONJ - O
the DET - O
expression NOUN - O
of ADP - O
p NN - B-ORG
- : - I-ORG
MEK1 NNS - I-ORG
and CCONJ - O
p PUNCT - O
- PUNCT - O
ERK1 PROPN - O
, PUNCT - O
and CCONJ - O
increased VERB - O
apoptosis NOUN - O
in ADP - O
nasal ADJ - O
polyp NOUN - O
- PUNCT - O
derived VERB - O
cells NOUN - O
compared VERB - O
with ADP - O
control NOUN - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
versus ADP - O
metoclopramide NOUN - O
for ADP - O
post ADJ - O
- ADJ - O
pyloric ADJ - O
spiral ADJ - O
nasoenteric ADJ - O
tube NOUN - O
placement NOUN - O
: PUNCT - O
a DET - O
randomized ADJ - O
non ADJ - O
- ADJ - O
inferiority ADJ - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Cost NOUN - O
- PUNCT - O
effectiveness NOUN - O
Analysis PROPN - O
and CCONJ - O
Safety PROPN - O
of ADP - O
Erythromycin NNP - B-MEDICINE
4%Gel NUM - O
and CCONJ - O
4 CD - B-PERCENT
% NN - I-PERCENT
Chlorhexidine PROPN - O
Scrub PROPN - O
for ADP - O
Pitted NNP - B-ORG
Keratolysis NNP - I-ORG
Treatment NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
has VERB - O
been VERB - O
recorded VERB - O
in ADP - O
coastal ADJ - O
waters NOUN - O
and CCONJ - O
could VERB - O
pose VERB - O
a DET - O
severe ADJ - O
threat NOUN - O
to ADP - O
marine ADJ - O
microbial ADJ - O
life NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
sensitivity NOUN - O
across ADP - O
different ADJ - O
taxa NOUN - O
of ADP - O
marine ADJ - O
phytoplankton NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Benzyl NNS - B-PERSON
penicillin NOUN - O
, PUNCT - O
Ampicillin NNP - B-PERSON
, PUNCT - O
Cefotaxime PROPN - O
, PUNCT - O
Ceftriaxone PROPN - O
, PUNCT - O
Levofloxacin NNP - B-ORG
, PUNCT - O
Erythromycin NNP - B-MEDICINE
, PUNCT - O
Clindamycin NNP - B-ORG
, , - I-ORG
Linezolid NNP - I-ORG
, PUNCT - O
Vancomycin NNP - B-ORG
, PUNCT - O
Tetracycline NNP - B-PERSON
and CCONJ - O
Cotrimoxazole NNP - B-GPE
, PUNCT - O
Olea NNP - B-GPE
europaea NOUN - O
leaf NOUN - O
extracts NOUN - O
and CCONJ - O
essential ADJ - O
oil NOUN - O
were VERB - O
tested VERB - O
against ADP - O
GBS PROPN - O
isolates NOUN - O
from ADP - O
South NNP - B-GPE
Africa NNP - I-GPE
and CCONJ - O
Namibia NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
( PUNCT - O
ERY NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
macrolide NOUN - O
antibiotic NOUN - O
, PUNCT - O
prescribed VERB - O
for ADP - O
human ADJ - O
and CCONJ - O
veterinary ADJ - O
medicines NOUN - O
but CCONJ - O
also ADV - O
used VERB - O
in ADP - O
aquaculture NOUN - O
and CCONJ - O
livestock NOUN - O
production NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
is VERB - O
an DET - O
antibiotic ADJ - O
employed VERB - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
infections NOUN - O
caused VERB - O
by ADP - O
Gram NNP - B-ORG
positive ADJ - O
microorganisms NOUN - O
and CCONJ - O
the DET - O
increasing VERB - O
use NOUN - O
has VERB - O
made VERB - O
it PRON - O
a DET - O
contaminant NOUN - O
of ADP - O
emerging VERB - O
concern NOUN - O
in ADP - O
aqueous ADJ - O
ecosystems NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
and CCONJ - O
Reflux NNP - B-ORG
Events NNPS - I-ORG
in ADP - O
Premature PROPN - O
Neonates PROPN - O
: PUNCT - O
A DET - O
Randomized VBN - B-ORG
Clinical NNP - I-ORG
Trial NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
ribosome ADJ - O
methylase NOUN - O
B NOUN - O
- PUNCT - O
erm(B PROPN - O
) PUNCT - O
was VERB - O
not ADV - O
detected VERB - O
in ADP - O
any DET - O
strain NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Identification NN - B-ORG
of IN - I-ORG
Pharmaceuticals NNPS - I-ORG
in ADP - O
The DT - B-ORG
Aquatic NNP - I-ORG
Environment NNP - I-ORG
Using VBG - I-ORG
HPLC NNP - I-ORG
- HYPH - I-ORG
ESI NNP - I-ORG
- HYPH - I-ORG
Q NNP - I-ORG
- HYPH - I-ORG
TOF NNP - I-ORG
- HYPH - I-ORG
MS NNP - I-ORG
and CCONJ - O
Elimination NOUN - O
of ADP - O
Erythromycin NNP - B-MEDICINE
Through ADP - O
Photo PROPN - O
- PUNCT - O
Induced PROPN - O
Degradation PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Serial ADJ - O
Gastric PROPN - O
Ultrasound PROPN - O
to ADP - O
Evaluate VB - B-ORG
Gastric NNP - I-ORG
Emptying NNP - I-ORG
After IN - I-ORG
Prokinetic PROPN - O
Therapy PROPN - O
With ADP - O
Domperidone PROPN - O
and CCONJ - O
Erythromycin NNP - B-MEDICINE
in ADP - O
a DET - O
Surgical PROPN - O
Patient PROPN - O
With ADP - O
a DET - O
Full ADJ - O
Stomach NOUN - O
: PUNCT - O
A DET - O
Case PROPN - O
Report PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
was VERB - O
strongly ADV - O
correlated VERB - O
with ADP - O
ermB NOUN - O
, PUNCT - O
ermC PROPN - O
, PUNCT - O
ermF PROPN - O
and CCONJ - O
ermY ADJ - O
genes NOUN - O
( PUNCT - O
r NOUN - O
  SPACE - O
= SYM - O
  SPACE - O
0.462 NUM - O
to ADP - O
0.667 NUM - O
, PUNCT - O
p X - O
  SPACE - O
< X - O
  SPACE - O
0.05 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
but CCONJ - O
no DET - O
significant ADJ - O
correlation NOUN - O
was VERB - O
observed VERB - O
between ADP - O
macrolides NOUN - O
and CCONJ - O
PKS NNP - B-ORG
genes NOUN - O
, PUNCT - O
suggesting VERB - O
other ADJ - O
environmental ADJ - O
factors NOUN - O
may VERB - O
have VERB - O
contributed VERB - O
to ADP - O
detected VERB - O
macrolides NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
resistance NOUN - O
was VERB - O
42 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
735 CD - B-CARDINAL
isolates NOUN - O
reported VERB - O
, PUNCT - O
0.1 CD - B-PERCENT
% NN - I-PERCENT
penicillin NOUN - O
of ADP - O
1,916 CD - B-CARDINAL
isolates NOUN - O
reported VERB - O
, PUNCT - O
and CCONJ - O
1.5 CD - B-PERCENT
% NN - I-PERCENT
TMP NNP - B-ORG
/ SYM - I-ORG
SMX NNP - I-ORG
of ADP - O
= PUNCT - O
135 CD - B-CARDINAL
isolates NOUN - O
reported VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
( PUNCT - O
12.5 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
four CD - B-CARDINAL
times NOUN - O
daily ADV - O
for ADP - O
3 CD - B-CARDINAL
  SPACE - O
days NNS - B-DATE
) PUNCT - O
exhibits VERB - O
similar ADJ - O
bacteriological ADJ - O
and CCONJ - O
clinical ADJ - O
success NOUN - O
and CCONJ - O
should VERB - O
be VERB - O
listed VERB - O
as ADP - O
a DET - O
second JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
therapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
is VERB - O
one NUM - O
of ADP - O
the DET - O
most ADV - O
widely ADV - O
used VERB - O
macrolide NOUN - O
antibiotics NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
resistance NOUN - O
correlated VERB - O
very ADV - O
well ADV - O
with ADP - O
the DET - O
presence NOUN - O
of ADP - O
ermD. PROPN - O

-DOCSTART- -X- - O

However ADV - O
, PUNCT - O
Erythromycin NNP - B-MEDICINE
- PUNCT - O
the DET - O
very ADV - O
closely ADV - O
- PUNCT - O
related VERB - O
parent NOUN - O
compound NOUN - O
- PUNCT - O
did VERB - O
not ADV - O
show VERB - O
any DET - O
senolytic ADJ - O
activity NOUN - O
, PUNCT - O
highlighting VERB - O
the DET - O
dramatic ADJ - O
specificity NOUN - O
of ADP - O
these DET - O
interactions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
assessed VERB - O
the DET - O
effect NOUN - O
of ADP - O
long ADJ - O
- PUNCT - O
term NOUN - O
erythromycin NN - B-MEDICINE
on ADP - O
oropharyngeal ADJ - O
microbiota NOUN - O
composition NOUN - O
and CCONJ - O
the DET - O
carriage NOUN - O
of ADP - O
transmissible ADJ - O
macrolide ADJ - O
resistance NOUN - O
genes NOUN - O
in ADP - O
84 CD - B-CARDINAL
adults NOUN - O
with ADP - O
bronchiectasis NOUN - O
, PUNCT - O
enrolled VERB - O
in ADP - O
the DET - O
Bronchiectasis PROPN - O
and CCONJ - O
Low PROPN - O
- PUNCT - O
dose NOUN - O
Erythromycin NNP - B-MEDICINE
Study NNP - I-FAC
( PUNCT - O
BLESS NNP - B-ORG
) PUNCT - O
48-week CD - B-CARDINAL
placebo NOUN - O
- PUNCT - O
controlled VERB - O
trial NOUN - O
of ADP - O
twice ADV - O
- PUNCT - O
daily JJ - B-DATE
erythromycin NN - B-MEDICINE
ethylsuccinate NOUN - O
( PUNCT - O
400 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
) PUNCT - O
. PUNCT - O

Erythromycin NN - B-MEDICINE
treatment NOUN - O
did VERB - O
not ADV - O
result VERB - O
in ADP - O
a DET - O
significant ADJ - O
increase NOUN - O
in ADP - O
the DET - O
number NOUN - O
of ADP - O
subjects NOUN - O
who NOUN - O
carried VERB - O
erm(A PROPN - O
) PUNCT - O
, PUNCT - O
erm(B PROPN - O
) PUNCT - O

-DOCSTART- -X- - O

OBJECTIVE NOUN - O
: PUNCT - O
Erythromycin NNP - B-MEDICINE
( PUNCT - O
ERY NNP - B-ORG
) PUNCT - O
is VERB - O
used VERB - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
gastroparesis NOUN - O
; PUNCT - O
however ADV - O
, PUNCT - O
this DET - O
medication NOUN - O
is VERB - O
associated VERB - O
with ADP - O
serious ADJ - O
side NOUN - O
effects NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
cardiac ADJ - O
arrhythmias NOUN - O
and CCONJ - O
consequent ADJ - O
cardiorespiratory ADJ - O
arrest NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
evaluation NOUN - O
of ADP - O
the DET - O
modulatory ADJ - O
activity NOUN - O
of ADP - O
fluoxetine NOUN - O
was VERB - O
performed VERB - O
by ADP - O
combining VERB - O
this DET - O
drug NOUN - O
with ADP - O
the DET - O
following ADJ - O
antibiotics NOUN - O
: PUNCT - O
Erythromycin NNP - B-MEDICINE
, PUNCT - O
Gentamicin NNP - B-ORG
, PUNCT - O
Imipenem NNP - B-ORG
, PUNCT - O
Norfloxacin NNP - B-ORG
and CCONJ - O
Tetracycline NNP - B-PERSON
at ADP - O
subinhibitory ADJ - O
concentrations NOUN - O
( PUNCT - O
MIC/8 NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

PccD PROPN - O
Regulates PROPN - O
Branched PROPN - O
- PUNCT - O
Chain NOUN - O
Amino PROPN - O
Acid NOUN - O
Degradation PROPN - O
and CCONJ - O
Exerts VERB - O
a DET - O
Negative PROPN - O
Effect PROPN - O
on ADP - O
Erythromycin NNP - B-MEDICINE
Production PROPN - O
in ADP - O
Saccharopolyspora NNP - B-ORG
erythraea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
could VERB - O
not ADV - O
alter VERB - O
the DET - O
mean ADJ - O
volume NOUN - O
of ADP - O
feeding NOUN - O
, PUNCT - O
duration NOUN - O
of ADP - O
parental ADJ - O
feeding NOUN - O
, PUNCT - O
length NOUN - O
of ADP - O
hospitalization NOUN - O
, PUNCT - O
and CCONJ - O
frequency NOUN - O
of ADP - O
feeding VERB - O
discontinuity NOUN - O
( PUNCT - O
p>0.05 NOUN - O
) PUNCT - O
; PUNCT - O
however ADV - O
, PUNCT - O
mean VERB - O
days NOUN - O
to PART - O
reach VERB - O
complete ADJ - O
feeding NOUN - O
in ADP - O
group NOUN - O
A PROPN - O
was VERB - O
significantly ADV - O
shorter ADJ - O
than ADP - O
in ADP - O
group NOUN - O
B NOUN - O
( PUNCT - O
9.80 CD - B-CARDINAL
vs. ADP - O
16.80 CD - B-DATE
days NNS - I-DATE
; PUNCT - O
p=0.001 ADD - B-DATE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NN - B-MEDICINE
, PUNCT - O
clindamycin NOUN - O
, PUNCT - O
tetracycline ADJ - O
, PUNCT - O
trimethoprim NOUN - O
- PUNCT - O
sulfamethoxazole NOUN - O
, PUNCT - O
and CCONJ - O
levofloxacin ADJ - O
resistant ADJ - O
rates NOUN - O
were VERB - O
30.4 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
15.6 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
16.3 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
16.3 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
and CCONJ - O
1.5 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Human NNP - B-ORG
Campylobacteriosis NNP - I-ORG
in ADP - O
Italy NNP - B-GPE
: PUNCT - O
Emergence NOUN - O
of ADP - O
Multi PROPN - O
- PROPN - O
Drug PROPN - O
Resistance PROPN - O
to ADP - O
Ciprofloxacin NNP - B-ORG
, PUNCT - O
Tetracycline NNP - B-PERSON
, PUNCT - O
and CCONJ - O
Erythromycin NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Sensitize PROPN - O
Group PROPN - O
B PROPN - O
Streptococcus PROPN - O
to ADP - O
Clindamycin VB - B-ORG
, PUNCT - O
Erythromycin NNP - B-MEDICINE
, PUNCT - O
Gentamicin NNP - B-ORG
, PUNCT - O
and CCONJ - O
Minocycline NNP - B-GPE
on ADP - O
a DET - O
Strain PROPN - O
Specific PROPN - O
Basis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin JJ - B-MEDICINE
poudrage NOUN - O
versus ADP - O
erythromycin JJ - B-MEDICINE
slurry NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
refractory ADJ - O
spontaneous ADJ - O
pneumothorax NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
resistance NOUN - O
was VERB - O
found VERB - O
in ADP - O
53 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
isolates NOUN - O
with ADP - O
inducible ADJ - O
macrolide NOUN - O
, PUNCT - O
lincosamide ADJ - O
and CCONJ - O
streptogramin VERB - O
B NOUN - O
the DET - O
predominant ADJ - O
phenotype NOUN - O
( PUNCT - O
63 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
with ADP - O
ermB ADJ - O
the DET - O
major ADJ - O
genetic ADJ - O
determinant NOUN - O
. PUNCT - O

Erythromycin NN - B-MEDICINE
and CCONJ - O
tetracycline NOUN - O
co NOUN - O
- NOUN - O
resistance NOUN - O
was VERB - O
found VERB - O
in ADP - O
39 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
tested VERB - O
GAS PROPN - O
isolates NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mechanism PROPN - O
of ADP - O
Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
Hydration PROPN - O
Based VERB - O
on ADP - O
the DT - B-ORG
Multi NNP - I-ORG
- HYPH - I-ORG
Rate NNP - I-ORG
Model NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Doxorubicin PROPN - O
Loaded VERB - O
Magnesium NN - B-MEDICINE
Oxide NNP - I-MEDICINE
Nanoflakes VERB - O
as ADP - O
pH PROPN - O
Dependent PROPN - O
Carriers PROPN - O
for ADP - O
Simultaneous PROPN - O
Treatment PROPN - O
of ADP - O
Cancer PROPN - O
and CCONJ - O
Hypomagnesemia NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Stabilization NOUN - O
of ADP - O
NaNO3-Promoted PROPN - O
Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
for ADP - O
High PROPN - O
- PUNCT - O
Temperature PROPN - O
CO2 PROPN - O
Capture PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Physically ADV - O
Transient ADJ - O
Threshold PROPN - O
Switching NOUN - O
Device NOUN - O
Based VERB - O
on ADP - O
Magnesium NNP - B-ORG
Oxide NNP - I-ORG
for IN - I-ORG
Security NNP - I-ORG
Application NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Cycle NNP - B-ORG
Stability NNP - I-ORG
and CC - I-ORG
Hydration NNP - I-ORG
Behavior NNP - I-ORG
of IN - I-ORG
Magnesium NNP - B-ORG
Oxide NNP - I-ORG
and CC - I-ORG
Its PRP$ - I-ORG
Dependence NN - I-ORG
on ADP - O
the DET - O
Precursor PROPN - O
- PUNCT - O
Related VERB - O
Particle PROPN - O
Morphology PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial NNP - B-ORG
Activities NNPS - I-ORG
and CCONJ - O
Mechanisms PROPN - O
of ADP - O
Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
Nanoparticles PROPN - O
( PUNCT - O
nMgO ADV - O
) PUNCT - O
against ADP - O
Pathogenic NNP - B-PERSON
Bacteria NNP - I-PERSON
, PUNCT - O
Yeasts NNPS - B-NORP
, PUNCT - O
and CCONJ - O
Biofilms NNP - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
Nanoparticles PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
Nanoparticles PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Influence NOUN - O
of ADP - O
Storage PROPN - O
Conditions PROPN - O
after ADP - O
One CD - B-CARDINAL
- PUNCT - O
dose NOUN - O
Packaging NOUN - O
on ADP - O
Stability PROPN - O
of ADP - O
Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
Tablets]. PROPN - O

-DOCSTART- -X- - O

Recently ADV - O
, PUNCT - O
the DT - B-LAW
" `` - I-LAW
Revision NNP - I-LAW
of IN - I-LAW
Precautions NNPS - I-LAW
on IN - I-LAW
the DT - I-LAW
Use NNP - I-LAW
of IN - I-LAW
Magnesium NNP - I-LAW
Oxide NNP - I-LAW
" PUNCT - O
has VERB - O
been VERB - O
issued VERB - O
by ADP - O
the DT - B-ORG
Japanese NNP - I-ORG
Pharmaceuticals NNPS - I-ORG
and CC - I-ORG
Medical NNP - I-ORG
Devices NNPS - I-ORG
Agency NNP - I-ORG
, PUNCT - O
warning VERB - O
against ADP - O
the DET - O
risk NOUN - O
of ADP - O
hypermagnesemia NOUN - O
with ADP - O
the DET - O
use NOUN - O
of ADP - O
MgO. NOUN - O

-DOCSTART- -X- - O

Pharmacokinetic PROPN - O
Studies PROPN - O
of ADP - O
Orally ADV - O
Administered PROPN - O
Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
in ADP - O
Rats PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Catalytic ADJ - O
Partial ADJ - O
Oxidation PROPN - O
of ADP - O
Cyclohexane PROPN - O
by ADP - O
Bimetallic NNP - B-ORG
Ag NNP - I-ORG
/ SYM - I-ORG
Pd NNP - I-ORG
Nanoparticles NNP - I-ORG
on ADP - O
Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Determination NOUN - O
of ADP - O
Magnesium NNP - B-ORG
Oxide NNP - I-ORG
Content NNP - I-ORG
in ADP - O
Mineral PROPN - O
Medicine PROPN - O
Talcum PROPN - O
Using VERB - O
Near PROPN - O
- PUNCT - O
Infrared PROPN - O
Spectroscopy PROPN - O
Integrated VERB - O
with ADP - O
Support PROPN - O
Vector PROPN - O
Machine PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Magnesium NN - B-ORG
Oxide NN - I-ORG
Embedded VBD - I-ORG
Nitrogen NNP - I-ORG
Self NNP - I-ORG
- HYPH - I-ORG
Doped NNP - I-ORG
Biochar NNP - I-ORG
Composites NNPS - I-ORG
: PUNCT - O

-DOCSTART- -X- - O

Magnesium NN - B-ORG
Oxide NNP - I-ORG
( PUNCT - O
MgO NNP - B-ORG
) PUNCT - O
pH NOUN - O
- PUNCT - O
sensitive ADJ - O
Sensing NNP - B-PERSON
Membrane NNP - I-PERSON
in ADP - O
Electrolyte NNP - B-ORG
- HYPH - I-ORG
Insulator NNP - I-ORG
- HYPH - I-ORG
Semiconductor NNP - I-ORG
Structures NNP - I-ORG
with ADP - O
CF4 NNP - B-ORG
Plasma NNP - I-ORG
Treatment NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Magnesium NNP - B-ORG
Oxide NNP - I-ORG
Nanoparticles NNP - I-ORG

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Food PROPN - O
Thickener PROPN - O
on ADP - O
Dissolution PROPN - O
and CCONJ - O
Laxative PROPN - O
Activity PROPN - O
of ADP - O
Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
Tablets PROPN - O
in ADP - O
Mice NNS - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
Suppresses VERB - O
Tablet PROPN - O
Hardness PROPN - O
Reduction PROPN - O
during ADP - O
Storage NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Label PROPN - O
- PUNCT - O
Free PROPN - O
Photoluminescence PROPN - O
Genosensor PROPN - O
Using VERB - O
Nanostructured VERB - O
Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
for ADP - O
Cholera PROPN - O
Detection PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Synthesis PROPN - O
of ADP - O
Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
Hierarchical PROPN - O
Microspheres VERB - O
: PUNCT - O
A DET - O
Dual PROPN - O
- PUNCT - O
Functional PROPN - O
Material PROPN - O
for ADP - O
Water PROPN - O
Remediation PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Oral PROPN - O
Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
Supplementation PROPN - O
on ADP - O
Cisplatin NNP - B-ORG
- HYPH - I-ORG
Induced NNP - I-ORG
Hypomagnesemia NNP - I-ORG
in IN - I-ORG
Cancer NNP - I-ORG
Patients NNPS - I-ORG
: PUNCT - O
A DET - O
Randomized VERB - O
Controlled PROPN - O
Trial PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Nano PROPN - O
- PUNCT - O
Structured VERB - O
Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
Coated PROPN - O
Iron PROPN - O
Ore PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Enhancing VERB - O
the DET - O
Heat PROPN - O
Transfer PROPN - O
Efficiency PROPN - O
in ADP - O
Graphene NNP - B-ORG
- HYPH - I-ORG
Epoxy NNP - I-ORG
Nanocomposites NNPS - I-ORG
Using VBG - I-ORG
a DT - I-ORG
Magnesium NNP - I-ORG
Oxide NNP - I-ORG
- HYPH - I-ORG
Graphene NNP - I-ORG
Hybrid NNP - I-ORG
Structure NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Activation PROPN - O
of ADP - O
Methane PROPN - O
and CCONJ - O
Carbon PROPN - O
Dioxide PROPN - O
Mediated VERB - O
by ADP - O
Transition NNP - B-ORG
- HYPH - I-ORG
Metal NNP - I-ORG
Doped NNP - I-ORG
Magnesium NNP - I-ORG
Oxide NNP - I-ORG
Clusters NNP - I-ORG
[ PUNCT - O
MMgO](+/0/- PROPN - O
) PUNCT - O

-DOCSTART- -X- - O

A DET - O
Polycarbonate PROPN - O
/ SYM - O
Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
Nanocomposite PROPN - O
with ADP - O
High PROPN - O
Flame PROPN - O
Retardancy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Method PROPN - O
for ADP - O
Efficient PROPN - O
Loading PROPN - O
of ADP - O
Ciprofloxacin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
in ADP - O
Cationic PROPN - O
Solid PROPN - O
Lipid PROPN - O
Nanoparticles PROPN - O
: PUNCT - O
Formulation PROPN - O
and CCONJ - O
Microbiological PROPN - O
Evaluation PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Correlation PROPN - O
of ADP - O
Adsorption PROPN - O
Behavior PROPN - O
between ADP - O
Ciprofloxacin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
and CCONJ - O
the DET - O
Active PROPN - O
Sites PROPN - O
of ADP - O
Fe PROPN - O
- PUNCT - O
doped ADJ - O
MCM-41 NNP - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Containing VERB - O
BCS PROPN - O
III PROPN - O
Drugs NOUN - O
, PUNCT - O
Acyclovir NNP - B-ORG
, , - I-ORG
Atenolol NNP - I-ORG
, PUNCT - O
and CCONJ - O
Ciprofloxacin NNP - B-ORG
Hydrochloride NNP - I-ORG
, PUNCT - O
Using VERB - O
Dissolution NOUN - O
Testing PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Radiolytic NNP - B-ORG
Decomposition NNP - I-ORG
of IN - I-ORG
Ciprofloxacin NNP - I-ORG
Hydrochloride NNP - I-ORG
in IN - I-ORG
Aqueous NNP - I-ORG
Solution NNP - I-ORG
Using VBG - I-ORG
γ IN - I-ORG
Irradiation]. PROPN - O

